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A bstract
The aim of this thesis was to examine the role that gene specific 
mutations play in leukaemogenesis of normal karyotype (NK) acute myeloid 
leukaemias (AMLs), by studying the number of genes involved, types of 
mutations, order by which they arise and their function. AML is a stem cell 
disease in which the bulk of the disease is perpetuated by a rare population of 
leukaemic stem cells (LSCs), which arise due to an accumulation of genetic 
events within the target cell.
Eight genes known to be mutated in AML were screened from a panel 
of 88 NK AML patients. One hundred and twenty-seven mutations were 
detected; multiple mutations were common and 44% of the AMLs contained 
mutations that affect both differentiation and proliferation, indicating a 
requirement for cooperating mutations. Regions of acquired uniparental 
disomy (aUPD) detected by SNP arrays were found to contain homozygous 
mutations in genes implicated in AML, such as homozygous FLT3-ITDs on 
13q, indicating that mitotic recombination can act as a second genetic event in 
leukaemogenesis. Semi-quantitative real-time PCR mutation specific assays, 
were designed against mutations in the transcription factor CEBPA. These 
assays were used to test AML samples which had been sorted into populations 
corresponding to stem cell and early progenitors in normal haematopoiesis. 
CEBPA mutation was detected in all compartments tested, indicating it is an 
early event in leukaemogenesis, which is supported by their occurrence in 
familial AML. Functional studies of mutations in CEBPA indicated that the 
30kDa isoform of the protein was able to direct differentiation of lineage 
depleted cord blood mononuclear cells towards the myeloid pathway, where 
the addition of an ITD within the C-terminal region promoted erythroid 
differentiation. The work presented here demonstrates that gene specific 
mutations play a key role in leukaemogenesis.
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2% FCS: PBS supplemented with 2% FCS
ALL: acute lymphoid leukaemia
AML: acute myeloid leukaemia
APC: allophycocyanin
APL: acute promylocytic leukaemia
APS: ammonium persulphate
ATRA: all-trans retinoic acid
BM: bone marrow
bp: base pair
BSA: bovine serum albumin
CD: cluster of differentiation
CFC: colony forming cell
CLL: chronic lymphoid leukaemia
CLP: common lymphoid progenitor
CML: chronic myeloid leukaemia
CMP: common myeloid precursor
CR: complete remission
CRUK: Cancer Research UK
dLLO: de-ionised water
DAPI: 4',6-diamidino-2-phenylindole
DHPLC: denaturing high performance liquid chromatography
DMEM: Dulbecco's Modified Eagle's Medium
DMSO: dimethyl-sulphoxide
DNA: deoxyribonucleic acid
DTT: 1,4-Dithiothreitol
EDTA: ethylenediaminetetraacetic acid
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ORF: open reading frame
PAGE: polyacrylamide gel electrophoresis
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TBS: Tris-buffered saline
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UK: United Kingdom
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WHO: World Health Organization
G e n e  N a m e s
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ABL: v-abl Abelson murine leukemia viral oncogene homolog 1
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AF9: ALL1 fused gene from chromosome 9
AML1: acute myeloid leukemia 1
BCR: breakpoint cluster region
Bmil: murine leukaemia viral onocogene homologue
CBF: core binding factor
CCND3: cyclin D3
CDK: cyclin dependant kinase
CEBPA: CCAAT enhancer binding protein alpha
cKIT: Proto-oncogene tyrosine-protein kinase Kit
E2F: family of transcription factors
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ERK: extracellular signal-regulated kinases
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GATA-1: globulin transcription factor 1
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FES: Feline sarcoma proto-oncogene
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MDS1: myelodysplasia syndrome 1
MEK: MAPK/ERK kinase
MLL: mixed lineage leukaemia
MYH11: myosin heavy chain 11
NPM: nucleophosmin
PDGFR: platelet-derived growth factor receptor 
PML: promyelocytic leukemia 
PU.l: PU-box 1
RARA: retinoic acid receptor alpha
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RAS: rat sarcoma 2 viral oncogene homolog 
Rb: retinoblastoma
RUNXI: runt-related transcription factor 1 
SCL: stem cell leukaemia
ST AT: Signal transducer and activator of transcription
Tal-1: T-cell acute lymphocytic leukaemia 1
TEL: ETS variant gene 6
TP53: tumor protein 53
TRIB1: tribbles homologue 2
UNG: uracil-DNA glycosylase
WT1: Wilms' tumour suppressor gene
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Amino Acids
A Ala alanine
C Cys cystine
D Asp aspartatic acid 
E Glu glutamic acid 
F Phe phenylalanine 
G Gly glycine
H His histidine
I lie isoleucine
K Lys lysine
L Leu leucine
M Met methionine 
N Asn asparagine 
P Pro proline
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Q Gin glutamine
R Arg arginine
S Ser serine
T Thr threonine
V Val valine
W Trp tryptophan
Y Tyr tyrosine
DNA/RNA
A adenine 
C cytosine 
G guanine 
T tryosine 
U uracil
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Bl o o d .
A word that evokes many images, blood is a substance that binds 
human life together. Over the years blood has come to represent many things, 
from family ties to hard work. Blood has been called upon by literary heroes 
like Shakespeare to describe courage and has even come to be a euphemism 
for life itself. When people die in violent ways, most often at the hands of 
fellow man, blood is spilt.
In many belief systems around the world and throughout history, blood 
plays a central role. The ancient Aztec civilization believed that the future 
could be prophesised by blood sacrifice of enemies and the spilling of blood 
from their high priests. Blood sacrifice was also practiced by ancient Germanic 
tribes, the sacrifice often of animals but hum an blood letting was also 
involved. The act of sprinkling blood associated with these rituals was called 
bleodsian in Old English and subsequently gave rise to a word that is very 
familiar today, blessing. To Catholics the ritual of communion remains central 
to their beliefs in which they partake of Christ's body and blood. Even in 
secular rituals blood plays a central role. The "blooding," occurs in fox 
hunting, where the lead huntsman smears the blood of the fox onto the cheeks 
of a newly initiated hunt follower. In a more light-hearted manner, a 
nosebleed in Japanese culture has come to represent sexual frustration or 
desire.
Although blood coveted such importance in what it came to represent, 
it itself as a substance has been poorly understood for the majority of human 
history. For thousands of years the human body and its inner workings were a 
mystery; illnesses were treated with a combination of trial and error and
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mysticism, of which such efforts were met with varying degrees of success. 
Hippocrates considered blood to be one of the four humours that made up the 
body and that illness was a result of imbalance between these humours. 
Evidence of blood-letting in practice dates as far back as 2500 BCE by the 
Egyptians and the technique remained in vogue until well into the 19th 
century.
As time passed the study of anatomy and physiology gradually 
stripped away the layers of mystery that encompassed the human body, but 
understanding of blood remained elusive until the advent of microscopy. 
Human red blood cells were first described in detail by the pioneering 
microscopist Anton van Leeuwenhoek in 1674, whereas the white blood cells 
or "globuli albicantes" as they were called were first noted by Joseph Lieutaud 
in 1749.
It comes of no surprise that the description and understanding of blood 
disorders is of relatively recent origin as well. Prior to microscopy, most 
afflictions of the blood, such as anaemia and some infectious diseases, were 
recognized not by studying the blood itself, but by associated enlargement of 
the spleen. Although a small number of cases of patients with uncommon or 
peculiar alterations of the blood were described early in the 19th century, it was 
not until the seminal papers by doctors John Bennett and Rudolf Virchow 
were published in 1845 that leukaemia was characterised as a disease in its 
own right.
Since those early days, understanding of leukaemia has leapt forward 
drastically and research into the disease has led the field of modem cancer 
research. Developments in microscopy, cellular staining and cytochemical 
techniques have resulted in better characterisation of leukaemias, in particular
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recognition of its heterogeneous nature. Within the past twenty years the 
development of monoclonal antibodies and the recognition of patterns of cell 
surface antigen expression have allowed scientists to further categorise 
different cell types that make up leukaemia.
As molecular techniques have improved over the years, research into 
leukaemia has also shifted gears, turning emphasis from phenotype to 
genotype. The discovery of the Philadelphia chromosome in chronic myeloid 
leukaemia was the first evidence that chromosomal damage is associated with 
cancer. Mustard gases developed for use in the Second World War marked the 
birth of chemotherapy as they went from being an agent of harm to helping 
treat leukaemia. Leukaemia is also the first cancer to be considered a "stem 
cell" disease, where a rare population of leukaemic stem cells are able to 
propagate the bulk of the disease.
A simple definition of leukaemia is a 'group of disorders characterised 
by the accumulation of malignant white blood cells in the bone marrow'. 
However with study, it soon becomes clear that leukaemia is no random mess 
of malignant cells, but there is order and a distinctive hierarchy involved. As 
Dante strove to understand hell by stratifying it into discriminate layers, 
scientists today strive to do the same with the process of leukaemogenesis.
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C h a p t e r  1: In t r o d u c t i o n
O verview
Acute myeloid leukaemia (AML) is a clonal, malignant proliferation of 
undifferentiated haematopoietic cells that is morphologically, genetically and 
therapeutically heterogeneous. In normal haematopoiesis, mature cell types 
arise from the pluripotent haematopoietic stem cell (HSC). In a similar fashion, 
the leukaemic blast population, which has a low proliferation potential, is 
perpetuated by a small population of leukaemic stem cells (LSCs) (Figure 1.1). 
As such, the response of the LSC to therapy is thought to be essential in 
determining the patient's outcome, and in a large part reflect the genetic 
damage within these cells1.
The relative rarity of LSCs compared to the myeloblasts which compose 
the bulk of the disease complicates the treatment of AML (Figure 1.2). The first 
phase of treatment, termed "induction therapy", attempts to destroy as many 
of the leukaemic blasts as possible in order to achieve complete remission 
(CR). CR is defined as the presence of less than 5% blasts in the bone marrow 
after treatment. Approximately 50-75% of de novo adult AMLs are able to 
achieve CR with induction therapy, though this is dependent on a number of 
prognostic factors. Once in remission, "consolidation therapy" is given in 
order to kill any remaining blast cells2.
Unfortunately, despite good rates of CR in AML, many patients 
subsequently relapse from their disease and die. The m ajority of relapses
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Figure 1.1: Normal and aberrant haematopoiesis
Normal haematopoiesis is driven by the haematopoietic stem cell (HSC), a 
pluripotent stem cell, which is able to self-renew and differentiate into all mature 
blood cell types. In AML, proliferation is dysregulated and differentiation is blocked, 
resulting in a mass of undifferentiated, non-functional blast cells perpetuated by the 
leukaemic stem cell (LSC). The LSC arises from an accumulation of genetic damage 
that targets genes involved in regulating proliferation and differentiation within 
HSCs or early progenitor cells. (Adapted from 3)
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Figure 1.2: Possible outcomes of post induction therapy
AML is a heterogeneous disease with variable responses to therapy. The goal of 
induction therapy is to reduce the leukaemic burden as rapidly as possible. 
Consolidation therapy aims to destroy any remaining leukaemic cells. There are 
three outcomes possible following therapy for AML. Sensitive cells are susceptible to 
therapy and eliminated. If the majority of blast cells are resistant, therapy fails and 
the disease persists. Often the bulk of the disease is eliminated and a remission is 
achieved, with the bone marrow consisting of less than 5% blast cells. However cells 
resistant to therapy persist and eventually repopulate the disease, resulting in 
relapse of the disease.
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occur when a small proportion of malignant cells manage to escape the 
previous therapy, proliferate and repopulate the disease. When relapse occurs, 
response to additional chemotherapy is less effective than initial therapy and 
is often poorly tolerated. Stem cell transplantation, performed in conjuncture 
to chemotherapy, is also difficult because of high treatment related mortality 
and lack of available donors2.
It is highly likely that the LSC is responsible for relapse due to its ability 
to give rise to leukaemic blasts and its largely quiescent nature, which allows it 
to escape conventional chemotherapy4. An understanding of the origin of the 
LSC is essential to elucidate the mechanisms of AML development and 
progression.
The LSC arises due to an accumulation of genetic events within the 
HSC or early progenitors. However, examination of the disease is focused on 
its progeny, the leukaemic blasts. Cytogenetic analysis of the blast cells, which 
reveals chromosomal aberrations, can be used to predict response to treatment 
(the patient's prognosis) however approximately fifty percent of AML cases 
have normal cytogenetics. Therefore, it is necessary to look beyond the 
resolution of cytogenetics to the molecular level and to examine gene specific 
mutations5. In AML, analysis of mutation status has been useful for risk 
stratification of patients, disease monitoring and the development of novel 
therapies.
Although knowledge of mutation status is useful for patient therapy; to 
more fully understand the disease it is important to address the question of 
how the LSC arises. As it is genetic aberrations which dictate the nature of the 
disease, there are several questions to address:
28
What types of mutations are present?
How many genes are involved?
What length of time does it take for the disease to develop?
In which order do the mutations arise?
What is the function of mutations in AML?
In this thesis we aim to address these questions. Mutation screening of a 
panel of normal karyotype (NK) AML patients allows us to see the number 
and pattern of gene mutations involved in leukaemogenesis. Long latency 
periods observed in familial AMLs indicate several genetic events are required 
for the development of overt AML. The discovery of acquired uniparental 
disomy giving rise to homozygous gene mutations shows clear progression of 
genetic events over time. To study the function of mutations in AML, we have 
examined the affects of mutations in the transcription factor CEBPA on normal 
haematopoiesis.
A c u te  M y e lo id  L e u k a e m ia  
I n c id e n c e
Leukaemia accounts for approximately 3% of all cancers in the United 
Kingdom. Grouped together, leukaemias are the ninth most common cancer in 
men and tenth in women. Age is an important risk factor in the development 
of AML. Although AML comprises roughly 75% of all cases of acute 
leukaemia it accounts for only 25 -  30% of cases of acute leukaemia in children 
aged 10 -  15 and less than 15% of cases of acute leukaemia in children under 
age 10. The incidence of AML rises dramatically for people over the age of 50 
(Figure 1.3)6 7. Unfortunately, older adults respond poorly to current therapies 
and most patients with AML will die from the disease.
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As age increases the rates and incidence of leukaemia also increase. Leukaemia is a 
disease that primarily affects older individuals, with age being a substantial risk 
factor for development of the disease. Leukaemia is the 9th and 10th most common 
cancer in men and women respectively.
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Nevertheless, early diagnosis and treatment can improve remission 
rates, particularly in younger adults.
Et io l o g y
The cause of AML remains unknown in most patients; with the disease 
primarily driven by sporadic rather than predisposed genetic events. There is 
evidence that certain environmental factors may play a role in the 
development of sporadic AML. The link between ionizing radiation and AML 
became apparent in the survivors of the atomic bomb explosions at Hiroshima 
and Nagasaki with the highest increases in incidence in people who were 
older than 45 at the time of exposure. Chemotherapy and therapeutic radiation 
can also be responsible for the development of AML. Alkylating agents, 
etoposides and topoisomerase II inhibitors have all been implicated in the 
development of secondary AML, following the treatment of other cancers. 
Significant exposure to chemicals such as benzene and other petrolum 
derivatives has also been associated with an increased risk2'8.
Certain inherited genetic conditions are also associated with an 
increased risk for the development of AML. Incidence of AML in Down's 
syndrome (trisomy 21) is higher than that of the general population. Also 
associated with an increased risk of AML are Fanconi's anemia and Bloom's 
syndrome, both of which are characterised by chromosome fragility2. Familial 
cases of syndromes such as neurofibromatosis and Noonan Syndrome have 
been useful for discovery of mutated genes that also yield leukaemia if they 
arise sporadically.
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C l in ic a l  P r e s e n t a t io n  a n d  D ia g n o s is
Pathologically, the acute leukaemias are defined as malignancies of 
immature haematopoietic cells. Blast cells constitute greater than 20% of the 
bone marrow cells and cause failure to produce normal cells resulting in 
cytopenias. The clinical presentation is usually a manifestation of these 
cytopenias and unrelated to the blast cells themselves. While clinical findings 
vary for person to person, common symptoms include anemia, bruising and 
haemorrhages.
Anaemia, while common, is not a universal symptom of AML, 
presumably because of rapid onset of the disease in some cases. Neutropenia 
and thromobocytopenia are usually present along with a reduction in 
numbers of normal leucocytes. Bleeding as the result of a diminished platelet 
count is another common finding, and can manifest itself as petechial 
hemorrhages observable on the skin or through gross haemorrhage8.
Organ infiltration by leukaemic blasts can be another presentation of 
leukaemia. The bone marrow is consistently infiltrated, but this cannot be 
observed upon physical examination. Enlargement of the gums, spleen and 
liver are rare but clinically assessable signs of leukaemic infiltration. 
Ultimately, leukaemia must be diagnosised by examination of the bone 
marrow itself8.
C l a s s if ic a t io n
Examination of the peripheral blood can often provide adequate 
information to diagnose leukaemia. Careful morphological assessment of 
normal and abnormal cell components of the peripheral blood and bone 
marrow remains essential to the diagnosis of the disease. Traditionally, AMLs
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were classified into different phenotypic groups based on the 
French-American-British (FAB) Cooperative Group classification scheme, 
which split the disease into subtypes based on differentiation (Table 1.1). This 
scheme was recently replaced by the World Health Organization (WHO) 
classification system.
The discovery of the Philadelphia chromosome in 1960 heralded a new 
era in cancer genetics. The realisation that this small marker chromosome was 
the result of a chromosomal translocation began a period of intensive study 
into leukaemic karyotypes, revealing many more recurrent chromosomal 
abnormalities9. Cytogenetics have since been used in prognosis, allowing the 
segregation of AML into potential outcome groups, either as favourable, 
intermediate, or poor (Table 1.2, Figure 1.4)10. AML with normal karyotype is 
classified within the intermediate prognosis group, however research has 
recently shown that the presence of certain molecularly detectable mutations 
can be used to further risk stratify5, which will be discussed in greater detail 
later in this thesis. The current classification system for malignant 
haematological conditions developed by the WHO takes into account 
cytogenetics. Leukaemias with consistent cytogenetic abnormalities and those 
which are related to myeloproliferative disorders (MDS) are divided into 
separate groups with the remaining following the traditional FAB system of 
classification (Table 1.3)11.
T h e r a py
Despite advances in the therapy of AML, the majority of patients will 
die from their disease. As discussed above, the most important prognostic 
factors determining the outcome of therapy are the acquired genetic changes
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FAB Subtype Name Approximate % of adult AML patients
MO Undifferentiated AML 5%
Ml Myeloblastic leukaemia with minimal maturation 15%
M2 Myeloblastic leukaemia with maturation 25%
M3 Promyelocytic leukaemia 10%
M4 Myelomonocytic leukaemia 20%
M4 eos Myelomonocytic leukaemia with eosinophilia 5%
M5 Monocytic leukaemia 10%
M6 Erythroid leukaemia 5%
M7 Megakaryoblastic leukaemia 5%
Table 1.1: FAB classification of AML
The French-American-British (FAB) classification system divides AML into 8 
subtypes, MO through to M7, based on the type of cell from which the leukaemia 
develops and its degree of maturity. Diagnosis is made based on phenotype of the 
cells. Different FAB types tend to have different prognosis outcomes, although this is 
based on the underlying geneotype of the disease.
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Risk Group Abnormality 5 year survival Relapse Rate
Favourable t(8;21)
t(15;17)
inv(16)
70% 33%
Intermediate Normal
+8
+21
+22
del(7q)
del(9q)
Abnormal llq23 
All other structural/ 
numerical abnormalities
48% 50%
Adverse 5
-7
del(5q) 
Abnormal 3q 
Complex
15% 78%
Table 1.2: Cytogenetic risk groups of AML
Hierarchical prognostic classification, derived taking into consideration the influence 
of additional cytogenetic abnormalities on outcome, and used for directing treatment 
approach in the current MRC AML 12 trial. The presence of certain genetic 
abnormalities indicates whether the AML will respond favourably or poorly to 
therapy. Prognosis may also be used to determine the nature of the therapy given, 
with more aggressive treatment for disease with adverse cytogenetics. (Adapted 
from 10)
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Figure 1.4: Prognostic risk based on karyotype in de novo AML
Overall survival of patients with AML is highly influenced by karyotype. In the MRC 
AML 10 and 12 trials, at 10 years, 65% of patients with favourable cytogenetics 
remained alive, 37% and 16% with intermediate and adverse cytogenetics survived 
for the same period of time respectively. (Adapted from 10)
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AML with recurrent
cytogenetic
translocations
• AML with t(8;21)(q22;q22) AMLl/CBFa/ETO
• Acute promyelocytic leukaemia:
AML with t(15;17)(q22;ql2) and variants 
PML/RARa
• AML with abnormal bone marrow eosinophils 
inv(16)(pl3;q22) vagy t(16;16)(pl3;q22) 
CBF|3/MYH1
AML with llq23  
MLL abnormalities
• With prior MDS
• Without prior MDS
AML with 
myelodysplastic 
syndrome, therapy 
related
• Alkylating agent related
• Epipodophyllotoxin related
• Other types
AML not otherwise 
categorised
• AML minimally differentiated
• AML without maturation
• AML with maturation
• Acute myelomonocytic leukaemia
• Acute monocytic leukaemia
• Acute erythroid leukaemia
• Acute megakaryocytic leukaemia
• Acute basophilic leukaemia
• Acute panmyelosis with myelofibrosis
Table 1.3: WHO classification of AML11
The current classification system for AML, developed by the WHO, takes into 
account cytogenetics and attempts to provide more prognostic information about the 
disease.
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within the leukaemic cells. These are also used to dictate the therapy that an 
individual patient recieves.
Younger patients (< 60 years old) undergoing a standard course of 
induction therapy can achieve an initial CR rate of 60-75%. Patients with APL 
(AML FAB type M3) through the addition of all-trans retinoic acid (ATRA) are 
able to achieve CR rates up to 80%12. The choice of post-remission therapy is 
determined by prognostic risk factors. Patients with favourable cytogenetics 
have an initial response to induction of approximately 85% and with intensive 
postremission therapy, the overall survival at 5 years exceeds 50%. For 
intermediate risk cytogenetics, many patients undergo allogeneic 
haematopoietic stem cell transplantation if there is a suitable donor, while 
those without receive intensive post-remission chemotherapy. Patients with 
unfavourable cytogenetics have the poorest outcome. While initial response 
rates may exceed 50%, the overall long term survival remains poor, regardless 
of the nature of postremission therapy13. Additionally, the development of 
resistance to chemotherapy is of major concern, with subsequent therapies 
being less effective in the case of relapsed leukaemias.
Older patients, which make up the majority of AML cases, have a 
dismal long-term prognosis. These patients tend to have more unfavourable 
prognostic factors at presentation and their treatment is made more difficult 
by an inability to tolerate intensive chemotherapy14. Therapy for this group 
provides the greatest challenge to AML care and the development of less 
severe and more targeted therapies is thought to be essential. These targeted 
therapies would not only benefit the older poor prognostic group but younger 
patients as well15.
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M in im a l  R e s id u a l  D is e a s e  (M R D ) m o n it o r in g
As many patients will relapse the possibility of predicting an 
impending relapse becomes imperative for deciding further therapeutic 
options. The persistence of malignant cells at a level below morphological 
detection is termed minimal residual disease (MRD). The molecular detection 
of MRD may identify patients at a higher risk of relapse. Due to the ability of 
these remaining cells to repopulate the blast population, it is not unreasonable 
to assume that in the majority of relapse cases, it is the LSC that escapes 
therapy and serves as the source for future relapsed disease.
The ability to detect low numbers of residual leukaemic cells would 
have a variety of benefits. It would allow for a more precise evaluation of the 
effectiveness of treatment, for MRD-adapted post-remission therapies and for 
earlier prediction of impending relapses prior to clinical manifestations16.
The study of MRD relies on modern technical methodology to identify 
disease below morphologically detectable levels. If the original leukaemic cell 
carries a molecular or antigenic marker that distinguishes it from 
non-leukaemic cells, then all cells that arise from that clone should contain this 
same marker. This property would allow for the application of techniques 
such as real-time PCR or flow cytometry to detect or quantify residual 
leukaemic cells17. Sensitive methods include cell cytometry, PCR against 
specific genetic lesions and increasingly against gene specific mutations and 
fluorescence in situ hybridisation (FISH), all of which have relative 
advantages, disadvantages and sensitivity for detecting MRD, which are listed 
in Table 1.416.
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Technique Sensitivity Disadvantage
Cytogenetics 1:20 Laborious
FISH 1 0 1 -  io-3 Limited probes available, variety of breakpoints
PCR Up to IO-6 Technically demanding, susceptible to false positives and contamination
RT-PCR Up to IO-6 Complex, labour intensive
Flow cytometry
oT-H1Or—1 Dependant on markers on leukaemia
Table 1.4: Methods of detection of MRD in AML
The persistence of these malignant cells at a level below morphological detection is 
termed minimal residual disease (MRD). The molecular detection of MRD may 
identify patients at a higher risk of relapse. (Adapted from 16)
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Chromosomal translocations are a common target for PCR based MRD 
detection techniques; however this method of detection is limited due to a 
high proportion of normal karyotype AMLs. Gene expression as detected by 
real-time PCR also plays a key role in MRD monitoring. High expression of the 
Wilms' tumour suppressor gene (WT1) in AML during remission is associated 
with impending relapse of the disease18. Flow cytometric detection of aberrant 
immunophenotypes is another method utilised for MRD monitoring. The 
identification of new markers of leukaemia by gene array technology should 
lead to the design of simple and reliable antibody panels for universal 
monitoring of MRD19. Irrespective of the method of detection correlation 
between high MRD and relapse in patients indicates the need for development 
of increasingly sensitive and diverse techniques for the monitoring of disease.
T h e  H a e m a t o p o ie t ic  S y st em
Since AML is the result of malignant haematopoiesis, the study of 
normal haematopoiesis and the processes by which it becomes deregulated is 
essential for understanding the disease.
N o r m a l  H a e m a t o p o ie s is
The variety of cells in normal blood is constantly being maintained by 
the haematopoietic system, which produces all cells of the blood lineage. The 
turnover of cells in the haematopoietic system in an average human weighing 
70kg is estimated to be close to one trillion cells per day, including 200 billion 
erythocytes and 70 billion neutrophilic leukocytes. This remarkable turnover is 
maintained by a small population of HSCs, which has one of the greatest 
powers of renewal of adult tissue20. Other components of the bone marrow 
include stromal cells, stromal stem cells, haematopoietic progenitor cells,
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mature and maturing white, red blood cells and platelets and their precursor 
megakaryocytes.
H a e m a t o p o e t ic  s t e m  c el l s
The HSC has the ability to both maintain itself and to differentiate into 
all cells of the blood lineage (Figure 1.5). A hierarchy exists within the system 
in which the pluripotent HSC has the greatest self-renewal and differentiation 
capacity of any haematopoietic cell. The hallmark properties of the HSC are 
the ability to balance self-renewal versus differentiation cell fate decisions to 
provide sufficient primitive cells to sustain haematopoiesis, while generating 
more mature cells with specialised capacities. Through the process of 
asymmetric cell division, a single division can result in the formation of both 
an identical stem cell and a more mature cell21. In order to assure a persistent 
pool of regenerating cells without outgrowth of immature cell types, tight 
regulation of HSC division is required. Unchecked growth of immature cells is 
thought to represent a paradigm for malignant outgrowth, at least for AML3.
As cells become more differentiated, they lose the capacity for 
self-renewal. The HSC yields committed haematopoietic progenitors which 
are restricted in their developmental potential. The common myeloid 
progenitor (CMP) produces red blood cells (erythrocytes) and platelets as well 
as the myeloid series; the monocytes, neutrophils, eosinophils and basophils. 
The common lymphoid progenitor (CLP) gives rise to cells of the adaptive 
immune system, the B, T and natural killer cells9.
HSCs have the potential to perform a variety of functions. They can 
self-renew, differentiate into a variety of specialised cells, mobilise out of the 
bone m arrow  in to  c ircu la ting  blood, undergo  apop tosis or rem ain in a
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Figure 1.5: Normal haematopoiesis
The variety of cells in normal blood is constantly being maintained by the 
haematopoietic system, a hierarchy of cells which is driven by the pluripotent 
haematopoietic stem cell which has the ability of self renew and is able to produces 
all mature cells of the blood lineage. Common myeloid and lymphoid progenitors 
have limited self renewal capacity and are restricted to differentiate into their specific 
lineages. As cells become increasingly differentiated, their ability to self-renew 
decreases as well.
Mature blood cells are broadly split into three major groups. The erythrocytes are the 
oxygen carrying red blood cells, lymphoid cells are the cornerstone of the adaptive 
immune system, primarily consisting of T-cells and B-cells. The third lineage is the 
myeloid lineage which includes the granulocytes, megakaryocytes and macrophages. 
The myeloid lineage is involved in diverse roles such as innate and adaptive 
immunity and blood clotting. (Adapted from 3)
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quiescent state. The variety of functions, especially the ability to self renew, 
make the HSC a suitable target for generation of the LSC. Therefore it is 
imperative to be able to study this rare population of cells directly. HSCs look 
and behave in culture like ordinary white blood cells and coupled with their 
low frequency it is difficult to identify them by morphology. HSCs are instead 
identified based on cell surface markers and self-renewal capacity.
Identification and isolation of HSCs
Over the years, various assays have been developed to examine 
haematopoietic stem and progenitor cells. As these assays were improved and 
progressively became more selective for stem cells, our definition of stem cells 
and understanding of haematopoiesis has developed.
The colony formation cell (CFC) assay involves the use of a semi-solid, 
methylcellulose-based medium supplemented with cytokines that promote 
differentiation and proliferation of haematopoietic progenitor cells. Long-term 
cultures of haematopoietic cells with stromal feeder layers are an attempt to 
recreate haematopoiesis in vitro. Within this system, committed cells and 
progenitors exhaust their proliferative potential within a few weeks and are no 
longer part of the culture, whereas cells with more extensive proliferative 
ability are able to form colonies beneath the stromal layer22' 23. This system is 
unable to assess for lymphoid and therefore, multilineage, potential and the 
assessment period is not excessively long. These problems were overcome by 
the development of systems which involved initially growing cells in a 
lymphoid supportive environment and subsequent transplant to a myeloid 
supportive environment2425. These systems however remain limited by 
requirements for external stimulation by cytokines and therefore do not 
replicate endogenous conditions well.
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Observing growth of cells in an endogeneous microenvironment where 
they would receive the appropriate signals would aid in overcoming these 
limitations. Xenotransplantation models involving inbred mice were 
developed which allowed the transplantation of haematopoietic cells from 
genetically similar mice to observe the growth of primitive haematopoietic for 
a significant proportion of time26'27.
Immuno-compromised mouse models offer the most suitable 
environment for the study of hum an haematopoietic cells. The severe 
combined immunodeficiency (SCID) mutation in mice causes a lack of 
functional T and B lymphocytes and with cytokine stimulation, human cells 
may develop in the marrows of these mice28. When the SCID mutation is 
combined with the non-obese diabetic (NOD) mutation, mice also have an 
impaired natural killer and antigen-presenting cell function and the growth of 
human cells in these mice is possible without cytokine stimulation29 31. Given 
ideal conditions, the NOD/SCID model can support multilineage (B-cell and 
myeloid) engraftment for over 3 months and can also support secondary 
engraftment32. In this way, the NOD/SCID assay can assess the self-renewal, 
proliferation and differentiation of hum an haematopoietic stem cells.
The mouse model has revolutionised the field by allowing further 
progress to be made into isolating the HSC. Primitive haematopoietic cells, 
including the HSCs, do not express certain cell surface markers that are 
associated with mature blood cell types. Lack of expression of a variety of 
mature lineage (Lin) markers, can therefore be used to distinguish immature 
cells from the more abundant differentiated cells33.
The expression of CD34 is commonly used to define the population of
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HSCs and early progenitors. CD34 expression is observed on the majority of 
the cells with in vivo repopulating potential, including the HSCs and long term 
repopulating cells as well as early progenitors, but not the majority of 
terminally differentiated cells. HSCs can further be defined by their patterns of 
expression of other markers. The majority of Lin-/CD34+ cells are also CD38+; 
these cells have short-term self-renewal properties and are able to yield a 
transient wave of repopulation in immunodeficient mice. Lin-/CD34+/CD38- 
cells have the ability for sustained multilineage haematopoietic reconstitution 
after transplantation into immunodeficient mice. This subset is generally 
considered to contain the HSC, although more recent research has 
demonstrated that cells with long-term repopulating ability may additionally 
reside within a Lin-/CD34- population33. The further development of more 
permissive murine models should allow for further refinement of the identity 
of human HSCs.
Extensive work has gone into further refinement and characterisation of 
specific markers on the surface of hum an HSCs, however that is beyond the 
scope of this thesis to discuss.
H S C  Fa te  C h o ic e
A HSC has the ability to self-renew, differentiate, undergo apoptosis, or 
to remain in a quiescent state. The decision to follow one of these routes is 
ultimately determined at the level of differential gene activity within the cell. 
Gaining understanding of how these processes work is important to the study 
of AML and other haematological malignancies as the dysregulation between 
self-renewal and differentiation in HSCs is an essential feature of 
leukaemogenesis.
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This sets out important questions, such as what types of mutations are 
required for this dysregulation and are there patterns of mutations commonly 
observed in AML.
Leu k a e m ia  is  a  s t e m  cell d ise a se
As described in the overview, AML is a stem cell disease where the bulk 
of the disease, the leukaemic blasts, is perpetuated by the LSC. LSCs exhibit a 
dramatic increase in self-renewal ability over normal HSCs, and a block in 
differentiation. The presence of a long-term initiating cell in leukaemia with 
the ability to self-renew in vivo was demonstrated by xenotransplant models 
into immune deficient mice3435. Leukaemia is not the only cancer which has 
been shown to have a stem cell origin, this has also been observed in brain, 
breast and more recently, colorectal cancers363738. Furthermore, it has been 
demonstrated that the majority of LSCs exist in a quiescent state39, thereby 
allowing them to escape therapies which are directed towards rapidly 
dividing cells. Leukaemia remains a useful system to study the process by 
which cancer stem cells arise due to good characterisation of the 
haematopoietic system and the HSC, and the ease of access to the cells.
S it e  o f  o r ig in  o f  t h e  LSC
A hallmark of all cancers is the capacity for unlimited self-renewal 
which is also a characteristic of normal stem cells. Due to this shared attribute, 
it has been proposed that leukaemia arises from transforming events within 
the HSC. Furthermore, if multiple mutations are required for transformation 
to a malignant state, stem cells which have greater longevity compared to 
other cell types, have sufficient opportunity to acquire the requisite genetic 
damage. Alternatively, it is possible that the LSC arises from a more restricted
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progenitor or even a differentiated mature cell which would first need to 
reacquire the ability to self renew before becoming tumourigenic (Figure 1.6)40.
It is therefore likely that AML represents aberrant haematopoiesis with 
the target cell for transformation lying within the HSC repertoire. The normal 
HSC compartment is made up of pluripotent stem cells and progenitors with 
more restricted self renewal and differentiation ability. Similarly, LSCs are not 
functionally homogeneous but comprised of distinct hierarchically arranged 
LSC classes41. Therefore characterising the LSC compartments, and examining 
how mutations affect these compartments is also important to understanding 
AML. For most AML subtypes, the only cells which are able to repopulate the 
disease within the NOD/SCID model have a CD34+/CD38- phenotype, similar 
to the normal HSC, whereas the CD34+/CD38+ leukaemic blasts cannot 
transfer the disease to the mice42 35. This however does not completely clarify 
the cell of origin which becomes a LSC.
Although the pluripotent HSC is an attractive target for transformation, 
there is experimental evidence which indicates that other types of early 
progenitor cells may serve as targets as well40. Cell populations transduced 
with a retroviral vector encoding the fusion proteins involving the mixed 
lineage leukaemia (MLL) gene could generate AML in vivo in a murine model 
of the disease. The fusion MLL-ENL was able to generate AML from 
transduction of HSCs, CMPs and GMPs. However it was not possible for 
erthyroid progenitors (MEP) to recapitulate AML. Similar studies using 
MLL-GAS743 and MLL-AF944 45 fusion proteins demonstrated that some early 
progenitor populations may give rise to AML when transformed with these 
fusion proteins (Figure 1.7).
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Figure 1.6: Site of origin of the leukaemic stem cell
The HSC is an attractive cell for the transformation into LSC, already having the 
ability to self renew and having longevity, allowing enough time for the 
accumulation of genetic events required for transformation. However the LSC could 
also arise from an early progenitor or mature cell that regains the ability to 
self-renew. Regardless of the site of origin, the bulk of the blast cells resulting would 
be the same. (Adapted from3)
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Figure 1.7: Relationship between cell type and leukaemic potential of 
various fusion proteins
Although some fusion proteins can indeed transform most stages of haematopoietic 
cell development, certain fusion proteins are only capable of transforming particular 
cell types or produce different leukaemias in different cell types. MLL-ENL can 
induce an AML in HSCs, CMP and GMP, but not MEPs. MLL-AF9 can cause AML in 
HSCs, this fusion protein cannot transform CLPs. MLL-GAS7  can cause only AML in 
CMP, GMP and MEP populations, but causes bi-phenotypic leukaemia when HSCs 
are transduced. These experiments demonstrate that the cell type is very important 
for leukaemic transformation. (Adapted from 46)
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These results confirm that the cell type is important for the 
leukaemogenic effect of certain fusion proteins. However, retroviral-mediated 
transduction of fusion proteins into various stages of haematopoiesis is a very 
artificial model and may not represent the leukaemogenic event in vivo. The 
phenotype of leukaemias generated from HSC, CMP and GMP cell 
populations is very uniform with no apparent hierarchy, in contrast to what is 
observed in AML from hum an cases. Furthermore, the frequency of AML 
initiating cells is greatly increased over what is reported for human AML cell 
populations47 48.
Ultimately, leukaemia is the result of mutations which deregulate 
normal haematopoiesis. To understand the process by which mutations are 
able to achieve this, the types and patterns of mutations that are involved must 
be examined, along with studying when and how mutations arise and their 
functional impact on normal haematopoiesis.
Le u k a e m o g e n e sis  -  T ypes a n d  Pa tte r n s  o f  m u t a t io n s
C a n c e r  is  c a u s e d  by a n  a c c u m u l a t io n  o f  g e n e t ic  e v e n t s  o v e r  t im e
Cancer arises from an accumulation of genetic and epigenetic changes 
in oncogenes and tumour suppressor genes that free cells from the 
mechanisms that control normal cell proliferation. The idea that cancer is 
caused by a series of successive somatic mutations has been supported by 
study of cancers such as retinoblastoma, in which the age of incidence is 
consistent with the requirement of two mutations or "two hits" for cancer 
development49 50. The fact that AML is a disease that primarily affects the 
elderly supports the idea of damage accumulating over time. In AML this 
damage occurs at the very least in the form of chromosomal aberrations as
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well as gene specific mutations.
Chromosomal aberrations
Unlike solid tumours which tend to have complex chromosomal 
abnormalities due to chromosome instability, the changes that are observed in 
haematological malignancies are often single translocations or numerical 
aberrations.
Gene and chromosomal deletions may involve a small part of the 
chromosome, such as the short or long arm (eg 5q-) or the loss of an entire 
chromosome (monosomy 7). Losses most commonly affect chromosomes 5, 6, 
7, 11, 20 and Y. Gains are common in chromosomes 8, 12, 19, 21 and Y. Gene 
amplifications are not a common feature of haematological malignancies.
While numerical changes in AML are not unusual, balanced 
translocations of chromosomes, where no material is gained or lost, are the 
most common chromosomal aberrations observed. To date, there have been 
approximately 300 balanced translocations described in AML51. There are two 
main mechanisms by which balanced translocations may contribute to 
malignant change, either by overexpression of a normal cellular gene due to 
the fusion of the promoter region from one gene to the protein coding region 
of another, or by the fusion of two genes to generate a chimeric gene that 
encodes a novel 'fusion protein'. In AML, balanced translocations exclusively 
result in fusion proteins.
Fusion proteins can act by a variety of mechanisms in AML. Resultant 
fusion proteins may affect transcriptional control such as in chronic myeloid 
leukaemia (CML) and acute promyelocytic leukaemia (APL). The first
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balanced chromosomal rearrangement of t(9;22), dubbed the Philadelphia 
chromosome, was observed in CML and causes a fusion of the genes BCR and 
ABL resulting in constitutively elevated tyrosine phosphokinase activity and 
subsequent deregulation of cell cycle control52 53.
APL (AML FAB type M3) is characterised by the t(15;17) translocation 
where the promyelocytic leukaemia gene PML on chromosome 15 is fused to 
the retinoic acid receptor a  gene, RARa  on chromosome 17. The resultant 
PML-RARa fusion protein functions as a transcriptional repressor whereas the 
wild-type RARa  is an activator54. However, not all translocations have 
dedicated partners; some genes such as the transcription factor MLL have 
many different fusions partners55. The functional consequence of the majority 
of fusion proteins is a block in differentiation. In the case of MLL and RA Ra , 
the primary function of various fusion partners is to promote dimerisation 
and/or homo-oligomerization of the transcription factors56 57.
Balanced translocations are often found in leukaemia, however it is 
uncertain whether these translocations alone are sufficient to cause overt 
leukaemia. Low levels of the BCR-ABL transcript are detectable in normal 
individuals58 indicating that while the translocation is important, it is not the 
only factor responsible for causing CML. Furthermore, a study on identical 
twins that developed childhood ALL demonstrated that the twins harboured 
the same TEL-AML1 translocation in utero, but had variable latency periods 
before the onset of overt disease, indicating once again that additional genetic 
events are needed before the development of overt leukaemia59.
Normal karyotype (NK) AML
While chromosomal aberrations, especially balanced translocations, are
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well characterised in AML, they are often unable to solely account for the 
formation of the disease. The 10 most common balanced translocations occur 
in approximately 15% of AMLs. The other rare recurrent balanced 
translocations are observed in only 5% of cases. Unique structural changes, 
numerical changes in chromosome number and complex abnormalities each 
contribute to approximately 10% of AMLs respectively. This leaves 
approximately 50% of AMLs with no detectable cytogenetic abnormalities 
(Figure 1.8)51.
Normal karyotype patients are generally classified as intermediate risk 
because as a group their CR rates, relapse risk and survival are worse than 
those of treated patients with favourable cytogenetics, but better than those 
with unfavourable cytogenetics10 13. However, there are patients within the 
intermediate group that have poor or favourable prognosis. The lack of overt 
chromosomal lesions makes it difficult to stratify normal karyotype patients 
into specific prognostic groups and to monitor MRD.
Gene specific mutations
Another form of genetic damage that is observed in leukaemia is gene 
specific mutations. The completion of the human genome sequence has made 
every gene accessible to mutation analysis. Gene specific mutations can alter 
both normal proliferation and differentiation. Some result in constitutive 
activation of tyrosine kinases and their subsequent pathways, or alter the 
function of transcription factors. Genes commonly mutated in AML include 
FLT3, NPM, CEBPA, RUNXI (AML1), MLL, cKIT and RAS.
The FMS-like tyrosine kinase 3, FLT3, encodes a membrane-bound 
receptor tyrosine kinase which is important in haematopoietic stem
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/progenitor cell survival and proliferation by signalling through the RAS 
pathway. It is mutated in about one third of AML patients and is also noted to 
be mutated in ALL and MDS, making it one of the most frequently mutated 
genes in haematological malignancies. FLT3 mutations present either as 
internal tandem duplications (ITD) of the juxtamembrane domain (30%) or by 
point mutations usually involving the tyrosine kinase domain (TKD) (7%). 
Both types of mutation constitutively activate FLT360 61. Due to its constitutive 
activation in the mutated form, inhibitors of FLT3 are being developed as 
therapy for use in AMLs with FLT3 mutations62.
Heterozygous mutations in the nucleophosmin gene (NPM1) have 
recently been described as the most frequent genetic abnormality in AML, 
occurring in approximately 50-60% of normal karyotype adult AMLs63. 
Transgenic mice heterozygous for Npml develop a haematological syndrome 
with features of a human myelodysplastic syndrome64 indicating that NPM1 
gene mutations are involved in leukaemogenesis although the underlying 
mechanisms are not yet fully understood.
CCA AT enhancer binding protein alpha, CEBPA, is a transcription 
factor that is involved in myeloid differentiation and proliferation control. 
Mutations in this gene have been implicated in familial cases of AML; and also 
occur in approximately 10% of somatic cases65. The function and mutations of 
this gene will be described in greater detail subsequently.
G e n e  s p e c if ic  m u t a t io n s  in  p r o g n o s is  o f  A M L
The genetic aberrations causing AML can also provide valuable 
information in regards to prognosis and treatment of the disease. AMLs with 
translocations involving the core-binding factors (typically t(8;21) and inv(16))
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Figure 1.8: Karyotype breakdown of AML
Approximately 50% of AML have no cytogenetic abnormalities. The ten most 
common balanced translocations observed in AML are detectable in approximately 
15% of cases. Rare recurrent balanced translocations, unique structural changes, 
numerical changes and complex abnormalities account for approximately 35% of 
AMLs. (Adapted from talk given by F. Mitelman at Charterhouse Square, 2007)
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tend to do well overall with therapy whereas AMLs with complex karyotypes 
and deletions in chromosomes 5 and 7 have poor overall outcome.
Mutations in certain genes are correlated with prognostic outcome. 
Mutations of KIT, CEBPA and TP53, for example, occur in 5-10% of cases of 
AML overall, but predominate in patients with 'favourable', 'intermediate' 
and 'poor risk' cytogenetics respectively66 67 68. Similarly, mutations in RUNX1 
occur with higher incidence in patients with FAB type MO or patients 
presenting with additional copies of chromosome 2169 and NPM1 mutations 
are found in AMLs with normal karyotype63.
Despite having the same karyotype, adults with de-novo NK AML are 
diverse in respect to the acquired gene mutations and gene expression 
changes. These alterations affect clinical outcome and may assist in selection of 
proper treatment. As mentioned previously, currently NK AMLs are classified 
as intermediate outcome AMLs, but research has demonstrated that the 
presence or absence of certain mutations can also be useful in segregating 
AMLs into good and poor prognostic groups5 70 (Figure 1.9).
FLT3-ITD mutation in the heterozygous state is a recognized poor 
prognostic risk factor for AML. Additionally, the loss of the wild-type FLT3 
allele occurs in ^10% of patients with normal karyotype AML and is 
associated with a worse outcome71. Recent studies have also shown that the 
size of the internal duplication of FLT3 may affect prognosis, with ITDs of over 
40bp in length having poorer outcome than those with shorter ITDs72.
Mutations in NPM1 are observed primarily within the normal 
karyotype subgroup, occurring in approximately 50-60% of all NK AMLs. 
Various studies have demonstrated that patients with NPM1 mutation, in the
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Figure 1.9: Mutations in normal karyotype AML can be useful in prognosis
Despite having the same normal karyotype, adults with de-novo NK AML are diverse 
in respect to the acquired gene mutations and gene expression changes. These 
alterations affect clinical outcome. The presence of FLT3-ITDs indicate poor 
prognosis. In the absence of FLT3-ITDs, the presence of N PM  mutations and CEBPA 
mutations are indications of favourable prognosis, while the presence of MLL-PTDs 
and high BAALC expression are indicators of poor prognosis. (Adapted from 5)
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absence of FLT3-ITD, have a CR rate similar to or significantly higher than 
patients with wild type NPM1. These studies have shown a statistical trend 
toward favourable outcome in event-free survival and overall survival in 
patients with NPM1 mutations73 74 75 76.
Mutations in CEBPA occur in approximately 15 - 20% of NK AMLs and 
are also associated with favourable prognosis77 78. Favourable prognosis 
conferred by mutations in CEBPA was initially demonstrated in patients in the 
intermediate cytogenetic risk category79 80 and later confirmed in patients with 
normal karyotype76 77 78. Patients with mutations in CEBPA are also less likely 
to have concurrent poor prognostic mutations in FLT3 and MLL-PTDs77.
Partial tandem duplication in the MLL gene (MLL-PTD) was the first 
molecular alteration shown to impact on clinical outcome of NK AML. 
MLL-PTD is detected in approximately 5-10% of cytogenetically normal adults 
with de novo AML and is associated with FLT3-ITDs74. Patients with MLL-PTDs 
have significantly shorter complete remission durations than patients without 
the mutation8182.
The overexpression of specific genes in normal karyotype AML can also 
be used in prognosis, with overexpression of BAALC78, ERG83, and WT184 all 
conferring poor prognosis.
C l a s s  I a n d  C l a s s  II c o o p e r a t i n g  m u t a t i o n s
AML is a heterogeneous disease genetically, with over 300 different 
chromosomal translocations and mutational events described85. The 
complexity of the genetic data can present difficulties in both the clinic and in 
the understanding of the disease. Grouping mutations into broad catergories
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based on their functional consequences is one way of simplifying the system.
Frequently genetically heterogeneous mutations target the same signal 
transduction and transcriptional pathways and therefore can be divided into 
groups. In an attempt to provide a more unified molecular theme to explain 
how different mutations can generate essentially similar phenotypes 
Gililland86 proposed a "two-hit" model for leukaemogenesis. This is not to be 
confused with Knudson's two-hit model of cancer development as is applied 
to retinoblastoma where two genetic events are required to completely remove 
function of the Rb gene50.
In Gililland's model, AML is the consequence of collaboration between 
at least two broad classes of mutation. Class I mutations confer proliferative 
and/or survival advantage to the cells, usually as a consequence of aberrant 
activation of signal transduction pathways. Class II mutations comprise 
mutations in transcription factors and transcriptional co-activators that are 
important for normal haematopoietic development with these mutations 
impairing differentiation (Table 1.5)86.
Class I mutations are made up of a group of proliferative mutations that 
are well recognised in myeloid disease, including activated RAS, FLT3, CKIT 
or the TEL-PDGFR and BCR-ABL fusion genes. Although there are differences 
between individual tyrosine kinases, their functions result in similarities in 
activation of downstream effectors, such as activating ST AT, PI3K and RAS 
signalling pathways. In murine models these genes cause myeloproliferation 
rather than true leukaemia86.
Chromosomal translocations in AML often target transcription factors 
and transcrip tional co-activators. The core b inding  factor (CBF) is often
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Class I mutations Class II mutations
BCR-ABL CBF|3-MYH11
N-RAS AML1-ETO
K-RAS TEL-AML1
c-KIT (exon 8 and Asp 816) PML-RARa
FLT3 (ITD and Asp 835) NUP98-HOXA9
PTPN11 PU.l
NF1 C/EBP a
TEL-PDGFR|3 AML1
AML1-AMP19
Table 1.5: Class I and Class II mutations in AML
Gilliland's "two hit hypothesis" postulates that the development of overt AML 
requires at least one mutation from each class. Class I mutations offer a survival or 
proliferative advantage to the cell, whereas Class II mutations are involved in 
blocking differentiation.
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targeted, being involved in over a dozen translocations and point mutations. 
In many cases, these Class II mutations result in a block in differentiation 
pathways or apoptotic mechanisms, causing impaired haematopoietic 
differentiation. In contrast, many of these mutations in murine models cause 
expansion of the stem cell pool rather than overt leukaemia86.
AML1-ETO is one of the most common fusion proteins observed in 
AML, however it is not able to induce leukaemia in experimental in vivo 
murine models on its own. Mice targeted to express AML1-ETO in the HSC 
compartment developed a non-lethal long-latency myeloproliferative 
syndrome but failed to develop acute leukaemia87. In a conditional AML1-ETO 
murine model the additional treatment with a mutagen was required before 
overt leukaemia developed88. To further support the two hit model, 
AML1-ETO was found to collaborate with FLT3-YID in inducing acute 
leukaemia in a murine bone marrow transplantation model89.
Gililland's two hit model suggests that a combination of both classes of 
mutations is required for leukaemogenesis, where both a block in 
differentiation and a proliferative and/or survival advantage are necessary to 
result in leukaemic transformation. Based on current large studies, the 
majority of AMLs have at least one genetic lesion described, however a 
proportion still remain with unknown genetic background.
Le u k a e m o g e n e s is  -  La ten cy  a n d  O r d e r  o f  m u t a t io n  in  d ise a se
DEVELOPMENT
In most cases of leukaemia, multiple genetic events are required before 
the overt development of disease. Examination of the blast cells provides 
information about the pattern and types of mutations that make up AML,
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however this does not give information about when the mutations arise and 
the order in which genetic events occur.
The simplest manner of examining order of mutation is by studying 
paired leukaemia samples. Changes in mutation status of genes between 
presentation and relapse may yield insight into the order by which they arose. 
A mutation which is maintained throughout the course of the disease is likely 
to have occurred early in the leukaemogenic process.
Progression of other haematological disorders to overt AML can help to 
demonstrate the requirement for accumulation of genetic damage for the 
development of disease. The progression from chronic phase to blast crisis in 
CML has been known to be associated with the gain of other mutations such as 
t(3;21)90 91. AML1-ETO fusion followed by a subsequent FLT3-ITD has been 
observed with the progression of MDS to AML92, which is also observed in 
murine models expressing these mutations89. Continuing with murine models, 
the co-expression of pairs of mutations such as BCR-ABL and AML1-EVI193, or 
PML-RARA and FLT3 m utant94 are necessary for the development of AML. 
Latency in PML-RARA knock-in mice before their development of APL 
suggests that the acquisition of new genetic lesions as necessary second 
events95. In humans, latency in AML development is best highlighted in the 
study of rare familial cases of the disease.
Fa m il ia l  A M L
Familial cases of AML, while rare, can offer insight into the more 
common sporadic cases of the disease, especially in respect to the order by 
which mutation events occur. In addition to syndromic cases of familial AML 
which are associated with certain inherited genetic syndromes, such as
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trisomy 8 and 21, single gene germline mutations can be responsible for 
predisposing families to AML96.
Familial cases of syndromes such as neurofibromatosis and Noonan 
Syndrome have been useful for discovery of mutated genes that also yield the 
syndrome if they arise sporadically. Noonan syndrome is inherited in an 
autosomal dominant manner and maps to chromosome 12q24.1. 
Approximately half of patients with Noonan syndrome carry gain of function 
mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2 which 
is involved in embryonic development that modulate cell division and 
differentiation. Subsequently this gene has also been found to be mutated in 
AML97.
Genes found to be involved in familial cases of AML include RUNX1 
(AML1), CEBPA and a yet uncharacterised gene located at 16q21-23.298. 
Germ-line heterozygous mutations in RUNX1 have been identified in familial 
AML99. Several families have also been described involving mutations in the 
transcription factor CEBPA100 101 102. These families exhibit long latency periods 
between birth and onset of the disease with up to 39 years before the 
development of AML102. All families described had normal karyotype. There 
are two main types of mutations that are observed in CEBPA, which will be 
discussed in greater detail in the CEBPA section of this introduction. 
Mutations in the 5' end of the gene result in the translation of a truncated 
isoform of the protein, mutations in the 3' end of the gene disrupt 
DNA-binding and dimerization domains in the C-terminus of the protein65. In 
familial cases of AML involving CEBPA, the germline mutation results in the 
truncated protein while additional C-terminal mutations are acquired 
somatically later in life. This manner of elucidating the order of mutations 
from familial cases can aid in understanding the molecular processes by
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sporadic cases of AML develop.
Leukaem og enesis -  Fu n c t io n  of m utatio ns
Prospective mutation screening for genes involved in AML often arises 
due to their function, whether it is an important player in differentiation or 
regulation of proliferation. Therefore besides understanding the types of 
mutations present and the mechanisms whereby combinations of mutations 
result in the development of AML, understanding how these mutations 
function is equally important.
D i s r u p t i o n  o f  D i f f e r e n t i a t i o n  -  t h e  r o l e  o f  t r a n s c r i p t i o n  f a c t o r s  in  
AML
Mutations that disrupt transcription factors in AML are classified as 
Class II mutations which block mature differentiation of haematopoietic cells. 
AML research therefore focuses on the myeloid branch of development, where 
the transcription factors PU.l, GATA1, and CEBPA play key roles (Figure 1.10).
Concentration of transcription factors
Besides simple gain or loss of function in transcription factors, the 
concentration of factors drives normal haematopoiesis and leukaemogenesis. 
A small group of transcription factors with mostly lineage-restricted 
expression have been demonstrated to play a crucial role in the control of 
normal haematopoiesis103. Amongst the best-studied examples are PU.l, 
CEBPA, AML1, GATA-1, c-myb and SCL/Tal-1. These transcription factors all 
regulate a broad range of target genes, which drive differentiation along 
different developmental pathways104. Profound haematopoietic defects were 
observed when the genes encoding these factors are knocked out in mice105' 106.
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Figure 1.10: Transcription factor involvement in myeloid development
The transcription factors PU .l ,  GATA1, and CEBPA are key players in the 
differentiation of the myeloid branch of the haematopoietic system. The common 
myeloid progenitor (CMP) differentiates into a granulocyte/macrophage progenitor 
(GMP) with the upregulation of CEBPA and is driven towards the 
megakaryocyte/erythroid progenitor (MEP) by the upregulation of GATA1 and 
downregulation of PU.l.  Terminal differentiation is also influenced by these 
transcription factors, with upregulation of CEBPA resulting in granulocytes and 
upregulation of PU .l  in monocytes from the GMP. The upregulation of GATA1 from 
the MEP results in the production of erthyrocytes. These transcription factors are 
involved in complex regulation pathways, which are beyond the scope of this thesis 
to discuss. (Adapted from 107)
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Although transcription factors are frequently mutated in AML, it is 
interesting to note that most of the mutations do not lead to biallelic 
null-mutations, as is commonly observed in solid tumours resulting in a 
complete loss of function. The mutations instead produce situations where 
residual transcription factor expression and function is preserved. 
Furthermore, many common translocations in AML cause decreased 
transcription factor expression and/or function. This implies that 
transformation from a normal HSC to a LSC is achieved in a large part due to a 
graded decrease of transcription factor activity to a critical threshold level, 
rather than by complete abolishment.
CCAAT En h a n c er  B in d in g  Protein  alpha  (CEBPA)
As has been previously mentioned the transcription factor CEBPA plays 
a key role in myeloid differentiation and is frequently found mutated in NK 
AML as well as underlying familial cases of AML. Due to the type of mutation 
progression observed within familial cases and evidence of similar mutations 
in somatic cases, we aimed to further study the function of mutations in this 
gene.
C/EBPa is the founding member of a family a group of basic region 
leucine zipper transcription factors that all bind to a similar DNA consensus 
motif. In mammals six identified C/EBPs (a, (3, y, 6, £, Q are expressed in a 
tissue-restricted manner106. These proteins share related N-terminal 
transactivating domains, basic DNA-binding regions and C-terminal 
leucine-zipper protein interaction domains. C/EBP family members are able to 
homo and heterodimerise via the leucine-zipper domains.
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The protein C/EBPa is expressed in many cell types and plays crucial 
roles in hepatocyte and adipocyte development, with highest concentrations 
of the protein occurring in terminally differentiated cells. C/EBPa is also 
expressed in intestine, lung, adrenal gland, breast, ovary and placenta 
tissues108. In haematopoiesis, C/EBPa is expressed in myeloid cells and is a key 
regulator of granulocytic differentiation65.
G e n e  a n d  P r o t e in  S t r u c t u r e
CEBPA is a single exon gene located on the minus strand of 
chromosome 19q. Although the gene is intronless; tightly regulated alternative 
start codon usage results in the generation of two protein isoforms, a full 
length 42kDa isoform and a truncated 30kDa isoform. The 30kDa isoform 
contains the same carboxyl terminus as the full-length 42kDa form, but lacks 
the first 117 amino acids. CEBPA mRNA consists of a short 5' untranslated 
region (UTR) containing a small 5' open reading frame (ORF), the coding 
region and a large 3' UTR (Figure 1.11a)109110.
The translation of the different sized isoforms of C/EBPa is governed by 
ribosome scanning under the control of the 5' ORF. This ORF is situated out of 
frame with the coding region of CEBPA and produces a small peptide (8 amino 
acids) that terminates just prior to the start codon for CEBPA. Ribosomes are 
loaded onto mRNA at its 5' end and slide along until they reach an 
appropriate Kozak sequence, where they pause and translation begins. When 
the small 5' ORF is translated, termination occurs just before the start codon 
and does not allow for sufficient time for repriming the ribosome once again. 
Thus the ribosome continues to travel along the gene until it reaches the 
second internal start codon and begins translation from there. Often the 
ribosome will skip the 5' ORF due to a less optim al Kozak sequence, and
68
a)
Start
Codon
Internal
ATG
cap 5'UTR 3 'UTR . poly A
5 'ORF
b)
TE-I
C/EBPa p42
E2F
TE-II
TAD1
TE-III
TAD2
SWI/SNF
I— --- 1P21 CDK
BR-LZ
D
DNA-binding / Dimerisation
Figure 1.11: CEBPA gene and protein
a) The translation of the different sized isoforms of C/EBPa is governed by ribosome 
scanning under the control of the 5' ORF. This ORF is situated out of frame with the 
coding region of CEBPA and produces a small peptide (8 amino acids) that 
terminates just prior to the start codon for CEBPA.
b) The basic region leucine zipper (BR-LZ) DNA-binding domain has been shown to 
mediate protein-protein interactions with other transcription factors involved in 
lineage-specific gene regulation (such as GATA1, PU.l, ETS1 and RUNX1) and 
growth control (such as c-JUN and E2F). N-terminal transactivation domains 
mediate interactions with the transcriptional machinery (TBP/TFIIB; CBP/p300; 
SWI/SNF). (Adapted from 65)
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translate from the start codon, leading to the production of the 42kDa protein, 
but the 5' ORF is necessary for the production of the 30kDa protein.
The C/EBPa protein contains several well characterised domains 
(Figure 1.11b). The C-terminal region of the protein consists of a basic region 
leucine zipper domain, in which the leucine zipper mediates 
homodimerisation of C/EBPa and its heterodimerization with other members 
of the C/EBP family. Upon dimerisation the basic region mediates binding of 
the protein to its cognate DNA sequence 
(A(-5)T(-4)T(-3)G(-2)C(-1)G(1)C(2)A(3)A(4)T(5))110. The basic region leucine 
zipper domain has also been demonstrated to be involved in protein 
interactions with other transcription factors involved in lineage-specific gene 
regulation (including E2F, GATA1, ETS1, PU1, c-JUN and RUNX165). Distinct 
N-terminal transactivation domains (defined as TE-I, TE-II and TE-III by 
Nerlov and Ziff111; TADI and TADII by Friedman and McKnight112) mediate 
interactions with transcriptional machinery. The TE-I/TE-II or TADI domain, 
which is missing in the 30kDa isoform has been shown to be involved in E2F 
repression and interaction with transcription machinery TBP/TFIIB and 
CBP/p300. The TE-III or TADII domain which is present in both isoforms has 
been found to interact with p21, the chromatin remodelling proteins SWI/SWF, 
cyclin dependant kinases CDK2 and CDK4. Several pathways have been 
implicated as the means by which C/EBPa mediates cell cycle arrest and 
proliferation, including p21, cyclin-dependent kinases and the E2F complex 
via c-Myc. The 30kDa isoform of C/EBPa lacks the domains required to 
mediate cell growth113.
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CEBPA IN LEUKAEMOGENESIS
Mutations in CEBPA
Mutations in CEBPA have been implicated in AML, most often in 
association with FAB types M l and M2, although it has also been found in M4 
and M5 types. Mutations occur in approximately 10% of all AMLs and are 
associated with normal karyotype AML. Mutations in CEBPA tend to confer 
favourable prognosis114, while low levels of its RNA expression have been 
noted in AML where it may reflect adverse prognosis. Although mutated 
CEBPA is primarily observed in AML, in rare cases it has been found to be 
mutated in MDS, lung and prostate tumours. Down-regulation of CEBPA has 
also been observed in blast crisis chronic myeloid leukaemia, lung, breast and 
liver cancers115116117.
Mutations in CEBPA tend to cluster to two regions. The first group 
affects the N-terminal region of C/EBPa. These mutations are often insertions 
or deletions which cause frameshifts which cause premature truncation of the 
protein. In this case, translation is reinitiated at an internal ATG and the 30kDa 
protein. Secondly, in-frame or missense mutations occur within the C-terminal 
region of C/EBPa, disrupting the basic zipper region and thus affecting DNA 
binding, protein interactions, as well as homo and heterodimerization with 
other C/EBP family members113.
Multiple mutations in CEBPA are common and often biallelic, although 
the allelic frequency of the mutations can change over the course of the 
disease118 80 119. Furthermore, the occurrence of both mutations on the same 
allele has been observed. Mutations are generally maintained between 
presentation and relapse and therefore may be useful for monitoring MRD.
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Regulation of CEBPA expression in AML
In AML CEBPA is rarely involved in translocations with other genes. 
However, in B-Cell Precursor Acute Lymphoblastic Leukaemia (BCP-ALL), 
along with other members of the C/EBP family of proteins, CEBPA has been 
found to be translocated to the immunoglobulin heavy chain locus 
t(14;19)(q32;ql3)120. The translocation does not affect the coding region of 
CEBPA but results in the downregulation of CEBPA expression. Additionally 
the gene retains its germline sequence.
Regulation of CEBPA expression is also commonly observed in AML 
and is ultimately heavily influenced by other common translocations. CEBPA 
expression is downregulated in the presence of fusion protein AML1-ETO 
indirectly by inhibiting positive autoregulation of the CEBPA promoter121. 
Translation of the C/EBPa protein is suppressed by the fusion gene 
AML1-MDS1-EVI1 via the activation of calreticulin122. Pericentric inversion of 
chromosome 16, inv(16)(pl3q22), which fuses the CBFB and MYH11 genes, 
with the latter encoding the smooth muscle myosin heavy chain (SMMHC) 
also suppresses translation of the C/EBPa protein via calreticulin123. The 
BCR-ABL fusion protein is able to suppress C/EBPa protein translation via 
inhibitory action of the poly(rC)-binding protein hnRNP E2124. Furthermore, 
not only do fusion proteins affect CEBPA expression, but mutations which 
constitutively activate FLT3 also inhibit C/EBPa function via ERKl/2-mediated 
phosphorylation125.
CEBPA expression levels were also found to be important in explaining 
the function of new genes implicated in leukaemogenesis. Retroviral 
transduction of Tribbles homolog 2 (Trib2) into primitive murine HSCs 
resulted in the onset of overt leukaemia in which C/EBPa was downregulated
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in transformed cells126' 127.
These examples demonstrate the importance of regulation of CEBPA 
activity in AML. Even if the gene itself is not mutated, it can still play a role in 
the leukaemogenic process.
M o d e l s  o f  CEBPA f u n c t i o n
Extensive study has been carried out on the function of C/EBPa using a 
variety of models, including mouse strains with genetic alterations in the 
CEBPA locus, transduced human cells and other animal models such as 
zebrafish.
Knock out murine strains with complete abolishment of C/EBPa 
expression results in perinatal lethality due to severe defect in glucose 
homeostasis127. The embryos suffer from differentiation defects in liver, lung 
and fat as well as lack of mature neutrophilic granulocytes128 129. To overcome 
the perinatal lethality, mouse strains with inducible knock out of C/EBPa 
results in an accumulation of blast cells in the bone marrow, blocked at the 
CMP to GMP transition, but without the development of overt leukaemia130. 
Within C/EBPa null murine HSCs, there is increased expression of the 
poly comb group gene Bmil which enhances HSC self-renewal ability. These 
cells were able to demonstrate a competitive advantage over wild type 
HSCs131.
Upregulation of C/EBPa in human cells with the potential to follow a 
granulocytic or monocytic differentiation pathway results in granulocytic 
differentiation, with a block on monocytic differentiation132. However, in the 
murine model, C/EBPa expression directs monocytic commitment of primary
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myeloid progenitors133.
The functions of the C/EBPa isoforms have also been studied although 
the data has not always concurred. Within a murine cell line, expression of the 
30kDa isoform of the protein limits G-CSF receptor expression134 which is 
necessary for myeloid development. The exclusive expression of the 30kDa 
isoform within the murine model results in increased proliferation of myeloid 
progenitor cells, resulting in either a myeloproliferative disorder or AML115. 
Furthermore, knock-in mice with a targeted mutation in the basic region that 
specifically inhibits the C/EBPa-E2F interaction, also developed AML 
symptoms115. This suggests that while disruption of CEBPA's cell cycle control 
is important for AML induction in mice, other CEBPA functions must be 
preserved.
The effect of the shortened isoform in the human system is not as well 
characterised. Expression of the 30kDa isoform in human CD34+ cord blood 
was shown to inhibit both myeloid and erythroid lineages135. In zebrafish, 
expression of the shortened isoform of C/EBPa results in an increase in 
primitive erythropoiesis136.
From the numerous studies that have already taken place, it is clear that 
the transcription factor CEBPA plays a key role in leukaemogenesis. However 
the exact mechanisms by how it contributes to leukaemia still remain unclear. 
Furthermore CEBPA mutations underlying familial AML warrants further 
study of this gene and its mutations.
Sum m ary  a n d  A im s  of T h e sis:
The importance of cytogenetics in AML is well established with
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implications for patient prognosis, treatment and options for disease 
monitoring. It is also accepted that changes at the molecular level are equally 
significant. Mutation analysis of candidate genes has been performed in a 
validated panel of AML identifying novel gene mutations and showing a 
temporal relationship between gene mutation and the occurrence of acquired 
homozygosity without copy number change.
Quantitative genomic assays have been developed for five patients with 
CEBPA mutations and used to examine the hierarchy of mutation events in the 
leukaemic stem cell pool. The functional aspect of these CEBPA mutations 
were tested by transduction of lineage depleted cord blood cells with these 
mutations to examine how they affect normal haematopoietic stem cells and 
contribute to the development of AML.
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C h a p t e r  2: M a t e r ia l s  a n d  M e t h o d s
Patient sam ples
St o r a g e  o f  S a m p l e s
Patient samples were collected and stored in the Centre for Medical 
Oncology, John Vane Science Centre, Charterhouse Square with informed 
consent. Samples arrived in either solutions of RPMI with heparin or in an 
EDTA solution to prevent clotting. Samples in EDTA were diluted with RPMI 
before processing. Whole mononuclears were enriched by density 
centrifugation. 5mL of lymphoprep (Axis-Shield PoC, Oslo, Norway) were 
added to a 15mL tubes (Coming, Sigma-Aldrich, Dorset, UK) and lOmL of the 
blood sample were layered on top with a plastic pipette. Samples were then 
centrifuged at room temperature for 25 minutes at 1500 rpm (Beckman GS6R, 
Beckman Coulter, Fullerton, USA) with no break. The layer of white blood 
cells was removed and diluted in lOmL of RPMI. The tubes were then spun at 
1300rpm for 10 minutes, high brake. Supernatant was discarded and cells were 
gently resuspended in an appropriate amount of freeze mix (final 
concentration of 10% DMSO) and transferred to cryovials. Cryovials were 
stored in liquid nitrogen. Various checks were carried out to insure fidelity of 
the sample.
DNA i s o l a t i o n  -  P h e n o l / C h l o r o f o r m
Genomic DNA from patient samples was extracted by standard 
phenol/chloroform methodology. In brief, cells were thawed rapidly and 
diluted with ice cold PBS and then pelleted by centrifugation. The cells were 
then resuspended in 1-2 m l  digestion buffer (recipe at end of this chapter)
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with added proteinase K and incubated at 55°C for 12-18 hours.
After incubation, an equal volume of phenol was added to the cell 
solution, mixed thoroughly by shaking and then spun for 10 minutes at 3000 
rpm. The aqueous supernatant was removed to a fresh tube without 
disturbing the interface. An equal volume of phenol/chloroform (ratio 1:1) was 
added, mixed well by shaking, and then spun for 10 minutes at 3000 rpm. 
Again, the aqueous supernatant was removed to a fresh tube, to which an 
equal volume of chloroform was added, mixed and spun. The supernatant was 
removed for a final time and DNA was precipitated by the addition of 3 M 
sodium acetate, pH 5.2, followed by 2 volumes of 100% ethanol. DNA was 
either immediately spooled out of solution or left to percipitate at -20°C for 30 
min to overnight before being spun down. DNA was then washed with 70% 
ethanol and resuspended in TE buffer.
DNA ISOLATION -  MC LYSIS BUFFER
In cases where there was insuffient number of cells for 
phenol/chloroform extraction genomic DNA was isolated via this method. 
Recipe for lysis buffer is provided at the end of this chapter. 50 pL of buffer was 
added to cells. Cells were incubated at 60°C for one hour and then at 95°C for 5 
minutes. DNA was stored at -20°C.
M utation  S c reening
S in g l e -s t r a n d  c o n f o r m a t io n a l  p o l y m o r p h is m  (SSCP) m u t a t io n
SCREENING
Mutation analysis of CCND3 was carried out by single-strand 
conformational polymorphism (SSCP) analysis (GenePhorll, Pharmacia
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Biotech, Amersham, UK). Precast 24-well 0.43 acrylamide gels (ETC, 
Elektrophorese-Technick, Kirchentellinsfurt, Germany) were rehydrated with 
20mL of SSCP Rehydration buffer, pH 8.3 (ETC, Germany), for an hour. 
Rehydration buffer was initially optimised by running a test sample using 
each of the three available buffers (pH 7.4, pH 8.3 and pH 9.0) and selecting the 
buffer system which yielded the clearest bands.
All patients samples with normal cytogenetics were screened for 
mutations in CCND3. Each exon of CCND3 (1-5) was amplified by PCR 
(primers and conditions at described at the end of this chapter). 1.5pL of PCR 
product was mixed with 4.5pL of formamide denaturing buffer (recipe at end 
of chapter), heated at 95°C for 5 minutes and then placed on ice. 6pL of 
product was loaded into each well of the rehydrated gel. Electrophoresis was 
carried out at 12°C beginning with 80V for 20 minutes, and then 510V until 
completion. Gels were then stained using the PlusOne DNA silver stain kit 
(Pharmacia-Biotech, Amersham, UK) on a Hoefer automated gel stainer 
(Amersham Biosciences, UK) following manufacture's instructions. Samples 
which appeared different from the others were sequenced.
WAVE MUTATION SCREENING
PCR reactions were preformed as described at the end of the chapter.
Denaturing high performance liquid chromatography (DHPLC) analysis
DHPLC was carried out using a Transgenomic WAVE Nucleic Acid 
Fragment Analysis system and DNASep column (Transgenomic, Crewe, UK). 
The composition of buffer A was 0.1M triethylammonium acetate (TEAA); 
buffer B contained 0.1M TEA A and 25% acetonitrile. Analysis was carried out
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at a flow rate of 0.9mL/min and a buffer B gradient increase of 2%/minute for 4 
minutes. Start and end concentrations of buffer B were determined empirically 
for each fragment. The column was run at two temperatures for each fragment. 
Temperatures are listed at the end of the chapter.
PCR products were prepared for DHPLC by denaturing at 95°C for 5 
minutes and then cooling slowly to 65°C to allow heteroduplex formation. 
Data analysis was by visual inspection of chromatograms, which were 
examined independently by two observers. Samples from which 
chromatograms were unusual were brought forward for sequencing.
D ir e c t  S e q u e n c in g
Direct sequencing was used to screen for mutations in CEBPA, FLT3, 
PU.l, RUNX1, WT1 and CCND3 in the aUPD study. The genes were amplified 
by PCR covered the coding regions indicated and directly sequenced.
DNA SEQUENCING -  SLAB AND CAPILLARY GEL
Unincorporated primers and dNTPs were removed from PCR products 
by ultra-filtration using Montage PCR centrifugal filter devices (Millipore 
corp., Bedford, MA, USA). Using the PCR product as template, a dideoxy 
chain termination method was used137, with fluorescently tagged terminators 
and AmpliTaq DNA Polymerase enzyme (PE Applied Biosystems, Foster City, 
CA, USA). PCR conditions are provided at the end of the chapter.
For sequencing with the ABI377 sequencer (Applied Biosystems, Foster 
City, CA, USA) the sequencing gel was prepared as outlined at the end of the 
chapter (Slab Gel). The products of the sequencing PCRs were recovered by
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ethanol/EDTA/sodium acetate precipitation. 2pL of 3M sodium acetate 
solution (pH 5.2), 2pL of 125mM EDTA and 50 jliL  of 100% ethanol were added 
to each sequencing reaction, vortexed and left at -20°C for 15 minutes to 
precipitate the extension products. The extension products were then 
pelleted by centrifugation at 14000 rpm in a bench-top centrifuge (Eppendorf 
Centrifuge 5417R) for 20 minutes and the supernatant aspirated and 
discarded. The pellets were washed with lOOpL of 70% ethanol and air-dried.
The pelleted sequencing reactions were re-suspended in 4pL 
MICROSTOP loading buffer (Microzone Ltd, Haywards Heath, UK), 
denatured at 95°C for two minutes and held on ice until loaded. 1.5pL of the 
denatured sequencing products were loaded per lane of a polyacrylamide 
sequencing gel, separated by electrophoresis and read by fluorescent detection 
on an ABI377 sequencer (Applied Biosystems, Foster City, USA).
Sequencing reactions carried out on the Applied Biosystems Prism 3730 
were purified using DyeEx 2.0 Spin Columns (Qiagen, Crawly, UK). Columns 
were vortexed to resuspend the matrix and then spun for 3 minutes at 750g. 
The sequencing PCR was then applied to the compacted column and again 
spun for 3 minutes at 750g. The purified samples were then dried using a 
vacuum centrifuge (DNA Speed Vac, DNA120; Savant). Samples were run on 
the Prism 3730 as a service provided by CRUK.
DNA SEQUENCE ANALYSIS
Sequencing data were analysed using the Editseq sequence editing, 
Seqman II sequence assembly/contig management and Megalign 
multiple/pair-wise sequence alignment software (DNASTAR Inc, Madison, 
Wisconsin, USA), or visually analysed by examining the sequencing traces in
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the 4Peaks program (http://mekentosj.com/4peaks/).
DNA sequences generated were compared with the sequences 
deposited in the Genbank Database using the National Centre for 
Biotechnology Information (Bethesda, USA) BLAST database searching 
facilities via the internet (http://www.ncbi.nih.gov). The Ensembl database 
(http://www.ensembl.org) was also used for interrogation of the human 
genome.
Real time PCR
The real-time PCR assays and their analysis were carried out using the 
ABI Prism 7700 Sequence Detector System (ABI/Perkin Elmer, Foster City, CA, 
USA). All the reactions were carried out in duplicate with the following 
conditions: an initial 50°C for 2 minutes and 95°C for 10 minutes, followed by 
40 cycles of a two stage PCR, consisting of 95°C for 15 seconds and 60°C for 
one minute. (3-2-microglobulin (|32M) was used as endogenous reference gene. 
Analysis was carried out using the software provided with the ABI Prism 
7700.
All real-time PCR reactions were carried out using Taqman technology. 
A probe is conjugated with a fluorescent reporter dye (TAMRA) on its 5' end 
and a quencher on the 3' end. The probe anneals to a sequence between the 
primer set. As the DNA is amplified the polymerase degrades the probe and 
the fluorescent dye is released from the influence of the quencher and 
produces a signal.
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Cl o n in g
A g a r o s e  G el v is u a l iz a t io n
DNA fragments were separated for analytical and preparative purposes 
by agarose gel electrophoresis, using Flowgen or Horizon 58 (Gibco, BRL - 
Paisley, Scotland, UK) gel electrophoresis apparatus tank apparatus. The 
electrophoresis solution used was IX Tris-Borate-EDTA (TBE) buffer with 
ethidium bromide at 0.5pg/mL. Agarose (Life Technologies, Paisley, Scotland, 
UK) diluted to 1% in IX TBE buffer was melted and upon cooling ethidium 
bromide solution added to a final concentration of 0.5pg/mL. The gels were 
cast into trays and an appropriately sized comb was used to form the loading 
wells.
Samples were loaded into the wells with 1/10 volume of gel loading 
buffer. Gels were electrophoresed at 100V and the appropriate DNA size 
ladder (lkb ladder - Gibco BRL, Paisley, Scotland, UK) was run in parallel. 
DNA was visualised by transillumination with ultraviolet light and 
photographed as a permanent record.
R e s t r ic t io n  En z y m e  D ig e s t s
DNA was suspended at approximately lpg/pL in the appropriate lx 
buffer, and digested with 1-10 fold excess of the appropriate restriction 
endonuclease (New England Biolabs, Hitchen, UK). For non-end cutting, 1 
unit of enzyme being sufficient to cut lpg  of DNA when digested for 1 hour, 
and 10 units for cutting near the ends of DNA under the same condition. The 
digests were incubated at the recommended temperature (usually 37°C) for 
1-16 hours as appropriate, the endonuclease heat inactivated and the digestion 
products stored at -20°C. The products of digestion were analysed by
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separation of an aliquot of the digest using agarose gel electrophoresis, as 
described above.
G el p u r if ic a t io n
Restriction enzyme digest products were run on a 1% agarose gel. The 
bands of the appropriate size were excised using a clean scalpel with all efforts 
to keep exposure to UV light minimal. Qiagen Gel Purification kit (Qiagen) 
was used to recover the digested DNA following manufacturer's protocol. 
Final elution volume was 30pL.
TA LIGATION
CEBPA was cloned into Topo 2.1 vector by TA ligation (Invitrogen). A 
final extension of 10 minutes at 72°C adds an A base overhang on the PCR 
products. The prepared vector contains T overhangs. The ligation reaction was 
carried out according to manufacture's instructions, with 0.5-4pL of PCR 
product ligated with lpL of Topo 2.1 vector in saline conditions for 5 minutes 
at room temperature. lpL  of the subsequent reaction was transformed into 
ToplO cells (Invitrogen), as described below.
S h r im p  a l k a l i n e  p h o p h a t a s e  (SAP) t r e a t m e n t
To prevent vector cut with a single restriction enzyme from reannealing 
during ligation reaction, the vector was treated with SAP enzyme (Promega, 
Madison, USA) to remove the phosphate group from the 5' overhangs, 
lunit/pg of DNA was incubated for a minimum of 15min at 37°C in lx  SAP 
reaction buffer. SAP was inactivated by heating to 65°C for 15min.
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T4 R e a d y -t o -g o  l ig a t io n
Cut vector and insert was ligated using Ready-To-Go T4 DNA ligase 
(Amersham Bioscience, Little Chalfont, UK). 50ng of vector was annealed with 
an appropriate amount of insert to achieve a 2:1 molar ratio between vector 
and insert in a final volume of 20pL. The DNA mix was added to the ligase 
tube and incubated at room temperature for 3-5mins, mixed and incubated at 
16°C for 30mins, followed by heat inactivation at 70°C for lOmins.
G a te w a y  C r o s s o v e r
Large genes were transferred into the lentivirus vector (LNT/Sffv-cddB 
MCS, Figure 2.1, plasmid a kind gift from Dr Adrian Thrasher)138 by the 
gateway cloning system (Invitrogen) which uses site-specific recombination 
properties of bacteriophage lambda. 150ng of destination vector (lentivirus 
vector) and 300ng of entry clone (pENTRlA vector) were incubated with the 
recommended amount of 5x LR Clonase Reaction Buffer (4pL) in a 20pL 
reaction along with 4pL of LR Clonase enzyme mix. Reactions were incubated 
at 25°C for 1 hour. 2jnL of Proteinase K solution was added to terminate the 
reaction, incubating at 37°C for lOmin. lpL was transformed into ToplO cells.
C l o n i n g  s t r a t e g y  f o r  m u t a n t  f o r m s  o f  CEBPA i n t o  l e n t i v i r u s
BACKBONE
A schematic of this cloning strategy is shown in Figure 5.3.
CEBPA from patient AML sample was cloned into a Topo 2.1 vector 
(Invitrogen) by first performing nested PCR on patient genomic DNA and 
using the TA cloning kit (Invitrogen). This approach was possible since CEBPA 
is an intronless gene. The plasmid was transformed into Top 10 cells, and
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Figure 2.1: Lentivirus vector used for expression of mutant forms of CEBPA
Key features of this lentivirus vector include ampicillin resistance for perpetuating 
the plasmid in bacteria, a mammalian SFFV promoter, HIV elements to allow for 
recombination into the genome of the target cell and recombination sites (attR) for 
cloning of the target gene into the vector.138
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colonies were picked based on blue/white selection. The plasmids were 
recovered by miniprep and tested for presence of the appropriately sized 
insert. Positive plasmids were then screened for mutations by direct 
sequencing from the Topo 2.1 vector (M13 sequencing primers). Plasmids 
which contained the proper m utant combinations were selected for further 
analysis. This step resulted in the appropriate mutant forms of CEBPA within 
the Topo cloning vector.
GFP expression was used to give a visual indicator of transduced cells. 
Enhanced GFP along with an internal ribosome entry site (IRES) was first 
cloned into the pENTRlA vector. The source of the IRES-eGFP was a modified 
pBluescript vector. Both pENTRlA and pBKSiresGFP were digested with 
EcoRI and NotL IRES-eGFP was recovered by gel purification and the vector 
pENTRlA was treated with SAP to ensure that the vector would not self 
anneal in cases of insufficient double digestion. The insert and vector were 
ligated using T4-ready to go ligation enzyme (Invitrogen) and transformed 
into ToplO cells. Plasmids were recovered and their authenticity tested. This 
step produced an entry vector containing IRES-eGFP.
The mutant forms of CEBPA from the Topo plasmids were then cloned 
into the pENTRlA-ires-GFP plasmid. A FLAG tag was added to the 
C-terminal end of the protein to allow differentiation between endogenous 
C/EBPa and introduced forms of the protein. Restriction enzyme digestion 
sites were introduced to the ends of the gene to allow for directional cloning; 
(Forward primer 5'-agtctggatcctcgccatgccgggagaactctaac-3' Reverse primer 
5,-attatggatccttatttatcgtcatcgtctttgtagtccgcgcagttgcccatggcctt-3/) The gene was 
amplified from the Topo vector using a high fidelity Taq polymerase 
(TaKaRa). The pENTRlA-ires-GFP plasmid and CEBPA PCR product were 
digested with appropriate restriction enzymes, with the vector undergoing
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additional treatment with SAP. Vector and insert were ligated and 
transformed into ToplO cells, the plasmids were recovered and tested for 
proper cloning. At this point, the entire length of CEBPA was sequenced to 
insure that no point mutations were introduced from the PCR steps. This step 
produced a plasmid with the m utant CEBPA gene along with GFP in the 
pENTRlA backbone.
The prepared pENTRlA-CEBPA-ires-GFP plasmid was recombined 
with the lentivirus vector, delivering the gene and GFP into the lentivirus 
backbone (Figure 2.1). Once again the entire length of the gene was sequenced 
to insure fidelity of the gene and mutation sequences. A mock construct was 
also made by recombining IRES-eGFP the lentivirus backbone. This final 
construct contained the m utant CEBPA gene along with IRES-eGFP within the 
lentivirus backbone.
Bacterial Cultures
T r a n s f o r m a t io n  in t o  T o p IO c el l s
One to two microlitres of plasmid were transformed into 50 pL of 
chemically competent Top 10 (Invitrogen) cells according to manufacturer's 
protocol. Briefly, DNA was incubated with the cells on ice for half an hour and 
then heat shocked at 42°C for 30 seconds. Two hundred and fifty microlitres of 
SOC media was added to the cells and incubated with shaking at 37°C for 1 
hour. Fifty and 200pL were plated onto LB agar plates containing the 
appropriate antibiotic and incubated overnight at 37°C. If the plasmids 
contained |3-lactose reporter gene, X-gal (20mg/mL) was added to the plates 
for blue/white selection.
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P l a s m id  P r e p a r a t io n s
Bacterial cultures were grown in LB broth supplemented with either 
50pg/mL of kanamycin or lOOpg/mL ampicillin in a 37°C shaking incubator.
Miniprep
Plasmid recovery from small amounts of bacterial culture (3mL) was 
carried out using Wizard® Plus Minipreps DNA Purification System 
(Promega) following manufacturer's instructions. Final elution volume was 
50pL of ddFLO.
Maxiprep
For purification of up to 500 pg of transfection grade plasmid DNA, 
QIAGEN Plasmid Maxi Kit was used, following manufacturer's instructions.
Megaprep -  endotoxin free
For purification of up to 2.5mg advanced transfection grade plasmid 
used in lentivirus production, QIAGEN EndoFree Plasmid Mega Kit was used, 
following manufacturer's instructions.
G ly c ero l  S t o c k s
Bacteria were stored at -80°C in 15% glycerol.
W estern  blo tting
P r o t e in  is o l a t io n
Pelleted cells were resuspended in 100-200pL of cell lysis buffer (recipe
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provided at end of chapter) and incubated on ice for 20 minutes. The solution 
was then spun at 4°C for 15 minutes at 14000 rpm and supernatant which 
contained the protein was collected. Protein concentration was measured by 
means of a chromatic assay in which a dye reagent (Biorad, Hercules, USA) 
changes colour in response to various concentrations of protein.
The standard curve was made by diluting commercial lyophilised 
bovine serum albumin (BSA, NEB) to concentrations ranging from 0-lmg/mL 
in double distilled water. 5pL of the standards and unknown samples were 
added to 250pL of 1:4 diluted Biorad dye reagent in a flat bottomed 96 well 
plate. Protein concentration was measured by plate reader at a wavelength of 
595nm.
L o a d in g  a n d  r u n n in g  t h e  g e l
For C/EBPa, 12% SDS-PAGE gel was chosen for good resolution of the 
42 and 30 kDa proteins. 1mm gels were prepared (end of chapter for recipe) 
and assembled using Biorad mini-PROTEAN gel electrophoresis system 
(Biorad, Hercules USA). Protein was mixed with loading buffer (end of 
chapter for recipe), denatured by boiling for 5 minutes at 95°C and kept on ice 
until ready to load. Once loaded, the gel was run at 80V for 10 minutes and 
then at 120V until completion. Each time a molecular weight marker (broad 
range kalediscope prestained ladder, Biorad) was run along side samples to 
allow for the identification of bands.
T r a n s f e r  a n d  b l o t t in g
To continue the western blotting, the protein was transferred from the 
gel to a solid membrane. The separated protein was transferred onto a
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Hybond-C membrane (Amersham Pharmacia) using mini Trans-Blot system 
(Biorad) in lx  transfer buffer, 4°C for 16h at 34V.
The membrane was blocked with 5% Marvel milk in TBST (lx TBS + 
0.05% Tween, TBS recipe provided at end of chapter) for 1 hour at room 
temperature, on a rocking shaker. The membrane was then washed 3 times 
with fresh TBST, with 5 minutes for each wash. Primary antibody was added 
at optimized dilutions (1:1000 for all C/EBPa antibodies; Santa Cruz 
Biotechnology, Santa Cruz USA) to 5% BSA in TBST and applied to the 
membrane for 1 hour, room temperature on a rocking shaker, or for overnight 
at 4°C on a rotating shaker. The membrane was then again washed three times 
as described above. Secondary antibody (1:2500 dilution, Pierce 
Biotechnology, Rockford USA) conjugated to horse radish peroxidase was 
added to 5% milk in TBST at appropriate dilution and applied to the 
membrane for 1 hour, room temperature on a rotating incubator. The 
membrane was then finally washed 3 times with fresh TBST for 10 minutes 
each on a rocking incubator.
The westerns were visualised by enhanced chemiluminescent (Pierce 
Biotechnology) and exposed to film (Kodak, Switzerland) for various lengths 
of time. Film was developed using a Hoeffman automatic developer.
Cell culture
M a in t a n e n c e  o f  a d h e r a n t  cells
293T and HeLa cells were maintained in Dulbecco's Modified Eagle's 
Medium (DMEM, Gibco Invitrogen) high glucose, supplemented with 10% 
fetal calf serum (FCS, Gibco Invitrogen) and 1% penicillin/streptomycin
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(CRUK) in cell culture treated flasks (Falcon, BD Bioscience, Oxford UK) in a 
5% CO2 incubator. Cells were maintained at healthy growing densities. To 
split cells, media was removed from the cells by aspiration and cells were 
washed with PBS. Trypsin (CRUK) was added to the cells and incubated for 5 
minutes at 37°C. FCS was added to stop the reaction and cells were spun at 
1300rpm with high break applied. Cells were resuspended in media and 
counted on a haemocytometer. An appropriate number of cells were 
perpetuated in fresh media.
St e m  cell p u r if ic a t io n
Stem cells were extracted from hum an umbilical cord blood. Informed 
consent was obtained from mothers awaiting caesarean section at the obstetric 
units of the Royal London Hospital, Whitechapel, London and the University 
College Hospital, Camden, London. Blood was extracted from the placenta 
and umbilical cords with a 20mL syringe and immediately supplemented with 
heparin (Sigma Aldrich, Dorset, UK) to a final concentration of lmg/mL in 
50mL falcon tubes. Tubes were transferred to the laboratory and stored 
overnight on a rocker at room temperature for extraction of stem cells on the 
next day.
The cord blood was diluted 1:4 with sterile PBS. Thirty-five mL of 
diluted cord blood was carefully layered on top of 15mL of Ficoll-paque plus, 
a solution of Ficoll 400 and Distrizoate Sodium with a density of 1.077g/mL 
(Stem Cell Technologies, Meylan, France) in a 50mL tube. Tubes were spun at 
400g for 30 minutes with no brake applied. Mononuclear cells which form a 
layer at the interphase of serum and ficoll were collected with a Pasteur pipette 
into new tubes. Cells were spun and then resuspended in a suitable volume of 
PBS supplemented with 2% FCS (to be referred to as 2% FCS) and at least three
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times the volume of ammonium chloride solution (Stem Cell Technologies, 
Meylan, France) for red cell lysis. The cells were stored on ice for five minutes, 
after which 2mL of foetal calf serum was added to stop cell lysis. Cells were 
spun again and resuspended in 2% FCS and counted on a haemocytometer.
L in e a g e  D e p l e t io n
Mononuclear cells isolated from hum an cord blood were depleted of 
cells expressing mature lineage antigens using the StemSep column system 
from Stem Cell Technologies (Meylan, France). Cells were diluted to 8x107 
cells/mL in 2% FCS. lOOpL of StemSep enrichment cocktail was added per mL 
of cells. The enrichment cocktail contains monoclonal antibodies for CD2, 
CD3, CD14, CD16, CD19, CD24, CD56, CD66b and Glycophorin A. An 
additional aliquot of lOpL/lmL cells of CD41 antibody was added to enhance 
depletion of platelets. After incubation on ice for 30 minutes 60pL/mL of 
thoroughly vortexed magnetic colloid was added. Following an additional 
incubation of 30 minutes on ice, cells were processed through a metal mesh 
column suspended in a strong magnetic field according to the manufacturer's 
recommendations. The flowthrough of the column, containing unmarked 
lineage negative cells was collected in 2% FSC. The cells were spun, counted 
and either frozen in FCS supplemented with 10% dimethyl-sulphoxide 
(DMSO, Sigma) or used immediately for transduction or transplantation. The 
column, containing the lineage positive cells, was washed with 2% FCS and 
the cells were either discarded, or frozen down and used as accessory cells in 
transplantation experiments.
T r a n sie n t  t r a n sf e c t io n  of  293T  cells
293T cells were transiently transfected with lentivirus plasmid
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containing the CEBPA clones to test for protein expression. Poly(ethylenimine) 
(PEI lmg/mL) was used as a transfection reagent, using a ratio of 1:1 between 
PEI and DNA. Transfection was performed in serum-free media (Optimem, 
Gibco Invitrogen). PEI was first mixed with 5% final transfection volume of 
media and left at room temperature for 5 minutes. DNA was added to 5% final 
volume of transfection. PEI and DNA were then mixed and left for 20 minutes 
at RT and then added to the cells. Cells were left in transfection media for 4 
hours in normal incubation conditions. The transfection media was then 
aspirated and replaced with standard growth media. Media was changed 24h 
after transfection and cells were harvested either 48 or 72h post transfection by 
scrapping into ice cold PBS. For western blotting, cells were pelleted, 
supernatant removed and stored at -20°C until use. For other assays cells were 
removed from the plate by trypsin.
Intracellular  St a in in g
Cells were resuspended to a concentration of lxlO6 in 500pL of PBS. 
500pL of RT 4% Paraformaldehyde was added and left to incubate for 15 
minutes at RT (final concentration 2% PFA). Cells were washed by adding 
3-4mL of PBS and spinning at 1300rpm for 7 minutes (low break). Supernatant 
was aspirated and cells were resuspended in 500pL of PBS. 500pL of 0.2% 
Triton-XlOO (Tx) was added and cells were left to incubate at RT for 10 minutes 
(final concentration 0.1% Tx). Cells were washed twice as described above and 
resuspended in 50pL 2% FCS. Primary antibody (14AA anti-C/EBPa, Santa 
Cruz) was added to the cells to a final concentration of lpg  /million cells and 
incubated for 1 hour at RT. Cells were washed and resuspended in 50pL 2% 
FCS. Secondary antibody conjugated to a fluorochrome (antirabbit-APC) was 
added to a final concentration of lpg/million cells and incubated at RT for 45 
minutes in the dark. Cells were washed, resuspended in 500jnL 2% FCS and
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analysed by flow cytometry (FACSCalibur, BD Biosciences, FL1-H channel for 
GFP, FL4-H channel for APC).
Le n t iv ir u s  P r o d u c t io n
The viral vector used to transduce lineage depleted cord blood cells was 
produced by transient transfection of three plasmids into 293T cells, the 
self-inactivating transfer vector plasmid containing the gene of interest (Figure 
2.1), a multideleted packaging plasmid and pMD.G which provides the viral 
envelope139.
A total of 4 x 106 293T cells were seeded in as 175cm2 flask 3 days prior 
to transfection. Cells were cultured in DMEM with 10% FCS, 1% penicillin and 
streptomycin in a 5% CO2 incubator. 17.5pg of the envelope plasmid, 32.5jag of 
packaging plasmid and 50pg of transfer vector plasmid were precomplexed 
with polyethylenimine (PEI, Sigma) in a 1:1 ratio of DNA to PEI in lOmL of 
Optimem media at room temperature for 20 minutes. The DNA plus PEI 
complexes were added to the cells with the addition of 15mL of Optimem, 
resulting in a final volume of 25mL. In general 6 flasks were transfected with 
the same viral vector at one time. The cells were incubated at 37°C for 4 hours, 
after which the media was replaced with fresh supplemented DMEM. After 24 
hours, the media was replaced with fresh media. After 48 hours the medium 
was harvested and cleared by filtering through 0.45nm filter. Virus was 
concentrated by spinning for 3 hours at 25,000rpm in a Beckman 
ultracentrifuge. After spinning, the supernatant was removed and 50pL 
Stemspan media (Stem Cell Technologies) added to the pellet, which was left 
to resuspend on ice for 1 hour. The virus was then aliquoted into lOOpL 
fractions, with 30pL being saved for titration purposes. This harvesting and 
concentrating procedure was also followed for 72 and 96 hours following
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transfection. If greater production was required, 12 flasks were used instead of 
6 .
To titre the virus, 50,000 HeLa cells were plated into each well of a 12 
well tissue culture treated plate (Falcon) in a volume of lmL normal growth 
media. Serial dilutions of the virus ranging from 1/100 to 1/100,000 for each 
day were prepared and added to the cells. After 72 hours the cells were 
analysed for GFP expression by flow cytometry on a FACScalibur (BD 
Bioscience, San Jose USA). Virus titre was calculated based on percentage of 
GFP positive HeLa cells.
T r a n s d u c t io n  o f  L in - c el l s
Lineage depleted cord blood mononuclears (Lin- MNCs) were 
aliquoted into 96 or 48 well flat bottom tissue culture plates at a concentration 
of 5 x 105/n iL  in Iscove's Modified Dulbecco's Medium (IMDM, Gibco) 
supplemented with cytokines (SCF, IL-6, FLT3) and left to activate under 
normal growth conditions (37°C, 5% CO2) for 4 hours.
Thirty virus particles were added for every Lin- MNC. If the change in 
the volume of the well was great, additional cytokines were added to maintain 
correct concentration. Cells were left to transduce with the virus for 16h under 
normal growth conditions. Following transduction, cells were checked for 
blebing (a sign of apoptosis) and washed twice in 2% FCS. Cells were counted 
again and used immediately for in vivo (NOD/SCID xenotransplantation) and 
in vitro (methylcellulose assays) experiments. Any remaining cells were 
analysed by flow cytometry (FACScalibur) for GFP expression to determine 
the efficiency of transduction.
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M e t h y l c e l l u l o s e  A ssa y
One thousand virus transduced Lin- MNCs were added to each mL of 
H4434 Methocult media (Stemcell Technologies) supplemented with 1% 
penicillin/streptomycin. Cells and media were vortexed gently to ensure even 
distribution of cells throughout the viscous media. lmL of methylcellulose and 
cells were dispersed into a 35mm cell culture plate (Falcon) using a lmL 
syringe and blunt end needle. All samples were plated in duplicate and 
maintained in high hum idity conditions. Plates were left for 14 days under 
normal growth conditions and then colonies were scored by visualisation 
under an inverted microscope.
S c o r in g  m e t h y l c e l l u l o s e  a s s a y s
Methylcellulose assays only allow us to infer the cell of origin and are 
therefore retrospective in nature. By observing the type of colony present, the 
cell of origin can be determined. More primitive cells are able to give rise to 
larger colonies of mixed cell types. Colonies are categorised based on the 
morphology of the cells. Figure 2.2 shows examples of the various colony 
types that have been observed in the assay. They can be assembled into the 
following 5 categories, BFU-E, CFU-E, GM, G and M.
BFU-E: Burst form ing unit-erythroid
BFU-E colonies are composed of at least three clusters of tightly packed 
cells. The colonies vary in size and arise from primitive erythroid progenitors 
that have a high proliferative capacity. The cells remain nucleated and are 
distinguishable by a red colour produces as they become haemoglobinised 
(Figure 2.2a, Figure 2.3).
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CFU-E: Colony form ing unit-erythroid
CFU-E colonies consist of one or two clusters of erythroid cells and 
represent more mature erythroid progenitors than BFU-E. These have less 
proliferative capacity than BFU-Es (Figure 2.2b) and they can also be 
distinguished from myeloid cells based on the presence of red-colouration.
G: Granulocyte
Clonogenic progenitors of granulocytes give rise to a homogenous 
population of eosinophils, basophils or neutrophils. The colonies are 
colourless with individual cells smaller in size than macrophages (Figure 2.2c).
M: Macrophage
Homogenous, colourless macrophage colonies are composed of cells 
which are notably larger than granulocytes or erythrocytes. Macrophages also 
tend to grow in sheets rather than clusters distinguishing them from 
granulocyte colonies (Figure 2.2d).
GM: Granulocyte, Macrophage
The progenitors of these colonies are able to give rise to a mixed 
population of macrophages and granulocytes and are thus of a more primitive 
cell. The colonies are colourless and can vary greatly in size. They are 
comprised of a tight centre of granulocytes surrounded by a halo of 
macrophages, although diffuse colonies are also observed (Figure 2.2e).
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a) BFU-E (erythroid)
b) CFU-E (erythroid)
c) G (myeloid
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d) M (myeloid)
e) GM (myeloid)
Figure 2.2: Examples of colonies types observed on methylcellulose plates
Colonies observed on methylcellulose plates are scored based on morphology. Each 
colony type observed in the assay is shown at a magnification of 50x and lOOx. Please 
see text for descriptions of colonies.
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a)
Figure 2.3: Scoring myeloid versus erythroid colonies
The simplest way to distinguish myeloid from erythroid colonies is through 
haemoglobin contained within erythroid colonies. Erythroblasts reach maturity by 10 
to 12 days and can be distinguished by the reddish color displayed. After day 14, the 
colony may appear brownish due to the lysed erythroblasts.
a) Erythroid (left) and myeloid (right) colonies under normal light (50x)
b) The same colonies under a cone aperture of light to highlight the difference in 
colour between the colonies.
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Xe n o t r a n s p l a n t  M o d e l
NOD/SCID and NOD/SCID (32 mice are maintained under sterile 
conditions in the animal facility at CRUK. Prior to engraftment experiments 
mice were sublethally irradiated (375 rads, cesium-137 source). Cells were 
injected via tail vein in a volume no greater than lOOpL 2% FCS. Analysis of 
human and AML engraftment from NOD/SCID xenotransplant model was 
carried out by flow cytometry.
H a r v e s t  o f  m u r in e  BM
Twelve weeks following transplantation, mice were sacrificed by 
cervical dislocation. Femurs, tibias and pelvis were dissected from the mice 
and stored in RT PBS. Bones were flushed into lmL of RT PBS in a 5mL 
snap-top polystyrene tube (BD Pharmingen, San Diego). Both ends of each 
bone were removed to provide an opening and an insulin syringe (microfine 
(29G), BD Pharmingen, San Diego) containing lmL of RT PBS was inserted 
into one end of each bone and the lumen of the bone was washed with 
medium pressure. Flushing was repeated twice for both ends of the bone until 
the bone appeared relatively white.
Red blood cells were lysed by cooling the cell suspension solution on ice 
for 5 minutes and then adding 3mLs of cold ammonium chloride solution 
(Stem Cell Technologies, Vancouver, BC, Canada) for 5 minutes at 4°C. The 
lysis reaction was stopped by adding 0.5mLs of FCS. Cells were spun down 
and resuspended in cold 2% FCS. Cells were stored on ice until ready for 
antibody labeling.
1 0 1
A n t ib o d y  La b e l l in g
A mix of human specific FITC-conjugated anti-CD19, PE-conjugated 
anti-CD33 and PerCP-conjugated anti-CD45 antibodies was prepared (5pL / 
sample / antibody for all stains and compensation/isotype controls; all 
antibodies from BD Pharmingen, San Diego). Also prepared were FITC, PE 
and PerCP single color compensation control tubes (5mL snap-top polystyrene 
as before) and a combined FITC/PE/PerCP matched isotype control tube. 
Fifteen pL of the antibody mix was aliquoted into each tube of a fresh set of 
tubes for antibody labeling. Forty pL of each cell suspension was dispensed 
into the appropriate antibody labeling tube and left to label for 30 minutes at 
4°C. Cells were washed in 2mL 2% FCS and resuspended in 500pL of 2% FCS 
supplemented with a cell impermeant DNA dye for live/dead discrimination, 
either lOOng/mL 4,6-diamidino-2-phenylindoiole (DAPI, UV excited, 
Sigma-Aldrich, St. Louis) or TOPRO-3 (HeNe (633nm) excited, Molecular 
Probes Inc., Eugene, OR).
Fl o w  C y t o m e t r y
Flow cytometry analysis was conducted on a BD LSRII (BD Bioscience, 
San Jose, USA) using CellQuest software (BD Biosciences). Subsequent 
analysis was preformed with Flowjo software (Ashland USA). Lasers and 
bandpass filters required for analysis are listed in Table 2.1.
During analysis, the photomultiplier gains were set so that the 
background signal from the combined isotype control gave 1-5% positive cells 
in each collection channel. Compensation amount was set according the 
detected spectral overlap. To analyse the engraftment, 4 dotplots were drawn 
as in A, B, C and D in Figure 2.4 (440/40nm vs sidescatter (SSC), forward 
scatter (FSC) vs SSC, 695/40nm vs SSC and 530/30nm vs 575/26nm). Dead cells
1 0 2
Laser Bandpass Filter Fluorochrome
488nm (blue) 440/40 DAPI
530/30 FITC
575/26 PE
660/20 Topro-3
695/40 PerCP
780/60 PE-Cy7
633nm (red) 660/20 APC
Table 2.1: Lasers and bandpass filters required for flow cytometry analysis 
on engraftment and sorting of cells
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were excluded from the analysis via a region (Rl) around the live, unstained 
cells as in Figure 2.4A. These cells were displayed on a FSC vs SSC plot and the 
lymphoid and myeloid cells were selected for further analysis but debris was 
excluded via a region (R2) as in Figure 2.4B. Cells that fell into the first 2 
regions were displayed on a 695/40nm vs SSC plot and generous region 
around the CD45-PerCP positive cells was drawn as in Figure 2.4C (R3). These 
CD45+ cells were displayed on a CD19-FITC vs CD33-PE (530/30nm vs 
575/26nm) dotplot and quadrants were drawn to define FITC+/PE cells and 
FITC/PE+ cell subsets as in Figure 2.4D. The scatter characteristics of cells was 
confirmed as consistent with myeloid (high FSC and SSC, example in Figure 
2.4E) and lymphoid (low FSC and SSC, example in Figure 2.4F (in this example 
there are no CD19+ cells)). Engraftment was classed as myeloid leukaemia if a 
population of CD45+/CD33+ cells was present without an accompanying 
CD45+/CD19+/CD33_ cell population.
For analysis of human cell engraftment (as in virus transduced CB 
MNC), bone marrow was harvested and analysed in the same manner as for 
AML engraftment. Figure 2.5 gives an example of the dot plots for analysis, 
layed out in the same manner as described in Figure 2,4. Lymphoid 
engraftment is apparent in this sample (Figure 2.5D).
Sorting  of leukaem ia  sam ples in to  stem  cell a n d  early
PROGENITOR POPULATIONS
P r e p a r a t io n  o f  s a m p l e s  a n d  a n t ib o d y  l a b e l in g
Leukaemia samples were removed from liquid nitrogen, rapidly 
thawed and washed in 50mL of ice cold 2% FSC. Cells were spun down at 4°C, 
resuspended in lm L of 2% FSC and counted. Cells were passed through a
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Figure 2.4: Analysis of AML engraftment in murine xenotransplant model
See text for description of figure.
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Figure 2.5: Analysis of human cell engraftment in murine xenotransplant 
model
See text for description of figure.
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70 pm cell strainer (Falcon) to remove any clumps.
A mix of hum an specific FITC-conjugated Lineage cocktail, 
PerCP-conjugated anti-CD34, PE-Cy7-conjugate anti-CD38, PE-conjugated 
anti-CD123 and APC-conjugated anti-CD45RA antibodies was prepared (5pL / 
sample / antibody for all stains and compensation/isotype controls; all 
antibodies from BD Pharmingen, San Diego).
Also prepared were FITC, PE, PerCP, PE-Cy7 and APC single color 
compensation control tubes (5mL snap-top polystyrene as before) and a 
combined isotype control tube. Leukaemia cells were incubated with antibody 
for 30 minutes at 4°C. Cells were washed in 2mL 2% FCS and resuspend in 
5 0 0 jliL  of 2% FCS supplemented with DAPI.
S o r t in g  C ells
Cells were sorted by FACS Aria system (BD Biosciences) with assistance 
of the FACS department at CRUK. Lasers and bandpass filters required to 
analyse this set of fluorochromes are listed in Table 2.1. Compensation and 
isotype controls were set up as described above. Cells were sorted into three 
subsets that correspond to distinct compartments in non-malignant 
haematopoiesis, HSC (CD34+/38-), CMP and GMP (Figure 2.6). Populations 
were sorted based on the lack of lineage markers in all cases, the stem cells 
express CD34 cell surface marker, but not CD38 (Lin-/CD34+/CD38-). The 
CMPs and GMPs express CD34, CD38, and CD123 and are distinguished by 
presence (GMP) or absence (CMP) of CD45RA. Cells were sorted into FCS and 
then recovered by centrifugation.
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Figure 2.6: Sorting leukaemia samples into subsets that correspond to stem 
and early progenitor population
Leukaemia samples are sorted based on the presence or absence of cell surface 
markers. The leukaemia sample is stained with fluorescent conjugated antibodies, 
including a cocktail of mature lineage markers, CD34, CD38, CD123 and CD45RA. 
HSCs are sorted for absence of mature lineage markers (Lin-), presence of CD34(+) 
and absence of CD38(-). CMP and GMP populations are Lin-/CD34+/CD38+/CD123+ 
with GMP expressing CD45RA(+) and CMP without.
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PCR PRIMERS, REACTION MIXES AND CONDITIONS
Standard PCR reactions
Unless otherwise stated, all PCR reactions were performed on PTC-225 
DNA Engine Tetrad automated thermocyclers (MJ Research, Watertown, 
Massachusetts, USA) in thin walled PCR tubes. PCR mixes were assembled on 
ice at the bench or in a laminar airflow hood using dedicated pipettes and filter 
tips. The PCR reactions were visualised by resolving the DNA fragments on a 
1% agarose gel as previously described. All primers were generated by 
Sigma-Aldrich (Gillingham, UK). Real time probes were generated by Applied 
Biosciences (Mumbai, India).
Mutation Screening
Primers
Name Primer sequence (5'-3')
Reaction
Mix*
annealing 
temperature (°C)*
CCND3
Exon 1 F ccctgcctgttcgctgcccga A 58
Exon 1 R tccagacccgggagcggtgg
Exon 2 F gctccagacccagcagtga A 55
Exon 2 R gggagacaatagctgtcggg
Exon 3 F ccactgaccccaccctttc A 55
Exon 3 R gcaaaaatgtgcatagggctc
Exon 4 F ctcatggttccctttcctcct A 57
Exon 4 R atgaatggagaggctgctgc
Exon 5 F cactcttctcccatgttccca A 52
Exon 5 R actccagagggcctctccag
CEBPA
IF tcgccatgccgggagaactctaac B 60
1R cctgctgccggctgtgctggaac
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2F cttcaacgacgagttcctggccga B 60
2R agctgcttggcttcatcctcct
3F ccgctggtgatcaagcagga B 60
3R ccggtactcgttgctgttct
4F caaggccaagaagtcggtggaca B 60
4R cacggtctgggcaagcctcgagat
FLT3
Exon 14-15 F gcaatttaggtatgaaagccagc A 56
Exon 14-15 R ctttcagcattttgacggcaacc
Exon 20 F ccaggaacgtgcttgtca A
Exon 20 R tcaaaaatgcaccacagtgag
PU.l
Exon 1 F tcacccagggctcctgtagctca B 62
Exon 1 R tcgtgggcaggcaggcaggcgtcc
Exon 2 F tgatggggaccagcgtgcggggt B 62
Exon 2 R tctctccagaccccaggaccaggc
Exon 3 F actataaccttttcctgccctgcc B 62
Exon 3 R agcctgtgtcagcttcctgtgaag
Exon 4 F tgcactccttctctccccagctgacc B 62
Exon 4 R acacacacgcgactcggtggcgtg
Exon 5 F ccgggcccctgtgcgtacgcaagg B 62
Exon 5 R ccgggagcgtcctccctgtgtccg
RUNX1
Exon 3 F gcctgtcctcccaccaccctctc B 60
Exon 3 R agctgcttgctgaagatccg
Exon 4 F gtgggtttgttgccatgaaacg B 58
Exon 4 R catccctgatgtctgcatttgtcc
Exon 5 F cccaaggaatctgagacatggtcc B 58
Exon 5 R tgttcaggccaccaacctcattc
WT1
Exon 7 F gacctacgtgaatgttcacatg A 60
Exon 7 R acaacacctggatcagacct
Exon 8 F cctttaatgagatccccttttcc A 58
Exon 8 R ggggaaatgtggggtgtttcc
Exon 9 F tgcagacattgcaggcatggcagg A 58
Exon 9 R gcactattccttctctcaactgag
Exon 10 F acttcactcgggccttgatag A 50
1 1 0
Exon 10 R gtggagagtcatacttgaaag
^Reaction mixes are listed immediate beneath. Annealing temperature listed takes 
place of x temperature in listed programs below.
Reaction Mixes
Mix A
Reagents Concentration Volume
Template 50-100 ng/pL 2 pL
Primer 1 20 pM 0.05 pL
Primer 2 20 pM 0.05 pL
dNTPs 25mM each 4 pL
Buffer lOx 2.5 pL
Pic Taq 5U /pL 0.25 pL
dELO To 25 pL
lOx buffer (Promega, Madison, USA), Taq (Perkin Elmer, Foster City, CA; Cancer
Research, London, UK), dNTPs (Cancer Research UK, London UK)
Mix B
Reagents Concentration Volume
Template 50-100 ng/pL 2 pL
Primer 1 20 pM 0.5 pL
Primer 2 20 pM 0.5 pL
dNTPs 25mM each 2 pL
Buffer lOx 2.5 pL
MgCh 25 mM 1.25 pL
DMSO stock 1.25 pL
Taq polymerase 5U/pL 0.1 pL
dEEO To 25 pL
Taq and lOx Buffer from Invitrogen (Paisley, UK)
PCR Programs Mutation Screening
CCND3
Step Temp (°C) Time (min)
1 96 2:00
2 96 0:30
3 x 0:30
4 72 0:30
5 Go to 2, 34 times
1 1 1
6 72 10:00
7 4 Hold
8 End
Annealing temperatures (x) are given in primer chart above.
CEBPA
Step Temp (°C) Time (min)
1 95 2:00
2 95 1:00
3 60 0:40
4 72 1:00
5 Go to 2, 39 times
6 72 10:00
7 4 Hold
8 End
FLT3
Step Temp (°C) Time (min)
1 94 3:00
2 94 0:30
3 56 1:00
4 72 2:00
5 Go to 2, 34 times
6 72 10:00
7 4 Hold
8 End
PU.l
Step Temp (°C) Time (min)
1 95 5:00
2 95 0:40
3 62 0:40
4 72 1:30
5 Go to 2, 34 times
6 72 10:00
7 4 Hold
8 End
1 1 2
RUNX1
Step Temp (°C) Time (min)
1 94 2:00
2 94 0:30
3 X 0:30
4 72 0:30
5 Go to 2, 34 times
6 72 10:00
7 4 Hold
8 End
Annealing temperatures (x) are given in primer chart above.
WT1
Step Temp (°C) Time (min)
1 92 2:00
2 92 0:45
3 X 1:00
4 72 1:30
5 Go to 2, 29 times
6 72 10:00
7 4 Hold
8 End
Annealing temperatures (x) are given in primer chart above.
WAVE analysis for FES mutation screening
Reagents Concentration Volume
Template 10 ng/pL 2 pL
Primer 1 100 pmol/ pL 0.05 pL
Primer 2 100 pmol/ pL 0.05 pL
dNTPs lOOx 0.1 pL
Amplitaq buffer II lOx 1 pL
MgCh 25 mM 1.2 pL
Amplitaq Gold 0.1 pL
dH2Q To 10 pL
Amplitaq Gold, buffer and dNTPs from Applied Biosystems (Foster City, USA)
Primers
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Exon Primer sequence PCR conditions DHPLC analysis 
temperature (°C)
13 tggaggacacagcccttcta AT6 6 63, 6 6
acaagtggggaatcagatgg
14 gggtaggaagcggagaagag touchdown 63, 6 6
ctgtgccatgcagtgtaacc
15 + 16 ccaagctcttctcccatcat touchdown 63, 6 8
gggccctaggggtataggta
17 cagcttttgtccttggcttt touchdown 61, 64
catggagtccagggtagaca
18 actcacgctgcctcacct AT6 6 62,65
gaaggttggcattaagggagt
19 tcatggtatcccccagagtc touchdown 63, 6 6
tgtcagcatatgagctggag
AT6 6  (FES)
Step Temp (°C) Time (min)
1 95 1 2 : 0 0
2 95 0:30
3 6 6 0:30
4 72 0:30
5 Go to 2 , 35 times
6 72 1 0 : 0 0
7 15 Hold
8 End
Touchdown (FES)
Step Temp (°C) Time (min)
1 95 1 2 : 0 0
2 95 0:30
3 60 0:30
4 72 1 : 0 0
5 Go to 2 4 times
6 95 0:30
7 60-0.5/c 0:30
8 72 1 : 0 0
9 Go to 6  19 times
1 0 95 0:30
1 1 50 0:30
1 1 4
1 2 72 1 : 0 0
13 Go to 10,15 times
14 72 1 0 : 0 0
15 15 hold
16 End
Sequencing
Template and Reaction Concentrations
Template Quantity used 
per reaction 
(ng)
Double Stranded 150-200
PCR Templates:
1 0 0 - 2 0 0  bp 1-3
200-500 bp 3-10
500-1000 bp 5-20
1 0 0 0 - 2 0 0 0  bp 10-40
Reaction Mix
Reagents Amount
Template (see above)
Primer 3.2 pmol
Terminator Ready Reaction 
Mix*
8.0 pL
dH2Q To 20 pL
*used at stock concentration for slab gels and 1:16 dilution for capillary gels 
*Big Dye Terminator v3.1 (PE Applied Biosystems, Foster City, CA, USA)
Sequencing PCR Program
Step Temp (°C) Time (min)
1 96 1 : 0 0
2 96 0 : 1 0
3 50 0:05
4 60 4:00
5 Go to 2, 24 times
6 4 hold
1 1 5
Real Time PCR reaction
Standard Real-time PCR
Reagents Amount (25pL reaction)
DNA varies
TaqMan Universal PCR master mix 12.5pL
Forward primer 300nM
Reverse primer 300nM
Probe 200nM
(Master Mix from Applied Biosystems, Foster City, CA, USA)
For visualization
Reagents Amount (25pL reaction)
DNA (lOOng/pL) 5pL
TaqMan Universal PCR master mix - 
UNG
12.5pL
Forward primer (lOOng/pL) 5pL
Reverse primer (lOOng/pL) 5pL
(Master Mix from Applied Biosystems, Foster City, CA, USA)
All the reactions were carried out in duplicate with the following 
conditions: an initial 50°C for 2  minutes and 95°C for 10 minutes, followed by 
40 cycles of a two stage PCR were used, consisting of 95°C for 15 seconds and 
60°C for one minute. |32M was used as an endogenous reference gene (forward 
primer, 5'ggaattgatttgggagagcatc; reverse primer, 5'caggtcctggctctacaatttactaa; 
probe, 5'agtgtgactgggcagatcatccaccttc). Analysis was carried out using the 
software provided with the ABI Prism 7700.
Nested PCR for CEBPA cloning
Using TaKaRa LA Taq (taq, buffer, dNTPs) kit (Takara Bio Inc, Shiga, Japan)
Reagents Concentration Volume
Template3 50-100 ng/pL 2.5 pL
Forward Primerb 10 pmol/ pL 0.5 pL
1 1 6
Reverse Primerb 10 pmol/ pL 0.5 pL
dNTP mixture 2.5 mM each 4 pL
LA PCR Buffer II lOx 2.5 pL
LA Taq 5 units/ pL 0.25 pL
dHiO To 25 pL
a: First round genomic DNA with a concentration of 50-100ng/pL is used. Second 
round, PCR product of first round PCR is used as template
b: First round CHR19P1 (5' -  TTGCCCAGATGAAACTGCTTCTTTACTGCG - 3’) and 
CHR19P4 (5’ -  CTGGAATTAGCACTGAACTCAGAGGGTTTG - 3').
Second round CEBPA IF and CEBPA 4R (as above).
Round 1
Step Temp (°C) Time
(min)
1 95 1 : 0 0
2 1 0 0 0:05
3 98 0:05
4 60 1 : 0 0
5 62 1 1 : 0 0
6 Go to 2 , 34 times
7 72 1 0 : 0 0
8 4 hold
Round 2
Step Temp (°C) Time
(min)
1 95 1 : 0 0
2 1 0 0 0:05
3 98 0:05
4 60 1 : 0 0
5 62 3:00
6 Go to 2, 34 times
7 72 1 0 : 0 0
8 4 hold
1 1 7
S o l u t io n s  a n d  recipes
Analytical or equivalent grade chemicals were obtained from Sigma, 
UK or BDH, UK. All buffers and solutions used de-ionised water as the diluent 
and were sterilised by autoclaving or filtration as appropriate.
Electrophoresis
lOx TBE electrophoresis buffer (1L1
108g Tris base
55g boric acid
40mL 0.5 M EDTA, pH 8.0
Working stock = lx
Agarose gel electrophoresis loading buffer (lOx)
25mM EDTA 
50% glycerol(v/v)
0.25% bromophenol blue (w/v).
Slab Sequencing Gel (50mLl 
5mL lOx TBE 
45mL Acrylamide Mix 
250pL 10% APS 
30 pL TEMED
Western Blotting
Cell Lysis Solution (lOmL)
lOmL CelLytic-M Mammalian Cell Lysis/Extraction Reagent (Sigma)
1 Complete Mini, EDTA-free Protease Inhibitor Cocktail Tablet (Roche 
Diagnsotics)
1 1 8
12% Resolving Gel (20mLl 
6 .6 mL dHzO
8.0mL 30% (w/v) acrylamide/0.8% bisacrylamide (UltraPure Protogel. 37.5:1; 
National Diagnosis)
5.0mL 1.5M Tris (pH 8 .8 ) (45.4g/250mL Trizma base, pH with HC1)
0.2mL 10% SDS (w/v 50g/100mL)
0.2mL 10% APS (w/v 1.5g/100mL, prepare fresh)
8.0 pL TEMED
5% Stacking Gel (4mL)
2.7mL dH20
670pL 30% (w/v) acrylamide/0.8% bisacrylamide
500pL 1.0M Tris (pH 6 .8 ) (30.3g/250mL Trizma base, pH with HC1)
40 pL 10% SDS 
40 pL 10% APS 
4.0pL TEMED
6 x Loading Buffer 
0.225M TrisCL (pH 6 .8 )
50% glycerol 
5% SDS
0.05% bromophenol blue 
0.25M DTT
lOx Running Buffer (1L1 
30g Trizma base 
144g Glycine 
lOg SDS
1 1 9
pH to 8.5
working stock = lx
Transfer Buffer (2L)
22.5g glycine 
4.84g Trizma base 
400mL methanol
lOx TBS (ID  
24.2g Trizma base 
80g sodium chloride 
pH to 7.6
working stock = lx
TBST (2D 
200mL lOx TBS 
lOmL 10% Tween
Blocking Solution 
5% marvel milk in TBST
Primary Antibody Solution 
5% BSA in TBST
Secondary Antibody Solution 
5% marvel milk in TBST
Bacteria Culture
LB-Agar
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LB-Broth 1 litre (CRUK)
15g bacto-agar
Melt then cool to 50°C prior to addition of antibiotics. Pour into petri dishes 
and leave to set at room temperature in laminar airflow hood. Dry plates in 
37°C incubator 2-3 hours before use.
Xzgal
Stock solution 2 0 mg/ml. 0.2g dissolved in 10ml of N,N-Dimethylformamide. 
Filter, sterilise through a 0.4pm filter and store at -20 °C.
Ampicillin
Stock solution 50mg/ml. Filter, sterilise through a 0.4pm filter and store at 
-20°C. Use at a final concentration of O.lmg/ml in media.
Kanamvcin
Stock solution 50mg/ml. Filter, sterilise through a 0.4pm filter and store at 
-20°C. Use at a final concentration of 0.05mg/ml in media.
Cell Culture
MC colony lysis buffer (20mLl
910pL Protease K (20mg/ml) (must be added fresh)
lOOpL Tween 20
lOOpL NP40
800pL 250mM Tris pH 7.5 
18.09mL dH20
Miscellaneous
TE buffer pH 7.4 or pH 8.0
lOmM Tris-HCl (pH titrated with 10M NaOH)
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ImM EDTA pH 8.0
Digestion Buffer for DNA extraction
lOOmM NaCl
lOmM Tris.Cl, pH 8
25mM EDTA, pH 8
0.5% SDS
SSCP loading buffer 
4.75ml formamide 
125pl 1% bromophenol blue 
125pl 1% xylene cyanol
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C h a p t e r  3: O c c u r r e n c e  a n d  Pa t t e r n s  o f
GENE-SPECIFIC M UTATIONS IN NORM AL KARYOTYPE 
ACUTE MYELOID LEUKAEMIA
Brief in t r o d u c t io n  a n d  d e s c r ip t io n  o f  stu d y
Cytogenetic analysis is important for the clinical management and 
prediciting prognosis in AML140 142. However, approximately half of all AMLs 
have normal karyotype. The lack of overt cytogenetic markers prevents risk 
stratification or minimal residual disease monitoring in these patients. These 
NK patients form a heterogeneous disease group with variable responses to 
therapy. They are classified as intermediate risk due to having worse outcome 
than those with favourable prognosis, but better than those with poor 
prognosis. While NK AML may appear to be the same on the chromosomal 
level, there is significant variation in this group at the molecular level. This 
molecular variability has been substantiated over the years with the discovery 
of gene-specific mutations and changes in gene expression levels that affect the 
clinical outcome of NK AML patients70. We are reaching a point therefore 
where the characterisation of mutations should be categorised at diagnosis in a 
similar manner to cytogenetic testing which has become part of the standard 
clinical routine in treatment of AML.
Aside from these clinical applications, documenting the mutations
1 2 3
which are present in NK AML can provide novel insights into the process of 
leukaemogenesis.
In this chapter, we have set out to examine the patterns and 
relationships between gene-specific mutations in NK AML. To accomplish 
this, we performed mutation analysis on a panel of 8 8  NK AML patient 
samples for genes known to be mutated in AML.
Ex a m in in g  M u t a t io n  S ta tu s  o f  N o r m a l  K aryotype  A M L
P a t t e r n s  o f  m u t a t io n s  in  NK AML
All samples screened were collected and analysed in accordance to the 
Local Research Ethics Committee. These 8 8  patients consisted of a cross section 
of age and FAB types. APL was excluded from this study due to the unique 
nature of this leukaemia. All other FAB types were represented except for MO 
(Table 3.1). Eighty-one of the samples were taken at diagnosis, 7 were taken at 
relapse. Samples were of peripheral blood (PB) in 55 cases, bone marrow (BM) 
in 13 cases and leucopheresis product in the remaining 20. All samples had 
undergone density centrifugation for mononuclear cell enrichment prior to 
cyropreservation.
Initially, to validate the patient panel, six genes previously implicated 
in AML were screened for mutations. Comparing the mutation frequencies 
observed for these genes in our panel to published frequencies would indicate
1 2 4
Total 8 8
Gender % M:F 51:49
Age (years) median 53
FAB type MO -
M l 35
M2 2 2
M4 19
M5 1 0
M6 2
Table 3.1: Characteristics of the normal karyotype panel
A panel of 88 patients with normal karyotype AML was validated by screening for 
genes known to be involved in leukaemogenesis. All FAB types were represented 
except for MO and M3. This panel was subsequently used for prospective screening 
of novel gene involvement in AML.
1 2 5
whether our panel and methodology was robust enough to be used to search 
for novel gene mutations.
The initial six genes screened were FLT3 (exons 14-15 and 20), CEBPA 
(entire coding region), RUNX1 (exons 1-5), NRAS  (exons 1 and 2), cKIT (exons 
8  and 17) and PTPN11 (exons 3 and 13). PCR for each exon indicated were 
carried out using DNA recovered from patient samples as template. Mutation 
detection was undertaken by single strand conformational polymorphism 
(SSCP). The amplified exons from patients were denatured to single strand 
fragments and then run through thin acrylamide gels. Under certain 
conditions, single stranded nucleic acids form secondary structure in solution. 
The secondary structure depends on the base composition and may be altered 
by a single nucleotide substitution. These substitutions result in a change in 
electrophoretic mobility under non-denaturing conditions. Fragments were 
detected by silver staining. When unusual banding patterns were observed the 
samples were directly sequenced for the gene and exon in question.
A total of 6 6  mutations in 56 patients were observed. Forty-seven 
patients had a single mutation (53%), 8  patients had two mutations (9%), one 
patient had 3 mutations (1%) and no mutation was observed in 32 patients 
(36%). The frequency of mutated genes was comparable to previously 
published screening studies143, validating this panel for further mutation 
screening.
More recently 2 additional genes, NPM1 (exon 12) and WT1 (exons 2-10)
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were investigated using a PCR direct sequencing approach to further refine 
the mutation profile of this cohort of patients. The addition of these genes to 
the screening panel increased the percentage of normal karyotype patients 
with a detectable mutation from 64% to 85% (75/88), with 54 mutations in 
NPM1 and 7 mutations in WT1 being added to the panel (Figure 3.1).
This panel now provides a more complete overview of the types of 
mutations that occur and the associations between these mutations in NK 
AML. Nearly half of the patients screened contained mutations in more than 
one gene (45%), supporting the idea that multiple genetic events are required 
for the onset of leukaemia (Figure 3.2). In our panel of 8 8  patients, 35 patients 
had a single mutation (40%), 28 patients had two mutations (32%), 11 patients 
had three mutations (12.5%) and one patient had four mutations (1%).
According to Gilliland's two-hit hypothesis, mutations affecting 
proliferation and self-renewal capacity (Class I) in association with mutations 
causing blocks in differentiation (Class II) are required for overt 
leukaemogenesis86. Based on the published functional properties of these gene 
products, we classified FLT3, NRAS, KRAS mutations as Class I and CEBPA, 
RUNXI, NPM1, WT1 mutations as Class II. In our panel of NK AMLs, 44% 
(39/88) of patients have mutations in genes from each mutation class, 32% 
(28/88) have Class II mutations alone and 9% (8 /8 8 ) had mutations restricted to 
Class I mutations (Figure 3.3).
1 2 7
NPM
FLT3 ITD
NRAS
CEBPA
RUN XI
FLT3 TKD
KRAS
CCND3
Total Patients Screened = 88
Figure 3.1: Gene specific mutations in Normal Karyotype AML
A panel of eighty-eight normal karyotype AML patients was screened for mutations 
in NPM  (exon 12), FLT3 (exons 14-15, ITD and 20, TKD), CEBPA (entire coding 
region), WT1 (exons 2-10), RUNX1  (exons 1-5), CCND3 (exons 1-5), NRAS  (exons 1 
and 2), KRAS (exons 1 and 2), cKIT (exons 8 and 17), and PTPN11 (exons 3 and 13) 
(no mutations were observed and therefore these genes were not included). Red bars 
indicate the presence of mutation, blue indicates a normal sequence for the particular 
gene.
1 2 8
two mutations
31.8%
three mutations
12.5%
no mutations 
14.8%
one mutation
39.8%
Figure 3.2: Most NK AMLs have mutations in more than one gene
A total of 128 mutations were identified in the 88 patients. Thirteen patients had no 
mutations in any of the genes screened, 35 patients had one mutation, 28 patients 
had two mutations, 11 patients had three mutations and one patient had four 
mutations.
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No mutations
Class I mutations 
|  9.1%
Class II mutations
31.8%
Figure 3.3: Class I and Class II mutations appear to cooperate in NK AML
It has been postulated that for leukaemia to arise, cooperating mutations that result 
in both the deregulation of proliferation (Class I) and block in differentiation (Class 
II) are required. In our study, 44.3% of patients screened had at least one mutation in 
each class.
1 3 0
MUTATIONS OCCUR IN A NON-RANDOM MANNER
In our screening panel, mutations in FLT3-YTD are observed more 
frequently in association with mutations in NPM1 than not. Of the 30 
FLT3-ITDs, 21 occur along with NPM1 mutations, with only 9 occurring 
without an associated NPM1 mutation. This association has also been 
described in other studies144. Similarly, NRAS  mutations are most commonly 
seen in patients with coexisting NPM1 mutations. Mutations in FLT3 and 
NRAS  are nearly always mutually exclusive, with only one patient of the 44 
displaying mutations in both of these genes. The negative association of NRAS  
and FLT3 mutations has also been reported in previous studies68. This mutual 
exclusion may indicate that NRAS  and FLT3 are individually sufficient for the 
deregulation of proliferation control required in leukaemogenesis.
M u ta tio n  s c r e e n in g  o f  n o v e l  g e n e s
Although the majority of patients in our panel were found to have at 
least one mutation in the eight genes screened, 15% (13/88) had no detectable 
genetic lesion, indicating that novel mutations are likely to be present in these 
patients. Two further candidates, CCND3 and FES, were selected for mutation 
analysis in our series of cases.
Cyclin D3 (CCND3)
Cell cycle regulation is driven by the cyclin family of proteins, working
in conjunction with cyclin-dependant kinases (CDKs) at various stages of the
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cell cycle. Cyclin D3, located on 6p21, plays a crucial role in the positive 
regulation of cell proliferation. CCND3 was chosen as a candidate gene for 
mutation screening because of its reported interaction and negative regulation 
of RUNX1 (AML1)145' 146. Cyclin D3 was identified to negatively regulate the 
transactivation activity of RUNX1 in a dose-dependent manner in competition 
with CBFp, leading to a decreased binding affinity of RUNX1 for its target 
DNA sequence145.
Cyclin D3 also interacts with other proteins that have been implicated 
in leukaemogenesis. The D type cyclins are regulated by the RAS/MEK/ERK 
pathway, with RAS an important mutational target in AML. Additionally, 
CCND3 knockout mice die in utero at 14-15 days of gestation due to defective 
haematopoietic and neuronal differentiation demonstrating the impact of 
CCND3 in normal haematopoiesis147. Cyclin D3 expression levels have also 
been used as a prognostic marker in other haematological malignancies such 
as follicular lymphoma, chronic lymphocytic leukaemia and large B-cell 
lymphoma148151. In addition, it is targeted for translocation to various partner 
genes in mature B-cell malignancies and multiple myeloma152' 153 and a variety 
of solid tumours154*156.
Eighty-six norm al karyo type  AML sam ples w ere screened for
mutations in all five exons of CCND3 via SSCP analysis as described above
(Figure 3.4). Samples which exhibited unusual SSCP traces were investigated
for mutation by direct sequencing of PCR products. Thirty-five samples were
selected for direct sequencing based on abnormal banding patterns. Direct
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Figure 3.4: Examples of SSCP gels for CCND3 screening
Single strand conformational polymorphism was used to screen all exons of CCND3. 
Each exon is amplified by PCR, the fragments then denatured and run on a thin 
acrylamide gel. Alterations in the DNA sequence caused by mutations can change 
the conformation of the fragment, causing it to migrate differently from wild type 
products. Bands were visualised by silver staining and traces which appear different 
from the majority were tested for mutations by direct sequence analysis.
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sequencing was required to exclude mutation in exon 1 (n=7 tested), exon 3 
(n=5), exon 4 (n=6) and exon 5 (n=16). No abnormal SSCP patterns were 
observed for exon 2.
A single in-frame 51 bp deletion of nt 940-990 (Genbank, NM_001760) in 
exon 5 resulted in the deletion of amino acids 259-275 
(AQTSSSPAPKAPRGSSS) at the carboxyl-terminus of CCND3 was identified 
in a single patient (Figure 3.5).
Several sequence variations in exon 5 were identified and shown using 
the ensemble database to correspond to previously reported polymorphisms 
(www.ensembl.org). Six patients with polymorphisms affecting codons 258 
and 259 were identified. Three patients contained a synonymous C > T point 
mutation at nucleotide 855, at codon 258 (A258A). This polymorphism 
occurred in conjunction with a T > G substitution at nucleotide 856 in 2 
patients, which results in the substitution of an alanine for serine at codon 259 
(S259A). The polymorphism alone was observed in one patient.
Fe lin e  s a r c o m a  p r o t o - o n c o g e n e  (FES)
The second gene tested in this series was FES (c-fes), it is located at 
15q26.1 and encodes a 93 kDa non-receptor tyrosine kinase that is 
preferentially expressed in myeloid and endothelial cells, with expression 
restricted to mature haematopoietic cells of the granulocytic and monocytic 
lineages. FES is involved in cytokine receptor signal transduction, neutrophil
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a)
940 990
W ildtype | 51 bp deletion
GGAAGCCGCTCAGACCAGCTCCAGCCCAGCGCCCAAAGCCCCCCGGGGCTCCAGCAGCCAAGGG
GGAAGCCCAAGGGC
Mutated
Figure 3.5: Sequencing trace of wild-type and mutated CCND3
a) Sequencing trace of wild-type and mutated CCND3. The wild-type sequence of 
exon 5 is demonstrated in the top panel with the corresponding sequencing trace 
from a cloned product showing the 51-bp deletion of nt 940-990 (Genbank, 
NM_001760) in the bottom panel. This mutation results in the deletion of amino acids 
259-275 (AQTSSSPAPKAPRGSSS).
b) The SSCP trace from this patient sample along side 3 wild type samples, with the 
miscellaneous bands indicated by arrows.
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survival and myeloid differentiation. The FES kinase contains an N-terminal 
domain with two predicted coiled-coil (CC) regions involved in 
oligomerization (residues 1 to 450), a central SH2 domain and a 
carboxy-terminal tyrosine kinase domain157.
Knock out mice are viable but exhibit lymphoid and myeloid 
homeostastic defects, compromised innate immunity and an increase in 
cytokine responsiveness which causes abnormal proliferation and functional 
defects in macrophages158. The myeloid lineage is overrepresented in bone 
marrow and peripheral haematopoietic tissues. The knock out model indicates 
that endogenous Fes acts primarily in the monocytic lineage as a negative 
regulator of Stat3 and Stat5 activation159.
As part of a larger mutational analysis study of the tyrosine kinome by 
the Vogelstein group160 point mutations in exon 17 and 18 of the tyrosine 
kinase domain of FES were identified in patients with colorectal cancer. 
Elevated expression of FES has been observed in AML161. In haematopoeisis, 
FES induces terminal macrophage differentiation of myeloid progenitors and 
activation of myeloid transcription factor PU .l162. FES also suppresses 
BCR-ABL driven cell outgrowth159. Increased levels of FES expression results in 
a reduction of BCR-ABL transcription but this is dependant on FES retaining 
its functional kinase activity. FES was therefore selected as a candidate gene 
based on its link to malignancy and its involvement in the myeloid branch of 
haematopoiesis.
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Samples from a mutation panel that included patients with favourable 
and poor risk cytogenetics (n=167) were screened for mutations in exons 13-19 
of FES. Exons 13-19 encompass the tyrosine kinase domain of the protein. 
Mutation screening was conducted by the WAVE mutation screening method. 
Exons were individually amplified from genomic DNA by PCR. The amplified 
fragments were then denatured and annealed slowly to allow heteroduplex 
formation (Figure 3.6). Heteroduplexes form due to mismatches of base pairs 
from point mutations and elute more slowly from the column as compared to 
homoduplexes.
Chromatograms that differed from the majority of the samples were 
studied by sequencing of the samples in question. Direct sequencing was 
undertaken for exon 14 (n=3), exons 15 + 16 (n=12), exon 17 (n=6), exon 18 (n=5) 
and exon 19 (n=2). No abnormal chromatograms were observed for exon 13.
No mutations were detected. As with the case with CCND3, several 
synonomous polymorphisms were observed. In exon 14, GCG > GCA at nt 
1839 coding for amino acid Ala, was observed (Genbank, NM_002005). In exon 
16, GGC > GGA at nt 2001 coding for Gly was observed (Figure 3.7).
Su m m a ry
The current study adds to the growing pool of information on mutation
events in AML and examines the interactions between specific mutations in
NK AML in patients attending St. Bartholomew's Hospital. To achieve this
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Homoduplexes
Wt Mt
H eat
A-T G-C ---------------►
Slow  Cool
A-T G-C
A llele  1 A lle le  2 /  \  /  \A  C G T
\ /  \ /
Heteroduplexes
Figure 3.6: Wave mutation screening relies on heteroduplex formation
Exons of interest are amplified by PCR. The subsequent fragments are heated to 
denature the double stranded structure and reannealed slowly. If heterozygous point 
mutations are present, this allows the generation of heteroduplexes which will elute 
differently from a homoduplex when run through a dHPLC column.
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Polymorphism CACCCTGGTGGCNGTGAAGTCTTGT  
wild Type CACCCTGGTGGCGGTGA AGTCTTGT
b)
Polymorphism ACCTGCAGGGGGAGACTTCCTGACC
wild Type a  c  c t  g  c a g G G G G C G  ACTTCCTGACC
Figure 3.7: Polymorphisms detected in
No mutations were detected in the tyrosine kinase region of FES. However the wave 
mutation screening protocol was sufficient sensitive to detect polymorphisms within 
this region of the gene, a) Polymorphism in exon 14 G > A at nt 1839 (Ala) (Genbank, 
NM_002005); b) Polymorphism in exon 16 C > A at nt 2001 (Gly)
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goal, a panel of NK AML patient samples was screened for mutations in genes 
involved in AML and subsequently used to search for novel mutations in 
candidate genes. Our data is in board agreement (Table 3.2) with the 
expansive literature describing mutational events in AML. Moreover, the 
recent discovery of mutations in the JAK2 tyrosine kinase163 165 in 
myeloproliferative disorders and NPM1 mutations in normal karyotype AML 
166,167 as weu as our group's study of W T l168 are examples of the continuing 
discovery of novel mutations and their involvement in haematological 
malignancies. In the absence of cytogenetic markers for NK AML, the profiling 
of genetic legions should be recommended as a means of improving molecular 
risk stratification in this group of patients.
M e t h o d s  o f  m u t a t io n  s c r e e n in g
Since mutation screening can be useful from a prognostic and 
therapeutic point of view, the development of high throughput techniques for 
screening remains important so that individual genetic profiles can be 
developed for patients from diagnosis. Moreover as AML is a heterogeneous 
disease with many patients doing poorly with current treatments, the tailoring 
of therapies towards specific genetic mutations may be the key to improving 
overall survival in this disease.
Besides clinical applications, high throughput screening methods are 
useful for discovering novel gene mutations, since large numbers of patient 
samples and individual gene exons m ust be screened to pick up rare genetic
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Our Frequency Literature Reference
NPM1 61% 50-60% 63
FLT3-ITD 34% 28-38% 169
NRAS 16% 13% 170
CEBPA 12.5% 4-15% 169
RUNX1 7% 7% 171
Table 3.2: M utation frequencies detected in our panel are similar to those 
reported in literature
The mutation frequencies of genes in our panel were similar to those reported in 
literature, indicating that the panel and screening techniques are sufficiently 
sensitive/reproducable to be used to search for novel gene mutations.
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events. Over time, more efficient and sensitive techniques have been 
developed for mutation detection, primarily based on separation of nucleic 
acids via molecular weights by electrophoresis172. Various electrophoresis 
techniques were utilised in our mutation screening protocols.
SSCP is able to detect heterozygous point mutations as well as more 
complex mutations such as insertions and deletions. Screening is faster with 
this method than direct sequencing, but mutation detection will vary 
depending on the size of product, its nucleotide sequence, the gel temperature, 
matrix and pH. The technique requires optimization by running at different 
conditions to increase the mutation detection rate173, which is labour intensive 
compared to newer methods. Mutation detection rate also falls as the size of 
the amplicon increases. It is fair to assume therefore that the mutation 
detection rate of SSCP is below 100%. However, the mutation frequencies of 
the assessed genes in our study are similar to those in the literature, indicating 
that SSCP is adequate for routine laboratory investigations but would not be 
applicable in a diagnositic situation.
The possibility for high throughput analysis makes the dHPLC
approach a valuable and altogether a more satisfactory tool in candidate gene
screening. A disadvantage to this technique is that homozygous mutations are
normally undetectable since mismatched heteroduplexes will not form. To
overcome this problem, wild type DNA can be added to the test samples,
thereby simulating heterogeneous mutation. Several studies have examined
the sensitivity and specificity of dHPLC and with a detection rate of between
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92-100% mutation174 176.
Although direct sequencing was used in this study to screen WT1 and 
in my later work relating WT1 mutations and aUPD (Chapter 4), our 
laboratory now utilises capillary fragment analysis for screening of this gene. 
Capillary fragment analysis offers the advantage of being a high throughput 
technique that allows easy visualisation of the nature of the mutation by 
discrimination of the mutational events based on product size and provides a 
semi-quantitative measure of mutation load. However capillary fragment 
analysis is unable to detect point mutations177. All WT1 mutations detected in 
our AML samples to date have been insertions or deletions, making this 
technique highly applicable for screening of this gene.
Ultimately, the goal is to be able to detect all mutations present in a 
panel of samples in a high-throughput and efficient manner. This ability is 
limited by the technology that is currently available. Confounding variables 
such as contamination with normal wild-type cells and clonal heterogeneity 
may make it difficult to pick up low levels of disease by electrophoretic 
techniques or direct sequencing technology.
C o o p e r a t iv e  M u t a t io n s  in  AML
By screening a panel of patients for a number of genes implicated in 
leukaemogenesis, distinct non-random patterns of mutations have now started 
to emerge. A large proportion of patients contained multiple mutations (45%)
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and mutations representative of both classes (44%) (which affect self-renewal 
(Class I) and differentiation (Class II)), indicating that the association between 
mutation types may play an important role in leukaemogenesis in NK AML.
With the discovery of new gene associations in NK AML, functional 
testing can be preformed to determine whether the mutations are sufficient for 
the development of AML. Transduction of human HSCs with mutant forms of 
the gene or the creation animal models mimicking the mutation status 
observed in AML samples could be useful for determining whether these 
mutations are sufficent to cause the development of overt disease.
The persistence of AMLs with no mutations detected however, indicate 
the necessity to continue searching for novel gene mutations.
N o v e l  G e n e  M u t a t io n s  in  N K  A M L  
CCND3
The CCND3 mutation detected in a single individual is the first 
reported case of this mutation in NK AML. Cyclin D3 has been previously 
reported to be involved in translocations in mature B-cell malignancies 
resulting in high expression levels of the gene152. Furthermore, increased 
expression of CCND3 is also observed in HSCs transduced with FLT3-ITDs178. 
The patient with mutation in CCND3 did not contain a FLT3-YTD.
Two patients carried a non-synonymous E253D substitution of CCND3
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that was also present in their remission samples. The availability of 
corresponding remission blood or buccal tissue DNA is therefore a valuable 
tool for excluding rare polymorphisms as part of investigations into novel 
mutations; this will become an essential part of mutational studies if genes 
with very few mutations, typically substitutions are to be validated and 
included in molecular risk assessment.
FES
No mutations were detected within the tyrosine kinase domain of FES. 
This cannot, however, completely exclude the involvement of FES in 
leukaemia since mutation screening for this study was restricted to exons 
13-19, the sites of previously reported mutations in colorectal cancer. 
However, mutations outside of this region may still be able to have an effect. 
Mutations or deletion within the first coiled-coil domain in the N-terminal 
region of FES activate the tyrosine activity. Additional mutations within the 
second coiled-coil domain result in loss of this activity179. These mutations are 
able to affect downstream STAT3 signaling pathways. Therefore it is possible 
that mutations occur within these regions that were not detected by the 
screening process.
The investigation described herein examines the relationships between 
mutations in NK AML. Mutation screening of leukaemic blasts can yield 
valuable information for prognosis and therapeutic options. However, it does 
not yield sufficient insight into the sequential steps by which leukaemogenesis
1 4 5
occurs. It was therefore important to study the temporal process by which 
genetic damage accumulates during the development of AML.
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C h a p t e r  4: La t e n c y  a n d  O r d e r  o f  M u t a t io n a l  
Ev e n t s  i n  Le u k a e m o g e n e s is
Brief in t r o d u c t io n  a n d  d e s c r ip t io n  o f  stu d y
The increasing incidence of cancer with age suggests a gradual 
accumulation of genetic damage overtime for the disease to develop (Figure
1.3). In familial cases of AML, latency periods can last up to forty years or 
more before the disease is manifested. Current diagnostic techniques focus on 
the bulk of the disease, the leukaemic blasts. These blasts are the end point of 
leukaemogenesis and reveal little of the transformation process by which the 
disease arose. In this chapter we set out to examine the process of 
leukaemogenesis by studying the order by which mutations are acquired and 
the stage in haematopoiesis in which mutations occur. This was accomplished 
in two ways.
1. Examining the relationship between regions of acquired 
homozygosity in AML samples and mutations.
2. Using quantitative approaches to examine the existence and 
frequency of mutations in leukaemia stem cells and early 
progenitors.
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O r d e r  o f  g e n e t ic  ev en ts  in  l e u k a e m o g e n e s is : A c q u ir e d  
U n ipa r en ta l  D is o m y  (a U P D )
D is c o v e r y  o f  aUPD in  AML
Traditionally, G-banding has been the backbone of genetic 
examinations in leukaemia. However, more sensitive techniques have been 
developed which allow us to examine the disease more precisely at the 
molecular level.
The development of single nucleotide polymorphism (SNP) genotyping 
technology allows for the easy visualisation of loss of heterozygosity within 
the genome and for the detection of deletions or amplification of genomic 
regions (copy number)180. A SNP is a DNA sequence variation occurring when 
a single nucleotide differs between members of a species or between paired 
chromosomes in an individual and occur about once in every 1000 bases of the 
3 billion bases in the human genome181. SNPs exist within coding sequences of 
genes, noncoding regions of genes, or in the intergenic regions between genes. 
SNPs in which both variants lead to the same polypeptide sequence are 
termed synonymous or silent while those which encode a different 
polypeptide sequence, are termed non-synonymous. The majority of SNPs 
(approximately 95%) either fall into the non-coding region of the genome or 
are silent, therefore do not have direct impact on protein sequence. However, 
SNPs that occur outside protein coding regions may still have consequences 
for gene splicing, transcription factor binding, or the sequence of non-coding
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RNA and silent SNPs within the protein coding region may influence the 
kinetics of protein translation182.
Gains and losses of chromosome number have long been observed in 
AML by karyotype analysis. More recently a novel abnormality in AML was 
revealed through the application of SNP genotype array technology183. The 
study by Raghavan et al revealed an acquisition of homozygosity without 
change in copy number. This aberration, which cannot be detected by 
conventional cytogenetic methods and was observed in approximately 20% of 
the AMLs studied.
This form of genetic lesion was termed acquired uniparental disomy 
(aUPD). Inherited uniparental disomy occurs when an individual receives two 
copies of a chromosome from a single parent with no copies from the other, 
resulting in homozygosity of the respective chromosome or chromosome 
region. aUPD is a somatic gain of homozygosity without gain or loss of 
chromosome material. The frequency by which this genetic lesion occurs in 
AML indicates that it may play an important role, or act as a signature in 
leukaemogenesis, even though it does not directly cause mutations in genes.
In AML, SNP profiling has detected several regions of aUPD, evident as
large stretches of somatically acquired homozygosity. These regions usually
continue from a variable location on the chromosome and continue to the
telomere. The telomeric location of aUPD suggests a mechanism of mitotic
recombination, because there is no net change in copy number in the affected
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region (Figure 4.1 and 4.2). Mitotic recombination results in the generation of 
two daughter cells homozygous for distinct chromosomal regions which were 
subject to recombination. The homozygosity observed in AML is due to the 
outgrowth of one of the daughter cells likely due to a selective advantage 
conferred to the cell by a mutation within the region.
In studies carried out by Raghavan et al, sixty-four primary AML 
samples covering a cross section of FAB types and cytogenetic groups were 
analysed using 10K Affymetrix chips. aUPD was observed in 13 samples 
(approximately 20%).
Although the regions of homozygosity covered large portions of the 
chromosomes, we noted that within these regions are genes known to be 
mutated in AML. Figure 4.3 shows an example of three cases of aUPD on l ip  
in which the gene WT2 lies within the area of overlap. To investigate whether 
there was a potential relationship between gene mutation and somatically 
acquired homozygosity in AML, mutation screening was conducted on genes 
known to be mutated in AML located within the detected regions of aUPD.
H o m o z y g o u s  m u t a t io n s  a r e  f o u n d  in  r e g io n s  o f  aUPD
For the thirteen patients with aUPD, mutation screening was 
undertaken for genes that lay within the region of homozygosity (Table 4.1). 
Due to the small number of samples, mutation screening was performed by 
amplification of the gene by PCR, followed by direct sequence analysis.
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Figure 4.1: Loss of heterozygosity by mitotic recombination resulting in 
homozygous mutation
Cross-over between non-sister homologous chromatids followed by segregation 
results in homozygous mutants or wild-type cells. Alleles are represented in blue 
and red. A mutation occurs in one allele (yellow). When cell division takes place 
crossover of material occurs between non-sister homologous chromatids. When 
segregation of the alleles takes place, one daughter cell contains two copies of the 
mutant allele.
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Figure 4.2: CEBPA mutation in association with aUPD 19q (taken from 
Snaddon et al)118
(a) Schematic of chromosome 19, blue dots indicates the presence of homozygous 
SNPs and red dots indicate the occurrence of heterozygous SNPs. Leukaemic blast 
DNA (patient 5) retains a large stretch of homozygousity covering the q arm of the 
chromosome which includes the CEBPA gene (location indicated by arrow).
(b) PCR gel analysis showing wildtype, heterozygous (patient 2) and homozygous 
(patient 5) gene mutation. FISH analysis using BAC clones show two copies of the 
CEBPA locus in patient 5, indicating that the homozygous 57bp ITD does not arise as 
a consequence of deletion of the wildtype allele.
(c) Sequencing trace of the homozygous mutation.
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Figure 4.3: Regions of aUPD do not appear to be random events
Although the regions of homozygosity covered large portions of the chromosomes, 
they coincided with locations of genes known to be mutated in AML. The WT1 gene 
is frequently mutated in Wilms' tumour and lies within the l ip  region of 
overlapping aUPD. Only 1 of 3 of the above cases of aUPD on l ip  showed mutation 
in WT1 suggesting other genes or mutational mechanisms may be involved.
Patient Karyotype UPD Gene Mutation
1 46,XY llp l3 - llp te r WT1, PU.l
1584 insl6bp 
(WT1)
2 46,XY 19ql2-19qter CEBPA
1038 ins57bp 
(CEBPA)
3 46,XY 21q21-21qter RUNXI
970 insA 
(RUNXI)
4 46,XX 13q FLT3
ITD 21bp
(FLT3)
5 46,XY t(6;9) 13q FLT3
ITD 63bp 
(FLT3)
6 46,XX 13q FLT3
ITD 36bp/ 
39bp* (FLT3)
7 46,XX 13q FLT3
ITD 108bp
(FLT3)
8 46,XX llp l l - l lp te r WT1, PU.l None
9 46,XX l lp l l - l l p l 4 WT1, PU.l None
10
46,XX,dic(7;22)
(qll.2;ql0),+8
llq l2 - llq te r M IL None
11 48,XY,+3,+10 6p21-6pter CCND3 None
12 46,XX 6pll-6pter CCND3 None
13
46,XY,der(12)t(l;12)
(qll;pll.2)/46,XY
9pcen-9pter
CDKN2A,
CDKN2B
None
Table 4.1: Patients, area of homozygosity, genes screened and result
aUPD was observed in 13 patients out of 64 tested. Genes known to be mutated in 
AML which are located within the areas of homozygosity were screened for 
mutations. Mutations were observed in 4 distinct loci, WT1, CEBPA, RUNXI,  and 
FLT3. Numbering of mutations is according to the following Genbank accession 
numbers: NM_024426 (WT1), Y11525 (CEBPA), and NM_001754 (RUNXI) .
1 5 4
Mutations were detected at four distinct loci (WT1, FLT3, CEBPA and 
RUNXI) in seven of the thirteen leukaemias examined (Table 4.1). In these 
seven cases, sequence analysis indicated a homozygous mutation. (Figure 4.3). 
Small background peaks of wild type sequence detected likely indicate 
infiltration of the tumour sample with normal cells. Four cases with aUPD 
across 13q were found to harbour homozygous internal tandem duplications 
in FLT3. The ITDs ranged from 21 to 108bp in length, with one sample 
demonstrating additional allelic evolution, with the additional insertion of 
3bp. One case of l i p  aUPDs was found to harbour a 16bp ITD in WT1 (Figure
4.4). A single case of aUPD was observed on 19q, in which a 57bp ITD was 
observed in CEBPA (Figure 4.2). A homozygous lbp  insert was observed in 
RUNXI within an area of aUPD in 21q (Figure 4.4).
These results allowed us to develop a proposed timeline by which the 
LSC may have developed mutations. An initial //hit,/ occurs involving the 
gene-specific mutation on one allele. This is followed at a later time by mitotic 
recombination resulting in the mutation being rendered homozygous in a 
subset of cells. This homozygous mutation confers a selective advantage to the 
cell and it proliferates, giving rise to overt leukaemia.
In the case of FLT3 in ternal tandem  duplication m utations, the
heterozygous state is a recognised poor prognostic risk factor for AML.
Additionally, the loss of the wild-type FLT3 allele occurs in 10% of patients
with normal karyotype AML and is associated with a worse outcome71. This
provides evidence that loss of heterozygosity can be viewed as a form of
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Figure 4.4: Sequencing traces of homozygous mutations discovered within 
areas of aUPD
Examples of homozygous mutations found within areas of acquired UPD. A 
homozygous 16 bp ITD in exon 9 of WT1 was observed in a patient with aUPD 
across chromosome lip . No mutation was detected in the other two cases. A single 
homozygous bp insertion in exon 5 of R U N X I  was observed in a patient with aUPD 
on chromosome 21.
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disease progression.
The occurrence of aUPD has not only been described in diagnostic 
samples, but has also been observed under pairwise analysis of relapse and 
remission samples. In one aUPD across 19q, a point mutation in CEBPA which 
results in the translation of the 30kDa form of the protein was observed to be 
heterozygous at diagnosis, but had become homozygous upon relapse.
Since relatively large regions of the genome are involved in the 
acquired homozygosity as observed in AML, there may be more than one 
potential mutational target in a given region. Investigation of 3 samples with 
aUPD of l ip  revealed a mutation of WT2 in only one case (Figure 4.3 and 
Figure 4.4). Additionally, no mutations were observed in PU.l, which also 
located in this region, suggesting that other gene mutations may be implicated 
in the remaining two cases. Similarly, no mutations were detected in the 
candidate genes, CCND3, CDKN2A and 2B, and MLL for aUPD on 6p, 9p, and 
l lq  respectively, indicating there may be other targets contained within these 
regions.
TIMING OF MUTATION EVENTS IN LEUKAEMOGENESIS
D e v e lo p m e n t  o f  q u a n t i t a t i v e  r e a l - t i m e  a s s a y  f o r  m u t a t i o n s  i n  CEBPA
With multiple mutational events occurring in normal karyotype AML, 
the order by which they arise may be important. The simplest way of studying
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order of mutation is to examine whether there is concordance in mutation 
status between diagnosis and relapse samples. For example, mutations in FLT3 
are often not concurrent between presentation and relapse184 indicating that 
mutations in this gene most likely represent secondary events. The same 
mutations in NPM1 and CEBPA are maintained between presentation and 
relapse185' 186 indicating that mutations in these genes are probably early 
initiating events.
In our centre, the availability of paired diagnostic and relapse material 
is limiting and so we have followed a different approach. AML is a stem cell 
disease which follows a similar hierarchy to normal haematopoiesis with the 
bulk of the disease driven by a LSC. Therefore, another way of examining 
order of mutational events is by studying in which HSC/progenitor 
compartment they occur. To do this, leukaemic cells were sorted into 
populations equivalent to stem cells and early progenitors in non-malignant 
haematopoiesis. These sorted cells were then tested for presence or absence of 
mutation.
To sort the leukaemic cells, the development of flow cytometery and the
characterisation of cell surface markers have allowed the specific selection and
study of different cell populations, including the LSC187. Functional
approaches to studying the LSC have involved animal models. The murine
xenotransplant NOD/SCID model has been an especially valuable resource in
this respect, with the mice being able to faithfully recapitulate human
disease35. The development of xenotransplantation technology has allowed for
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accurate modelling of human AML growing within an animal system and the 
ability to characterise distinctive subpopulations of leukaemic cells.
Sensitive assays developed for specific mutations in AML, coupled with 
FACS technology to sort these rare leukaemic cells which have the ability to 
self renew and propagate the disease, can be used to determine whether a 
specific mutation exists within the earliest most potent cells. In this respect, 
investigation was undertaken to determine whether mutations in CEBPA are 
present within the leukaemic stem cell in normal karyotype AML. To achieve 
this, sensitive real-time quantitative mutation specific PCRs were developed 
and utilised for testing sorted leukaemic stem cells and early progenitors from 
patients for which the mutations were present in the blast compartment.
D e s ig n in g  m u t a t io n  s p e c if ic  PCR
Patients with normal karyotype AML FAB type M l were selected for 
study based on availability of diagnostic and/or relapse BM samples and on 
the presence of CEBPA mutations identified within during previous 
screening118 (Table 4.2).
To develop an assay for CEBPA mutations, mutation specific forward 
primers were designed using the unique tumour specific sequences generated 
by the mutations. Insertion mutations introduce unique sequence 
arrangements at the junction of the insertion (Figure 4.5). Primers with the 3' 
end lying across these regions were designed and tested for specificity. An
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Patient Age FAB type CEBPA mutation
1 37.9 M l 1138 ins (57bp)
2 38.2 M l 1081 ins (AGA)
3 19 M l 1091 ins (GCA)
4a 72.5 Ml 363ins (GGCC)
4b 1096 ins (27bp)
Table 4.2: Characteristics of patients w ith CEBPA m utations included for 
real-time PCR analysis
Mutation specific real-time PCR assays were developed for four patients with 
mutations in CEBPA. Three of the patients had assays designed against mutations 
within the C-terminal region of the gene (Patients 1-3) The remaining patient 
contained biallelic N and C-terminal mutation for which a specific assay was 
developed for both. (Genbank Y11525)
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5 ' . . . TGGAACAGCAGAAGG. 
M utant 3 , ACCTTGTCGTCTTCC.
T 5 ' . . . TGGAACAGCTGAGCC. . .  
Wild typ e  3 , _  .ACCTTGTCGACTCGG. . .
M u ta n t m m m ACCTTGTCGTCTTCC
Wild Type 3 , _ _ .ACCTTGTCGACTCGG
Figure 4.5: Strategy for design of specific primers for mutations in CEBPA
The duplication of 3-57bp in CEBPA results in the generation of a unique tumour 
specific sequence. Insertion mutation is shown in red, wild type sequence in black. 
Primers (blue bars) were designed to lie across these unique regions with the 3' end 
of the primer designed not to anneal with the wild type sequence, therefore no 
polymerisation would occur.
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additional bp change from the wild type sequence introduced 1-5 bp from the 
3' end of the primer improved the selectivity of the assays.
Due to the clustering of C-terminal mutations in CEBPA, it was possible 
to use the same reverse primer and probe in each of the assays designed for 
that region. Mutation specific amplification was therefore based on a single 
patient specific primer (Figure 4.6). Probes and primers were designed with 
the assistance of the PrimerExpress program.
This strategy was applied to mutations in 8 patients, including one 
patient with biallelic N and C-terminal region CEBPA mutations as well as the 
single base pair substitution contained within the Kasumi-6 cell line, a human 
acute myeloid leukaemia cell line established from an M2 patient. This cell line 
contains a point mutation in the C-terminal region of CEBPA which results in 
the altered protein structure of R305P.
Specificity of the assay was initially tested by amplifying wild type 
DNA and mutation containing DNA in a standard PCR reaction. If the primer 
set did not appear to amplify the wild type DNA, we proceeded to test the 
assay using quantitative real-time PCR (Figure 4.7). To help confer specificity, 
adjustments to primer length, identity of substituted base, and position of 
substituted base were made. In general 4 different base pair substitutions and 
2 primer lengths were attempted for each mutation.
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Insertion
Mutations
Common Probe Common Reverse Primer
Mutation Specific 
Forward Primers
Figure 4.6: Schematic for development of mutation specific real time assays 
against mutations in the C-terminal region of CEBPA
Mutations in the C-terminal region cluster, allowing the use of a common probe and 
reverse primer. Mutation specific forward primers were developed, taking 
advantage of the unique tumour specific sequence generated by the corresponding 
insertion mutations.
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Figure 4.7: Testing of mutation specific assays for specificity
a) Real-time PCR with a master mix that does not degrade the final product was 
performed using the mutation specific primer set using DN A containing the 
mutation, wild type D N A  and a non-template control (NTC). The product was 
visualised by gel electrophoresis. Only the sample which contained the mutation 
generated a product.
b) As in (a) the real time assay was conducted against DN A with and without the 
mutation. The mutation specific assays would not produce signal for WT DNA. 
Amplification was only observed in the duplicates shown in yellow  and blue which 
contained mutant DNA.
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S u c c e s s f u l  A ssa y s  a n d  p a t ie n t  d e t a il s
Ultimately, five real-time quantitative PCR (RQ-PCR) assays were 
developed that selectively amplify mutated CEBPA DNA from 4 patients 
(Figure 4.8). Three patients (1, 2 and 3) had insertion mutations in the region of 
the gene that codes for the C-terminal DNA-binding/basic leucine zipper 
domain of the protein, the fourth contained mutations in both the N- and 
C-terminal regions of the C/EBPa protein (4a and 4b respectively). Mutations 
in 1, 2, 4a, and 4b are all tandem duplications ranging from 3 to 57bp in length 
while patient 3 has a 3bp insertion.
Designing a m utation specific probe
Another strategy that was attempted was to design a mutation specific 
probe. The probe was designed for a patient which had a 6 bp insertion of 
ACCCGC at nt 729 (Genbank Y11525). Since the ITD occurred in an area of 
highly repetitive sequence a unique sequence arrangement at the junction of 
the insertion was not generated. Therefore it was attempted to take advantage 
of the additional length of the sequence generated by designing a probe that 
would anneal only to the mutated DNA. The sequence of the probe covered 
the region 5'-ACCCGCACCCGCACCCGCACCCGCCGCCCGCGCACCT-3' 
with FAM conjugated to the 5' end and TAMRA to the 3' end, the ITD is 
underlined. However when tested, this did not allow specific differentiation 
between wild type and mutant DNA.
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 TGACCAGTGACAATGACCGCCTGCGCAAGC
TGACCAGTGACAATGACCGCCTGCGCAAGC
C-terminal
WT GC CGCGAC AAGGC CAAGCAGC GCAAC GTGGAGAC GCAGC AGA-------- AGGTGCT------ GGAGC----------------------------------------
P I  GC C GCGAC AAGGC CAAGCAGC GCAAC GT GGAGAC GCAGC AGA-------- AGG T GC T------ GGAGC----------------------------------------
PZ GC C GCGAC AAGGC CAAGCAGC GCAAC GT GGAGAC GCAGCXGA|GAACGTGH-------- H H -----------------------------------------------------------
P 3  GC C GCCACAAGGC CAAGCAGC GCAAC GT GGAGAC GCAGCAGA------ AGGT GC T | ----- J M -------------------------------------------
P 4 b  GCCGCGACAAGGC CAAGCAGC GCAACGTGGAGAC GCAGCAGA— AGGTGCT— GCACCMg G A G A C G C A G C A G A A G G T G ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ B
F T  GGGT GGAACAGC------------------
P I  GGGTGGAACllCAGAA&GTG
PZ GGGT GGAACAGC------------------
P3  CGGTCGAACAGC------------------
P 4 b  CGGTCGAACAGC------------------
----------------------------- TGAGCCGCGAACTGGACACGCTGCGGGCCATCTTCCGCCAGCTGCCAG
iGGGTGGAACAGCTGAGCCGCGAACTGGACACGCTGCGGGGCATCTTCCGCCAGCTGCCAG
----------------------------- TGAGCCGCGAACTGGACACGCTGCGGGGCATCTTCCGCCAGCTGCCAG
----------------------------- TGAGCC GCGAAC T &GAC AC GC T GC GGGCC AT C T TC C GC C AGC TGC CAG
----------------------------- TGAGCCGCGAACTGGACACGCTGCGGGGCATCTTCCGCCAGCTGCCAG
FT  AGAGCT C C T T GGT CAAGGC CAT GGCCAAC T GCGC GT GAGGCGC GC GGC T
A G A G C T C C T T G G M aH B M |M aM H H B & A G G C G C G C G G C T  
PZ AGAGCT C C T T G G ^ ^ ^ ^ ^ ^ ^ ^ ^ H g C & C G T  GAGGC GC GC GGC T
AGAGCTCCTTGG^^^^^^^^^BBBICAGGCGCGCGGCT  
P 4 b  AGAGCT C C T T G G ^ ^ ^ ^ ^ ^ ^ ^ ^ H g C G C G T  GAGGC GC GC GGC T
N-terminal
FT  CCATCGACATCAGCGCCTACATCCACCCGGCC GC C T TC AAC GAC GAGT T C C T GGCCCAC C TGTTC C AGC AC AGC C GGC AGCAG&AGAAGGCC AA
P 4 a  C C A T C C A C A T C A C C C C C T A C A T C G A C C C G f C t ' H B H H H H H B H H H H ! I H ^ ^ H ^ ^ H H H AG^ C c c ^ A
Figure 4.8: Diagram of successful mutation specific assays
RQ-PCR approach for the specific detection of CEBPA  mutations. For the 
C-terminal and N-terminal mutations, all patient sequences are shown (PI, P2, P3, 
P4b). Forward and reverse primer sequences are highlighted in yellow  and purple 
respectively and Taqman probe location is indicated in green. A patient specific 
forward primer was designed to preferentially anneal to unique sequence generated 
by insertion mutation (red text and underlined) (see also Figures 4.4 and 4.5 for 
overall strategy). Base changes (lower case and blue highlighted) were introduced to 
the primer to prevent annealing and extension from WT sequence. The mean 
amplicon length was 158bp (range 150-164) for patient assays 1,2,3 and 4b. Amplicon 
length was 78bp for patient assay 4a.
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T e s t in g  s p e c if ic it y  a n d  s e n s it iv it y  o f  r e a l -t im e  a s s a y s
Real-time PCR analysis was performed on 25 pi reaction mixture in 
duplicate using Taqman chemistry on the ABI PRISM 7700 Sequence Detector 
with default settings. Beta-2-microglobulin was used as the endogenous 
reference gene to assess total cell number per well.
The specificity of each RQ-PCR assay was tested by amplifying 750ng 
(equivalent to 125000 cells) of each patient's diagnostic BM DNA, wt DNA, 
patient diagnostic BM DNA serially diluted in wt DNA and no template 
controls, in duplicate. An assay was deemed to be specific if no amplification 
was observed with wt DNA (Figure 4.7).
To test the sensitivity of each assay, a standard curve was generated by 
five serial dilutions of diagnostic DNA in water into 5 set standards (ranging 
from 125000 to 4 cells per well). The assays were also tested by diluting DNA 
containing mutation in wild type DNA and overall sensitivity was not affected 
(Figure 4.9). In all amplification plots, the same threshold was maintained, 
allowing comparison between experiments. The correlation coefficient of the 
standard curves was at least 0.95, indicating the assays had a high probability 
of precise quantification. The mean Ct for DNA equivalent to 125000 cells was 
24.6 (range 24-27). The mean slope of the dilution curves was -3.2 (range -3.5 to 
-2.8) indicating good amplification efficiencies (the perfect theoretical slope is 
-3.3). The maximum reproducible sensitivity (defined as the dilution for 
which duplicates were both positive) for all the patient m utation assays was
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Figure 4.9: Testing sensitivity and specificity of real time assays. Example of 
standard curves for P2
a-b) Serial dilution of patient DNA in wild type DNA showing CEBPA mutation 
specific assays.
c) Same assay with (3-2 microglobulin control to measure total DNA content.
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104 (8.0 xlO'5; 10 in 125000) and therefore were of sufficient sensitivity for MRD 
monitoring <10^ (Table 4.4).
D e te r m in in g  t h e  p o i n t  o f  o r i g i n  o f  CEBPA m u ta t io n s ,  t h e
LEUKAEMIC STEM CELL AND EARLY PROGENITORS
These assays were also utilised to address the question of where within 
the primitive populations of leukaemia cells, the LSC and subsets that 
correspond to CMP and GMP populations in non-malignant haematopoiesis, 
in which the mutation arises.
AML peripheral blood samples from 4 patients were flow sorted into 
three distinct hierarchal compartments, (i) The LSCs, which correspond to the 
most primitive haematopoietic stem cells that have the potential for long-term 
repopulation of multiple haematopoietic lineages; (ii) the common myeloid 
progenitors (CMPs) which in normal haematopoiesis have limited 
self-renewal capacity and the ability to differentiate into all myeloid cell types 
and their downstream progeny, and (iii) the granulocyte/macrophage 
progenitors (GMPs), which in non-malignant cells, also have limited 
self-renewal capacity and restricted in their differentiation ability to 
granulocytes and macrophages.
These populations were sorted based on the lack of mature lineage 
markers (CD2, CD3, CD14, CD16, CD19, CD24, CD41, CD56, CD66b and
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Assay Mutation Sensitivity Ct125k Ct 10 Slope correlation
1 1138 ins 
(57bp)
8.0 e-5 25 38 -3.4 0.994
2 1081 ins 
(AGA)
8.0 e-5 26 37 -2.8 0.945
3 1091 ins 
(GCA)
8.0 e-5 24 37 -3.2 0.991
4a 363ins
(GGCC)
8.0 e-5 24 37 -3.2 0.986
4b 1096 ins 
(27bp)
8.0 e-5 25 37 -3.0 0.981
Table 4.4: Summary of sensitivity and specificity testing of real-time PCR 
analysis for CEBPA mutations
A standard curve was generated by five serial dilutions of diagnostic DNA in water 
(ranging from 125000 to 4 cells per well). In all amplification plots, the same 
threshold was maintained, allowing comparison between experiments. The 
correlation coefficient of the standard curves was at least 0.95, indicating that the 
assays had a high probability of precise quantification. The mean Ct for DNA 
equivalent to 125000 cells was 24.6 (range 24-27). The mean slope of the dilution 
curves was -3.2 (range -3.5 to -2.8) indicating good amplification efficiencies (the 
perfect theoretical slope is -3.3).
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glycophorin A). In addition, the majority of LSCs express CD34 cell surface 
marker, but not CD38 (Lin-/CD34+/CD38-). The CMPs and GMPs express 
CD34, CD38, and CD123 and are distinguished by presence (GMP) or absence 
(CMP) of CD45RA (as described in Chapter 2)187. Unfortunately due to limited 
availability of patient samples, there was insufficient material for re-analysis 
of the populations by FACS before isolating DNA for mutation analysis.
DNA isolated from each compartment was tested with the RQ-PCR 
assays for mutation. In the stem cell compartment (Lin-/CD34+/CD38-), 
CEBPA mutation was detected in all patients, with the exception of patient 1 
and the second mutation in patient 4 where insufficient cells were collected for 
testing. The downstream populations, CMPs and GMPs, tested positive for the 
mutations in all cases, except for patient 3 where insufficient cells were 
collected for the CMP population. This data is summarised in Table 4.5.
These assays show that the CEBPA mutations are present within the 
stem cell compartment in evaluated patients; however the ability to accurately 
quantify the amount of mutation present in these compartments is limited. 
Due to limited amounts of sample available for sorting and testing, the sorted 
populations were not reanalysised for purity. Therefore it is possible for the 
tested populations to contain cells that do not strictly fall within the target 
population. Furthermore, the BM tested had an average blast count of 70.25% 
(range 40-95%) therefore the amount of mutation could also be diluted by 
presence of non-leukaemic cells.
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HSC CMP GMP
PI n=2 n/a 11%* 21%
P2 n=l 34% 100% 100%
P3 n=2 17%* n/a 40%
P4a n=2 100%* 16% 53%
P4b n=2 n/a 15% 54%
n/a: Insufficient amount of sample was recovered for testing 
* Mutation testing was only successful for one of the two cases
Table 4.5: Mutation detection in sorted AML samples
AML peripheral blood samples from 4 patients were flow sorted into three distinct 
hierarchal compartments, equivalent to the HSC, CMP and GMP in normal 
haematopoiesis. DNA isolated from each compartment was tested with the RQ-PCR 
assays for mutation using (32M as a control for numbers of cells tested. The average 
percentage of cells from the sorted populations is indicated for each patient.
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En g r a f t m e n t  of A M L  sa m pl e s
A further approach to determine whether mutations within CEBPA 
occur within a primitive cell type was to utilise the in vivo NOD/SCID model of 
leukaemia engraftment. As discussed in the introduction to this thesis, the 
ability of human cells to engraft within the murine host indicates that cells 
injected have the ability to self-renew. With AML, when engraftment occurs, 
the disease is faithfully reproduced, giving rise to cells with the same 
phenotype as the original disease.
Leukaemia samples from patients with RQ-PCR assays for CEBPA 
mutation were sorted into the stem cell compartments described above and 
injected into NOD/SCID mice to examine the population's engraftment 
potential. Following engraftment, the cells would be recovered and then be 
tested for presence or absence of mutation. This would demonstrate if the 
mutation is contained within a primitive cell type which is able to repopulate 
the mouse bone marrow.
AML cells from P4 were sorted by flow cytometry into
Lin-/CD34+/CD38-, CMPs, and GMPs populations. The recovered cells were
then injected into sub-lethally irradiated NOD/SCID (32 mice. The mice were
maintained under normal care conditions with the addition of antibiotics for
12 weeks. The mice were then killed, their bone marrow collected and
analysed by flow cytometry for engraftment of human cells (Table 4.6). Due to
an infection of the mouse colony several mice died before the experiment had
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Fraction Mice injected Mice Survived Engraftment
Lin- 34+ 38- 4 1 0/1
GMP 5 2 0/2
CMP 4 2 0/2
Whole Mononuclears 5 5 0/5
Table 4.6: LSC and early progenitors from P4 were sorted and injected into 
NOD/SCID p2M mice
Cells were sorted into HSC, CMP and GMP compartments and injected into lethally 
irradiated NOD/SCID (32M mice. Mice were left for 12 weeks and then bone marrow 
was harvested and examined for the engraftment of human cells.
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run its course. No human engraftment was observed from any compartment 
(Figure 4.10).
To confirm that the patient had a non-engrafting phenotype, whole 
mononuclear cells from the patient were injected into 5 NOD/SCID |32 mice, 
with 100,000 cells per mouse. After 12 weeks the mice were killed and 
analysed. Once again no engraftment was observed (Figure 4.11).
As has been described by our group during the duration of this thesis47, 
the ability of a particular AML to engraft in the NOD/SCID model is related to 
the prognosis of individual AML cases. In general it was found that AMLs 
with favourable prognosis were unable to engraft within the murine model. 
Since mutations in CEBPA are associated with favourable prognosis within the 
normal karyotype subset of AML, our results are consistent with this 
observation.
Sum m ary
In contrast w ith  C hapter 3 w here we restric ted  analysis to the
occurrence of m utation in the myeloblast Chapter 4 has addressed the
questions as to the order by which these mutational events might arise. The
data has provided fresh insight into how changes in gene dosage arises
(throught a mechanism of aUPD), have reestablished the importance of WT2
mutation as a cause of AML, shown the application of mutation specific PCR
to the study  of MRD and its parallel use to investigate  the cellular
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Figure 4.10: Sorted P4 cells did not engraft
Analysis of mouse bone marrow 12 weeks post injection of sorted P4 cells. Cells were 
examined for expression of human CD45 and CD33. The small population of events 
which was positive for both markers did not represent true engraftment.
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Figure 4.11: Whole mononuclear cells from P4 do not engraft
Analysis of mouse bone marrow 12 weeks post injection of whole mononuclear P4 
cells. Cells were selected for lack of expression of murine CD45 and then for dual 
expression of human CD45 and CD33. The small population of events which was 
positive for both markers did not represent true engraftment.
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compartment in which mutation arise. These new data have changed how the 
group views AML and has laid the foundation for the current direction of the 
groups' studies.
aUPD a s  a  m e c h a n is m  o f  l e u k a e m o g e n e s is
The presence of a mutation and the absence of the wild-type sequence 
has been previously reported in AML: W T l188, CEBPA114, and RUNX1189. Such a 
situation can arise by several mechanisms, including the deletion of wild-type 
allele to yield a hemizygous state, amplification of the mutant allele, or mitotic 
recombination. Without accurate copy number information, it has been 
difficult to distinguish between these possibilities. However with the 
application of SNP arrays, copy number information is provided.
Not all stretches of aUPD in this study were found to contain mutations 
in the genes examined, indicating that there must be other factors that underlie 
the outgrowth of clones containing these homozygous regions. In that respect, 
the study of aUPD can provide clues into the location of novel genetic events 
which are important in leukaemogenesis.
In solid tumours, acquisition of homozygosity without loss in copy 
number has been observed in breast cancer190' 191, uveal melanoma191, Wilms' 
tumours192, and retinoblastoma193. In addition, the background rate of mitotic 
recombination has been measured194 in normal human and mouse cells to be 
approximately 104 to 105 Thus, given the widespread nature of mitotic
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recombination, it is therefore very probable that the acquisition of 
homozygosity has a similar role in other tumours, besides leukaemia.
C h a l l e n g e s  a n d  a p p l ic a b il it y  o f  d e v e l o p in g  m u t a t io n  s p e c if ic  a ssa y s
Although CEBPA is a gene that plays an important role in AML there 
are difficulties involved in designing specific assays for mutations in this gene. 
Unlike genes such as JAK2 or NPM1, where the mutations found within the 
gene are the same from case to case, mutations in CEBPA are variable and 
therefore require specific design for each. This difficulty is partially alleviated 
by the clustering nature of mutations in CEBPA and the prevalence of insertion 
mutations, for which the assay design is applicable.
As about 60% of CEBPA mutations in AML reported in the literature77 
are insertions or deletions this makes them an attractive RQ-PCR target. 
Indeed a survey of the sequences shows clustering of mutations and indicates 
that Probe 1, 2, 3, 4b described herein could be applied to about 40% of these. 
Many of these mutations result in the insertion or deletion of a small number 
of additional nucleotides that should allow for the design of a specific primer 
against the unique sequence generated by the mutation67.
Unfortunately, lack of appropriate remission and relapse samples made 
it difficult to test the mutation specific PCRs for application as a MRD 
monitoring technique. However, with favourable prognosis it is of potential 
therapeutic significance to stratify patients containing CEBPA mutations and
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monitor them over the course of their disease. Its application and correlation 
with clinical outcome may now be evaluated, alongside other approaches 
assay such as multiparametric flow cytometry and WT1-expression changes, 
for its ability to quantify MRD in AML informatively. Applying the same 
principles mutations in other genes also have potential as appropriate targets 
that may increase the number of AML patients with normal karyotype 
amenable to MRD monitoring.
CEBPA MUTATIONS IN STEM CELL AND EARLY PROGENITORS
As studies have shown that the location of mutations and genetic 
events can play an important role in AML development it is important to 
determine where these key events take place. In our study, leukaemia samples 
were sorted into LSC, CMP and GMP compartments and then tested for 
presence of CEBPA mutations by specific real time PCR analysis. In general, 
CEBPA mutations were detected in all compartments for all samples.
Unfortunately it was not possible to examine further whether 
mutations in CEBPA did indeed take place within long-term repopulating cell 
type due to the lack of engraftment from the AML samples tested. Our lab has 
recently reported that the ability of a particular AML to engraft in the 
NOD/SCID model is related to the prognosis of individual AML cases which 
will be discussed further in the final chapter.
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C h a p t e r  5: F u n c t i o n a l  C o n s e q u e n c e s  o n  
H a e m a t o p o i e s i s  o f  m u t a n t  f o r m s  o f  C E B P A
Brief  in t r o d u c t io n  a n d  d e s c r ip t io n  o f  stu d y
Through the course of this thesis, we have examined the pattern and 
relationship between mutations as well as the timeline through which 
mutations give rise to AML. However, understanding the function of these 
mutations is an essential next step in addressing their role in leukaemogenesis.
Although CEBPA is a well studied transcription factor, the molecular 
mechanisms underlying the mutations of this gene and its role in 
leukaemogenesis have not been clearly defined. We have chosen to investigate 
this gene for several reasons. Mutations in CEBPA are the third most common 
genetic defect observed in normal karyotype AML, occurring in 
approximately 15% of NK AML patients77' 114' 143. CEBPA mutations have been 
implicated in familial AML100 102, and remain consistent between diagnosis and 
relapse119 indicating that these are likely to be early events in leukaemogenesis. 
Biallelic mutations in CEBPA are common and in our m utation studies we also 
noted that both mutations occurred on the same allele in some patients.
Familial cases of AML involving mutations in CEBPA provide 
particular insight into the importance of the two types of mutations observed
1 8 1
in this gene. Recently, our laboratory described a familial case of AML 
involving mutations in CEBPA100. The latency period for development of AML 
in this family ranged from 10 to 30 years. The family contained a heterozygous 
germline mutation of del (C) at nucleotide 212 (GenBank DNA sequence 
number Y11525; Swiss-Prot protein sequence number P49715). The mutation 
resulted in the premature termination of the C/EBPa protein at codon 158 and 
the selective production of the 30kDa isoform by way of an internal ATG site. 
In this chapter, these out of frame mutations which cause the selective 
translation of the 30kDa isoform will be referred to as N-terminal mutations.
In one affected family member, a second CEBPA mutation, an internal 
tandem duplication resulting in disruption of the DNA binding/dimerisation 
domain of the protein, was detected. This mutation was observed to have been 
somatically acquired in addition to the germline mutation. These in-frame 
mutations which disrupt the basic leucine zipper (DNA binding/dimerization) 
region of the protein will be referred to as C-terminal mutations. It is 
important to note that similar germline and somatic events have since been 
noted to occur in other familial pedigrees.
As in familial cases, biallelic mutations of CEBPA with an N-terminal
mutation on one allele and a C-terminal mutation on the other allele are found
in somatic AML119' 195. Furthermore, 2 mutations on the same allele have been
reported by our laboratory and others119 (Figure 5.1). In this part of the project
we have examined the significance of the acquisition of two distinct mutations,
N and  C -term inal, on the sam e allele  and  th e ir affect on no rm al
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Figure 5.1: Biallelic mutations in CEBPA are observed in AML
Cloning the gene can reveal information about the nature of the mutations. Biallelic 
mutations with N and C terminal mutations on separate alleles have been observed 
as well as the mutations occurring on the same allele.
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haematopoiesis. To investigate the transforming properties of CEBPA 
mutations and to test the significance of the double mutation variant of the 
gene, CEBPA containing an N-terminal mutation and both N and C-terminal 
mutations were cloned into lentivirus vectors and used to transduce 
lineage-depleted cord blood mononuclear cells. These cells contain the HSC 
and early progenitors of the haematopoietic system. Using transduced cells, in 
vitro colony forming cell assays and in vivo engraftment assays were 
performed to determine the effect of CEBPA mutations on normal 
haematopoietic proliferation and differentiation.
C l o n in g  m u t a n t  f o r m s  o f  CEBPA
A  patient with biallelic CEBPA mutations was selected as a template for 
functional analysis of dual N and C-terminal mutations. The patient contained 
an insertion at base 363 of four base pairs GGCC (N-terminal mutation) and an 
in-frame internal tandem duplication of 27 base pairs at 1096 (C-terminal 
mutation) (GenBank Y11525). Real-time quantitative PCR assays for the 
mutations in this patient were previously developed (see Chapter 4, P4 for 
details).
As mentioned previously, familial cases involving CEBPA mutations
begin with a germline N-terminal mutation and subsequently acquire a
C-terminal mutation. To emulate this, two mutant constructs were cloned, one
containing the N-terminal mutation ("N" construct) and one with both
mutations ("NC" construct). In these studies, we did not attempt to eliminate
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or downregulate normal CEBPA expression.
The cloning strategy for the creation of a lentivirus containing the 
mutant CEBPA gene is outlined in Figure 5.2 and described in detail in chapter 
2. Briefly, CEBPA from the patient was cloned into Topo vector and screened 
for mutations. The appropriate constructs were then cloned into an entry 
vector (pENTRlA) containing IRES-eGFP. The mutant gene and IRES-eGFP 
was next cloned into a lentivirus vector, resulting in the final construct of 
mutant CEBPA and GFP. The choice of a lentiviral vector reflects their ability 
to transduce non-proliferating cells, therefore this virus delivery system was 
chosen to target the primarily quiescent HSCs.
In addition to the two m utant constructs ("N" and "NC") and the mock 
(IRES-eGFP only), a wild type CEBPA and a construct containing only the 
C-terminal mutation were cloned. Despite several attempts, the presence of 
additional point mutations in the C-terminal mutation construct rendered this 
construct unusable for the remaining experiments. The generation of an 
appropriate C-terminal construct forms part of ongoing experiments in the 
laboratory.
T e s t i n g  m u t a n t  CEBPA l e n t i v i r u s  c o n s t r u c t s  f o r  p r o t e i n  e x p r e s s io n
To ensure that the correct protein forms of C/EBPa was produced by 
the lentivirus vector, 293T cells were transiently transfected with the CEBPA 
constructs. Cells were harvested two days after transfection and protein
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Figure 5.2: Cloning strategy for production of lentivirus containing CEBPA 
mutations
a) CEBPA was amplified directly from myeloblast genomic DNA by way of nested 
PCR approach, using external primers (black) and internal primers (blue). This PCR 
product was ligated into Topo 2.1 vector (Invitrogen) and transformed into ToplO 
bacteria. Colonies positive for successful ligation were selected, grown and plasmid 
DNA was extracted. The authenticity of the clones was confirmed by direct 
sequencing analysis.
b) PCR was performed using the Topo vectors as template to insert a FLAG sequence 
to the C-terminal portion of the protein and appropriate restriction enzyme sites to 
allow for digestion and ligation into a linerised pENTRlA vector which contains 
IRES-eGFP gene. The flag sequence and GFP were included to allow for visualisation 
of the gene during the cloning and transduction process.
c) The mutant CEBPA gene along with IRES-eGFP was next recombined into the 
lentivirus vector producing the final mutant construct.
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isolated. Western blotting with an antibody specific against C/EBPa was used 
to visualise the protein (Figure 5.3). Both the "N" and "NC" constructs 
produced a 30kDa protein.
GFP AND C /e b pa  a r e  c o e x p r e s s e d  in  t r a n s f e c t e d  c ells
With the production of the correct CEBPA mutant constructs it was 
necessary to demonstrate that GFP positivity would coincide with expression 
of C/EBPa. 293T cells were transiently transfected with the lentivirus plasmid 
for CEBPA construct and mock virus (containing IRES-eGFP only). 
Intracellular staining with an antibody specific against C/EBPa was performed 
on the cells, which were analysed by flow cytometry (Figure 5.4). 
Approximately 20% of cells expressed GFP for both viruses. The majority of 
the GFP positive cells for the CEBPA construct were also positive for C/EBPa, 
demonstrating that cells which express GFP also express C/EBPa.
F u n c t i o n a l  c o n s e q u e n c e s  o f  m u t a n t  CEBPA o n  l i n e a g e
DEPLETED CELLS
The aim of this study was to determine the effect of CEBPA on normal 
haematopoiesis using mutations observed in patient samples, and to ascertain 
if the combination of mutations is important.
FISC studies rely on several standard in vivo and in vitro assays for the 
assessment of haematopoietic stem cell activity. Presently, the best model used
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Figure 5.3: Western blotting to confirm expression of C/EBPa
The mutant lentivirus constructs were tested for C/EBPa expression by western 
blotting. 293T cells were transiently transfected with the mutant plasmids as 
described. Protein was isolated and run on a 12% SDS-PAGE gel with a Bio-Rad 
Kaleidoscope ladder for molecular weight determination and visualised by western 
blotting with a C/EBPa specific antibody (a) and p-tubulin for loading control (b).
Both "N" and "NC" constructs contain a frameshift mutation in the N-terminal 
region of the protein which forces the production of the 30kDa isoform. This isoform 
was observed for both constructs. The "Wt" construct, containing wild type CEBPA 
and the "C" construct, containing only the C-terminal region ITD, both produced the 
42kDa isoform. Cells transduced with the mock "M" construct which contains only 
GFP does not express C/EBPa.
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Figure 5.4: C/EBPa and GFP are co-expressed
293T cells transiently transfected with lentivirus plasmid expressing mutant CEBPA 
and IRES-eGFP show co-expression of C/EBPa and GFP. Cells were fixed and 
permeabilised following 48 hours of transfection, stained with an antibody specific 
for C/EBPa and analysed by flow cytometry.
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to define the repopulating capacity of human HSCs is the NOD/SCID mouse 
model196, an in vivo assay that measures the long-term ability of HSC to 
self-renew and reconstitute. Although there are a variety of in vitro assays 
available for the characterisation of HSCs, the colony-forming cell (CFC) assay, 
also referred to as the methylcellulose assay, is the most commonly employed 
in vitro assay for the quantification of haematopoietic progenitors197.
Since CEBPA is known to play an important role in myeloid 
development in a variety of cell compartments (HSC, CMP, GMP), we decided 
to examine the effects of the m utant forms of CEBPA constructs on primitive 
lineage depleted cord blood mononuclears (Lin- MNCs), which contains all of 
the aforementioned subsets.
TRANSDUCTION OF LINEAGE DEPLETED CORD BLOOD CELLS
A schematic of the strategy used in these experiments is shown in 
Figure 5.5. Lin- MNCs were transduced with virus containing various mutant 
combinations of CEBPA (details of methodology are given in chapter 2). These 
cells were then applied to the NOD/SCID xenotransplant model to assess the 
effects of mutant CEBPA on long-term repopulation ability of the cells and to 
methylcellulose assays to assess short-term repopulation and differentiation 
effects. Remaining cells were tested for GFP expression by flow cytometry to 
determine transduction efficiency.
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Figure 5.5: Schematic for set up of functional assays to test for the effects of 
mutant CEBPA
Lineage depleted cord blood mononuclear cells were incubated with cytokines and 
transduced with lentivirus containing the mutant forms of CEBPA. Cells and virus 
were incubated overnight (16h) and then the cells were used in the following assays. 
Long term repopulating capacity of the cells was tested by injecting NOD/SCID mice 
with cells transduced with virus expressing the mutant constructs. Short term 
repopulation and differentiation was tested by CFC assays. Transduction efficiency 
was tested by examining GFP expression of transduced cells.
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I n  V i t r o : S h o r t  t e r m  r e p o p u l a t i n g  a b i l i t y  a n d
DIFFERENTIATION
Methylcellulose assays were completed as described in Chapter 2 using 
media supplemented with cytokines to allow the growth of both erythroid and 
myeloid colonies. To reduce variation, Lin- MNCs from the same preparation 
were used within each assay. Non-transduced cells from the same aliquot of 
Lin- MNCs were used as a negative control.
Colonies on each plate were scored based on morphology of the 
colonies into 5 categories; BFU-E, CFU-E, GM, G and M (as described in 
Chapter 2). Initially a total colony count was performed. GFP positive colonies 
were then also scored based on colony morphology.
A n a l y sis  o f  m e t h y l c e l l u l o s e  a s s a y s
GFP visualisation
In total, four in vitro assays were carried out testing the "N" and "NC" 
constructs. Colonies were counted using a Lieca DM1L inverted microscope 
under 50x magnification. GFP was visualised by excitation from a UV lamp. 
Figure 5.6 shows examples of GFP positive colonies from various constructs. 
While some GFP positive colonies are brighter than others, they are clearly 
distinguishable from non-GFP expressing constructs, as demonstrated in 5.6a 
and c in which GFP negative colonies are observed in the same field of view as
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a) GFP positive myeloid colony from N mutation construct
b) GFP positive erythroid colony from N and C mutation construct
c) GFP positive myeloid colony from mock construct
Figure 5.6: Examples of GFP expressing methylcellulose colonies
GFP expression was visualised using an inverted fluorescence microscope. While 
some GFP positive colonies are brighter than others, they are clearly distinguishable 
from non-GFP expressing constructs, as can be seen in a) and c) where GFP negative 
colonies co-exsist in the same field of view.
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GFP positive colonies.
C h e c k s  a n d  C o n t r o l s
The lentivirus and GFP do not have an effect on proportion of colony types
To ensure that the effect observed within the assay was not due to GFP 
expression or due to the viral construct itself, transduction of the Lin- MNC 
cells was also performed using a viral construct containing only IRES-eGFP 
(mock). A total colony count of the plate was performed, assigning each of the 
colonies into one of the five categories. Colonies were then scored based on 
GFP expression. The proportion of each colony type within the GFP positive 
and GFP negative population was calculated and compared to the proportions 
in the non-transduced control.
For the mock construct, the proportion of colony types was the same 
between GFP positive and negative colonies, and did not differ from the 
non-transduced controls. This demonstrates that the effects which are 
observed within Lin- MNCs transduced with the CEBPA constructs are due to 
the expression of the mutated protein (Figure 5.7).
GFP expression correlates with mutant CEBPA
To ensure that the colonies which appear as GFP negative under the 
microscope do not express the mutant CEBPA gene, both GFP positive and
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Comparison of cells transduced with mock virus to non-transduced cells
100%
-------
70.1%
22.7%
Ju
1 ---------------\
55.4%
30.1%
| _________ 1
L - ______ 1
Mock GFP+ Mock GFP-
M GM BFU-E CFU-E
Mock GFP+ 0.0% 2.3% 25.6% 69.8% 2.3%
Mock GFP- 1.8% 4.0% 22.7% 70.1% 1.4%
NT 5.2% 4.9% 30.1% 55.4% 4.5%
Figure 5.7: Comparison of Lin- MNC transduced with mock virus to 
non-transduced cells
To ensure that the affect observed within the assay was not due to GFP expression or 
due to the virus construct itself, transduction of the Lin- MNC cells was performed 
with a virus construct containing only IRES-eGFP. The proportion of colony types 
were the same between transduced and non-transduced cells, indicating that the 
effects that are observed within the mutant transduced cells are due to the expression 
of the mutated protein and not due to viral or GFP expression.
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negative colonies were picked from the methylcellulose assays. DNA was 
isolated and tested for the presence of the N-terminal mutation via the specific 
real-time assay developed and described in Chapter 4. Real time detection of 
|32M was used as a control (Figure 5.8). All colonies yielded a signal for |32M
(a), while only GFP positive colonies tested positive for the CEBPA mutation
(b).
These experiments demonstrate that any effects observed as a result of 
transduction with the lentiviral constructs are due to expression of the mutant 
forms of CEBPA.
A n a ly s is  o f  i n  v i t r o  a s s a y s
The experiment was performed 4 times on separate occasions, resulting 
in the assays 1-4 reported in this section of the study. The results are tabulated 
in Figure 5.9 and show that both the "N" and "NC" constructs have an effect 
on the proportion of colony types. Cells successfully transduced (GFP 
positive) with the "N" construct resulted in a marked increase in the 
proportion of myeloid colonies and the "NC" construct resulted in an increase 
in proportion of erythroid colonies.
Analysis of the m utant constructs was performed by calculating the
proportion of the five colony types counted present for both GFP positive and
GFP negative colonies for each construct. Proportions of colony types were
utilised ra ther than  absolute num bers to facilitate com parison betw een
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Figure 5.8: Real-time PCR results show that colonies visualised as GFP 
positive also express mutant forms of CEBPA
To ensure that colonies that appeared to be GFP negative via microscopy did not 
express the mutant CEBPA gene, both GFP+ and GFP- colonies were picked from the 
methylcellulose assays. DNA was isolated and tested for the presence of the 
N-terminal mutation via the specific real-time assay developed and described in 
Chapter 4 and with real time against |32M as control. While all colonies resulted in a 
signal for |32M (a), only GFP positive colonies contained the CEBPA mutation (b).
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Figure 5.9: Analysis of in vitro experiments with mutant CEBPA constructs; 
results for each set of experiments are shown separately
Four assays were carried out in which a consistent trend was observed between each 
experiment. An increase in myeloid colonies was observed in cells transduced with 
the N-terminal mutation and an increase in erythroid colonies produced by cells 
transduced with the construct that contains both N and C-terminal mutations.
a) Assay 1: N-terminal mutation
Assay la: "N"
100%
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10%
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N  GFP - 2.1% 4.8% 15.0% 63.2% 14.8%
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b) Assay 1: N and C-terminal mutation
NCGFP + NCGFP
G M GM BFU-E CFU-E
NC GFP + 0.0% 0.0% 5.2% 93.3% 1.5%
NC GFP - 0.0% 0.0% 34.8% 64.6% 0.7%
NT 0.0% 2.1% 26.6% 68.4% 3.0%
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c) Assay 2: N and NC mutation
Assay 2: "N" and "NC"
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NGFP+ 0.0% 0.0% 46.7% 30.5% 22.9%
NGFP- 3.2% 0.0% 13.7% 64.5% 18.5%
NC GFP+ 0.4% 0.4% 14.5% 67.9% 16.7%
NC GFP- 0.9% 2.6% 29.3% 58.6% 8.6%
NT 1.1% 5.7% 24.6% 46.6% 22.0%
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d) Assay 3: N and NC mutation
Assay 3: "N" and "NC"
100% | a aP H O T
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NGFP+ 5.4% 2.7% 75.7% 10.8% 5.4%
N  GFP - 4.0% 6.7% 21.0% 66.1% 2.3%
NC GFP+ 0.0% 0.0% 2.2% 81.7% 16.1%
NC GFP- 3.2% 4.1% 32.7% 58.3% 1.7%
NT 5.2% 4.9% 30.1% 55.4% 4.5%
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e) Assay 4: N and NC mutation
Assay 4: "N" and "NC"
100% -  
90%-p 
80%- 
70%- 
60%- 
50%-t 
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30% 4  
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NGFP+ 0.0% 3.6% 60.7% 35.7% 0.0%
NGFP- 1.4% 2.5% 27.8% 66.1% 2.2%
NC GFP+ 0.0% 0.0% 22.2% 74.1% 3.7%
NC GFP- 4.3% 7.6% 14.6% 68.6% 4.9%
NT 2.6% 3.0% 26.1% 59.6% 8.6%
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experiments and to account for variation in transduction efficiency between 
assays.
S t a t is t ic a l  A n a l y s is
An increase in myeloid or erythroid colonies, for "N" and "NC" 
respectively, was consistently observed across the four assays (Figure 5.10 and 
Figure 5.11). Statistical analysis was performed comparing the GFP positive 
and negative myeloid (G, M, GM) and erythroid (BFU-E, CFU-E) colonies from 
each assay. Mean and standard deviation for the assays were calculated and is 
tabulated in Figure 5.11. Paired T-tests were used to determine statistical 
significance between the proportion of myeloid and erythroid colonies 
between transduced and non transduced cells (Table 5.1).
For "N", the difference in proportion of myeloid and erythroid colonies 
is statistically significant between the colonies transduced with the mutant 
construct and both the non-transduced control cells (myeloid p=0.013, 
erythroid p=0.014) and GFP negative cells within the assay (myeloid p=0.0044, 
erythroid p=0.0046). There was no statistical difference between GFP negative 
colonies and non-transduced controls (myeloid and erythroid p>0.05).
For "NC", the difference in proportion of colony types is significant 
between the GFP positive transduced colonies and the non-transduced control 
(myeloid and erythroid p=0.038). The GFP negative colonies were not 
statistically significantly different in proportion to the non-transduced control
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Average Results of methycellulose assay, n = 4
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N  GFP- mean 2.7% 3.5% 19.4% 65.0% 9.4%
NC GFP+ mean 0.1% 0.1% 11.0% 79.3% 9.5%
NC GFP- mean 2.7% 5.1% 24.0% 59.8% 8.6%
NT mean 1.9% 3.4% 27.5% 59.3% 7.9%
Figure 5.10: Combination of methylcellulose results obtained from assays 
1-4
The observation of a consistent trend across the assays indicates that the results are 
unlikely to be due to random insertion events of the lentivirus.
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Figure 5.11: Mean of transduced myeloid and erythroid colonies
To simplify analysis colonies were pooled into either myeloid lineage (G, M and GM) 
or erythroid (BFU-E, CFU-E). The mean and standard deviation are calculated across 
the 4 assays performed.
2 0 5
Myeloid Erythroid
N GFP+ to GFP- 0.0044 0.0046
N GFP+ to NT 0.013 0.014
N GFP- to NT 0.073 0.071
NC GFP+ to GFP- 0.055 0.055
NC GFP+ to NT 0.038 0.038
NC GFP- to NT 0.836 0.837
Table 5.1: Statistical analysis of methylcellulose experiments
The difference in proportion of erythroid and myeloid colonies observed is 
statistically significant for transduced colonies (GFP+) compared to non-transduced 
controls for both N and NC mutant constructs (p<0.05, t-test). The proportion of GFP- 
colonies is not significantly different from the non-tranduced controls (p>0.05, t-test). 
There was significant difference between GFP+ and GFP- in the N-mutation 
construct and a strong trend for the NC construct.
2 0 6
(myeloid and erythroid p>0.05). Although it did not reach significance, there 
was a strong trend (p=0.055) for an increase in erythroid colonies upon 
transduction with the "NC" between GFP positive and negative cells.
M u t a n t  C/EBPa d o e s  n o t  a p p e a r  t o  a f f e c t  p r o l if e r a t io n
The total number of colonies per plate for each assay was compared to 
determine whether expression of the mutant proteins significantly altered the 
ability of the cells to form colonies within the methylcellulose assays (Figure 
5.12). Although absolute numbers of colonies per plate varied between assays, 
there was no difference in colony formation for either "N" or "NC" transduced 
plates compared to the N t plates.
The percentage of GFP positive cells was measured 1-3 days following 
transduction with the lentivirus constructs. This was compared to final 
percentage of GFP colonies observed to determine whether an outgrowth of 
transduced cells occurred during the experiments. In general there was a trend 
for an increase in percent of GFP positive colonies for "NC" constructs and a 
decrease for "N"; however this was not consistently observed across all 
experiments (Figure 5.13).
T r a n s d u c t io n  w it h  w il d  ty pe  CEBPA
To ensure the changes observed with the transduction of Lin- MNCs 
with "N" and "NC" constructs was caused by the mutations in gene lentivirus
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N u m b ers  o f c o lo n ie s  p e r 1000 ce lls  p la ted
Exp 1a
■ N
■ NC 
□ Nt
Exp 1b Exp 2 Exp 3 Exp 4
Figure 5.12: Comparison of absolute colony numbers
There is no consistent trend between the numbers of colonies scored on each plate 
and a particular construct, indicating that variation is not influenced by the 
particular mutant constructs.
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Figure 5.13: Overall there is no significant outgrowth of GFP positive cells 
for either construct
To determine whether the mutant constructs provided a proliferative advantage to 
the cells they transduced, % GFP was calculated at initial transduction (left hand side 
of chart) and at the end of the assay (right hand side of chart). "N" constructs are 
depicted with thin lines, "NC" with thick. Overall, there was no significant 
outgrowth or depletion of transduced cells for either construct.
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containing wild type CEBPA was also attempted. Of the three assays for which 
the wild type construct was used, the percentage of cells successfully 
transduced was very low for assays 2 (0.5%) and 4 (2.5%) therefore provided 
insufficient data for further meaningful analysis. In assay 3, 11.6% of the 
colonies expressed GFP (Figure 5.14). Although it appears that there could be 
a difference in proportion of colony types between the GFP+ and GFP- 
populations, it is not possible to drawn definitive conclusions from the result 
of a single assay. It is therefore imperative for future work to include the wild 
type construct to determine whether any of the effects observed from the 
mutant constructs are due to expression of CEBPA through the lentiviral 
system rather than from the effect of the mutations themselves. These results 
however suggest that the effects observed are not only due to general CEBPA 
expression since the "N" and "NC" constructs resulted in different outcomes.
I n  V i v o : L o n g  t e r m  r e p o p u l a t i n g  a b i l i t y
The short term in vitro methylcellulose assays indicate that differentiation of 
Lin- MNC is influenced by expression of mutant forms of CEBPA. To examine 
whether the mutant genes have any affect on long-term repopulating cells, 
NOD/SCID assays were used to examine self renewal ability of transduced 
Lin- MNCs.
Two in vivo experiments were carried out to test the mutant forms of
CEBPA. These assays correspond to Assay 1 and 2 in the in vitro study, with
the same transduced cells being used for both assays. As previously described,
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Wild Type CEBP: Assay 3
27.80%
Wt GFP+
G M GM BFU-E CFU-E
Wt GFP+ 0.00% 0.00% 19.40% 78.50% 2.20%
Wt GFP- 2.80% 4.40% 27.80% 56.40% 8.50%
NT 5.20% 4.90% 30.10% 55.40% 4.50%
Figure 5.14: Transduction of Lin- MNC with wild type CEBPA
The lentiviral expression of wild type CEBPA could account for some of the effects 
observed from the assays involving the mutant constructs. Unfortunately 
transduction efficiencies with the wild type construct were quite poor with only 
Assay 3 having sufficient GFP+ colonies for analysis. Although there appears that 
there could be a difference in proportion of colony types between the GFP+ and GFP- 
populations, it is not possible to drawn definitive conclusions from the result of a 
single assay.
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Lin- MNCs were transduced with lentivirus containing the m utant constructs. 
Approximately 100,000 of these cells were injected into lethally irradiated 
NOD/SCID mice. Mice were assessed for engraftment of human cells 
following approximately 12 weeks.
A ssa y  1
To test the "NC" construct, 5 mice were injected with cells transduced 
with the "NC" lentivirus via tail vein injection. One mouse was injected with 
Nt cells from the same pool of Lin- MNCs.
To test the "N" construct, 3 mice were injected with Lin- MNCs 
transduced with the "N" construct. One mouse was injected with Nt cells from 
the same pool of Lin- MNCs.
Transduction efficiency of Lin- CB MNCs
Following injection of transduced cells, the remaining cells were 
returned to media with additional cytokines. These cells were maintained for 
1-3 days and then analysed by flow cytometry for GFP expression to 
determine the efficiency of transduction. In the first assay, "NC" virus resulted 
in 21% GFP positive cells and "N" virus yielded 17% of GFP positive cells.
Engraftment of "NC" construct (Assay la)
Two of the mice that were injected with transduced cells died before the
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end of experiment due to illness unrelated to the experiment. The remaining 3 
"NC" mice and the 1 Nt control were analysed for engraftment of human cells 
by flow cytometry. Antibody against human CD45 was used to test for overall 
engraftment of human cells within the mouse system. Myeloid and lymphoid 
engraftment was tested by using CD33 and CD19 markers respectively. 
Overall human engraftment ranged from 51 to 72% in the transduced cells and 
was 71% for the non-transduced control (Figure 5.15).
Three distinctive populations of GFP expression were observed, no GFP 
expression (negative), low GFP expression and high GFP expression. The cells 
in the low GFP expression were also observed within the non-transduced 
controls and when examined on a CD19 vs CD33 plot the GFP low population, 
appear to consist of debris and not fall into populations of a specific cell type. 
Therefore, this population of cells was not classified as being GFP positive, 
only those with high expression of GFP (Figure 5.15). The amount of GFP 
positive cells in the transduced populations varied from 36 to 77% of all 
human cells expressing GFP.
Within the human GFP positive and negative populations, the cells
were analysed for myeloid and lymphoid lineage. On average 3% of GFP
positive cells expressed CD33 (myeloid marker) and 95% expressed CD19
(lymphoid marker). GFP negative cells from these mice showed on average
4.5% CD33+ and 90% CD19+. The Nt control had 6.5% CD33+ cells and 89%
CD19+. A slight reduction in the percentage of GFP positive myeloid cells was
observed compared to GFP negative cells; however there was not enough
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a) Non-transduced control
>  CD33FSC --------► hCD45  ► GFP
*■
b) N and C-terminal mutation
*  FSC  ^  hCD45  ► GFP
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<860/20-Red-A>
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c)
NC % total 
engraftment
GFP positive cells GFP negative cells
% CD 33 + % CD 19 + % CD 33 + % CD 19 +
1 51 36 54
2.8 95 4.5 91
2 64 77 13.5
3 95 2.4 92
3 72 44 44
2.8 95 6.6 88
Nt 71 - 6.5 89
Figure 5.15: First in vivo experiment examining the NC mutation
Engraftment of transduced Lin- MNCs was analysed as described in chapter 2. 
Overall engraftment was determined by percentage of cells expressing human CD45 
within the murine bone marrow. Cells transduced with the "NC" construct ranged in 
engraftment from 51-72%, and was comparable to the non-transduced (Nt) control. 
Within the hCD45 population, 3 GFP populations were observed, negative, low and 
high. The low GFP population was disregarded as it contained mainly debris and no 
specific myeloid or lymphoid cells and therefore accounts for the proportions of GFP 
positive and negative cells not equalling 100%. Myeloid (expressing CD33) and 
lymphoid (expressing CD19) proportions within the GFP positive and negative 
populations were compared.
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information to draw definitive conclusions.
Engraftment of "N" construct (Assay lb)
The 3 transduced mice and the 1 Nt control were analysed as described 
for the "NC" transduced cells. Overall engraftment was lower than the 
previous "NC" experiment, ranging from 2.6 - 6.1%. Engraftment of the Nt 
control was 16.3%. GFP positive engraftment was below 1% of engrafted cells 
and therefore of insufficient number for further analysis (Figure 5.16).
A ssa y  2
The in vivo experiment was repeated, with Lin- MNCs from the same 
preparation transduced with both "NC" and "N" constructs along with an Nt 
control. Four mice were injected with cells transduced with "N", 2 mice for 
"NC" and 1 mouse for the Nt control. Mice were sacrificed at 11 weeks and 
analysed for engraftment as described previously for assay 1 (Figure 5.17).
As in the previous experiment, overall engraftm ent was greatly 
reduced in the "N" cells (1.4 - 5.1%) as compared to the Nt control (29.8%). 
Engraftment of GFP positive cells was observed only in one of the four mice 
(N3, 0.34%). Engraftment of the "NC" cells was varied. The first mouse had 
13.9% human engraftment, with 4% GFP positive cells. The second mouse had 
59.8% engraftment with 28% of the cells being GFP positive. Of the GFP 
positive cells 18.4% were myeloid and 79.8% were lymphoid and showed a
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a) N-terminal mutation
>
<695/40-Blue-A> <530/30-Blue-A>
hCD45
*CD33
N %  total GFP positive cells GFP negative cells
engraftment % CD 3 3 +  % CD 1 9  + % CD 3 3  +  % CD 1 9  +
1 5 .5 0 .2 5 3 0 .5
- - 11 2 7
2 2 .6 0 .1 1 0 .6
- - 1 .6 1 4
3 6 .1 0 .0 4 6 7 .1
- - 9 6 9
Nt 1 6 .3 - - 6 85
Figure 5.16: First in vivo experiment: N-mutation
Engraftment of transduced Lin- MNCs was analysed as described in chapter 2. 
Overall engraftment was determined by percentage of cells expressing human CD45 
within the murine bone marrow. Cells transduced with the "N" construct ranged in 
engraftment from 2.6-6.1%, lower than the non-transduced (Nt) control. There was 
very little GFP positive engraftment within the "N" construct, preventing further 
analysis.
10* -
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<695/40-Blue-A> <695/40-Blue-A> <695/40-Blue-A>
N t N  NC
*  hCD45
% total 
engraftment
% GFP positive  
cells
% GFP negative  
cells
N C I 13.9 4 11.4
NC 2 59.8 28 57.5
N  1 1.4 - 19.4
N  2 5.1 - 62.7
N  3 1.4 0.34 12.3
N  4 2.1 - 3.55
Nt 29.8 - 82.5
Figure 5.17: Engraftment results corresponding to the second in vivo  
experiment.
Engraftment of transduced Lin- MNCs was analysed as described in chapter 2. 
Overall engraftment was determined by percentage of cells expressing human CD45 
within the murine bone marrow. Cells transduced with the "NC" construct ranged in 
engraftment from 13.9-59.8%, comparable to the non-transduced (Nt) control. Cells 
transduced with the "N" construct had lower engraftment as compared to the 
control. Similar to the previous experiment there was little GFP positive engraftment, 
preventing further analysis.
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similar ratio to the 21.1% and 76.8% observed within the GFP negative 
population. Due to the low levels of engraftment of GFP positive cells, further 
analysis was not possible for this experiment. Based on the results of assay 1 
and 2 further NOD/SCID experiments were not performed.
Su m m a ry
This study has started to test the contribution of m utant forms of 
CEBPA on haematopoietic development. To accomplish this, Lin- MNCs were 
transduced with lentiviral constructs containing mutant forms of CEBPA and 
assessed for changes in short term repopulation ability and differentiation by 
in vitro methylcellulose assays and for long term repopulating ability by in vivo 
xenotransplant models. The results of the in vitro experiments indicate that the 
mutant forms of CEBPA play an important role in determining the lineage fate 
of Lin-MNCs.
P o s sib l e  m o l e c u l a r  m e c h a n is m  f o r  c h a n g e  in  c o l o n y  t y pe s  d u e  t o  
MUTANT FORMS OF C/EBPA
CEBPA has been shown to play an important role in myeloid lineage 
development and it is therefore not surprising that mutant forms of the protein 
are observed to have an effect on differentiation of Lin- MNCs. 
Methylcellulose assays primarily examine early progenitors, cells with limited 
self-renewal capacity and it is important to note that the colonies scored do not 
consist of terminally differentiated cells.
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Both the "N" and "NC" constructs appear to function in a dominant 
negative manner against wild type C/EBPa since no attempt was made to 
silence the endogenously expressed protein. To perform its function as a 
transcription factor, C/EBPa must dimerise before it is able to bind to its DNA 
recognition sequence. It can either form homodimers or heterodimers with 
other C/EBP family members. In the case of the 30kDa isoform (which 
corresponds to the "N" mutation construct), the protein retains its 
dimerisation and DNA binding capabilities, however it has reduced 
transcriptional activation ability due to the lack of the first transactivating 
domain65.
In the in vitro experiments presented in this chapter, expression of the 
"N" construct in Lin- MNCs was shown to promote colony differentiation 
down the myeloid lineage. It is possible that this isoform retains sufficient 
functional capacity to initiate myeloid differentiation, but below a threshold 
level to allow terminal differentiation of the cells, which was not assessable by 
this assay, resulting in an accumulation of myeloid progenitors. Furthermore it 
is possible for other members of the C/EBP family help to compensate for the 
lack of functional C/EBPa and allow haematopoiesis to proceed.
As discussed in the previous chapter, mutations within the C-terminal 
region of C/EBPa tend to cluster together. The majority of internal tandem 
duplications and in-frame duplications fall within the small region separating
the DNA-binding basic domain from the leucine zipper dimerisation domain.
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Figure 5.18 shows the location of mutations for the 4 patients studied in this 
thesis along with the DNA binding and dimerisation domains of the protein.
It is possible that in the cells expressing the mutant proteins that the 
dimerisation function is maintained and therefore endogenous wild type 
C/EBPa is sequestered. However, the altered protein structure in the adjoining 
region results in the dimerised protein losing DNA binding ability. Due to the 
alpha helical nature of the protein in this region, even small insertions are 
sufficent to disrupt its binding ability and therefore cause the loss of function 
as a transcription factor and its ability to promote myeloid development198. As 
is shown previously in Figure 1.9, C/EBPa activity is upregulated during the 
differentiation process from the CMP to the more committed GMP population. 
Therefore, a loss of function for C/EBPa may result in cells differentiating 
towards the erythroid lineage due to a block in myeloid differentiation, rather 
than promoting erythroid differentiation.
The "NC" mutant construct did not completely abolish myeloid colony 
formation within the system. Although the mutant isoforms may function in a 
dominant negative manner by sequestering the wild type protein, is it likely 
that sufficent endogenous C/EBPa remained in a functional state to produce 
the myeloid colonies observed.
There is ample evidence that expression of CEBPA plays a crucial role in
myeloid development. Murine models have demonstrated that enforced
expression of CEBPA in HSCs results in the loss of erythroid progenitors and
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Figure 5.18: Mutations in CEBPA cluster in the region between the basic 
motif and leucine zipper
The C-terminal domain of C/EBPa is involved in DNA binding and dimerisation 
through its basic region and leucine zipper, respectively. In the four patients studied 
for mutations in CEBPA, all the C-terminal insertion mutations fall in between the 
basic region and the leucine zipper. The insertion of amino acids disrupts the alpha 
helical secondary structure of this region. In the case of the mutations between the 
regions, it is possible that the protein is able to retain it dimerisation ability, but loses 
its ability to bind to its target DNA sequence.
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an increase in myeloid progenitors199. CEBPA has also been observed to direct 
MEPs and CLPs to produce functional macrophages200. Similar experiments 
using human cells has shown that the expression of CEBPA in CD34+ cells 
leads to granulocytic differentiation and inhibits erthyroid differentiation201.
Schwieger et al135 demonstrated that expression of the 30kDa isoform in 
human CD34+ cells isolated from cord blood inhibits the differentiation of 
both myeloid and erthyroid lineages. While this is not consistent with our 
results (overall number of colonies not reduced) this can be explained by the 
difference in methodology where we analysed of immature cell types rather 
than examining fully differentiated cells. In keeping with our results using the 
"NC" contruct, Liu et al136 demonstrated that primitive erythropoiesis is 
stimulated in zebrafish upon expression of the 30kDa isoform.
Furthermore, in familial cases of AML involving CEBPA mutations, 
patients are able to live for many years with a germline "N" mutation, 
indicating that the effects of a single mutation is necessary but not sufficient 
for leukaemogenesis, which is in accordance with our observed effects. The 
"N" construct allows for myelopoiesis, where the addition of the C-terminal 
mutation results in a block in this differentiation pathway.
En g r a f t m e n t  A ssa y s
A major limitation of the in vivo experiments was the quality of 
lentiviral production. Engraftment of GFP positive cells was low for cells
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transduced with the "N" construct and overall engraftment was lower for 
these cells than for the non-transduced controls and cells transduced with the 
"NC" construct (Figure 5.19). It is likely that the reduction in levels of 
engraftment from the cells transduced with "N" construct is due to the virus 
preparation itself since GFP negative (non-transduced) cells within the 
transduction assay also exhibited reduced engraftment potential. While the 
same viral preparation was used in our parallel in vitro experiments, fewer 
cells and therefore less virus was required for these experiments.
To determine whether viral toxicity played a factor in the reduced 
engraftment of the "N" construct another preparation of the lentivirus should 
be prepared and tested. Although it is unlikely that toxicity of GFP would play 
a role, the transduction of a mock virus construct would help to eliminate that 
possibility.
For the cells transduced with the "NC" construct, overall engraftment 
levels were comparable to those of the non-transduced control, although as in 
the in vitro assays transduction efficiency was variable. In Assay 1, no 
significant change w as observed betw een the lym phoid and m yeloid 
p o pu la tions of the  e n g ra fted  cells w hen  com paring  tran sd u ced  to 
non-transduced cells. However, as the in vitro experiments demonstrated, the 
significant difference is between the proportion of myeloid and erythroid 
progenitor cells. A limitation of the NOD/SCID model is that to achieve 
human erythroid engraftment, the mice require supplementation with the
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Figure 5.19: Overall engraftment for in vivo experiments
Each mouse is represented by a blue diamond. Mean % engraftment is represented 
by a red bar. A reduction in overall engraftment (both GFP positive and negative 
cells) for "N" construct transduced cells indicates potential toxicity in the viral 
preparation. Although engraftment levels for the "NC" construct varied, the mean 
engraftment percentages were similar to the Nt controls.
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cytokine EPO during the engraftment process. Future experiments of this 
nature should strive to examine the myeloid compartment of the engrafted 
cells in greater detail.
The results can also be explained for the lack of effect observed in the in 
vivo cases, as opposed to the in vitro experiments, by the target cell. The in vivo 
models examine cells with longer term self-renewal potential (stem cells) 
whereas the in vitro experiments examine more mature cells (early 
progenitors). Since C/EBPa has its greatest affect on early progenitor cells, it 
may be that the effect of these mutations are not manifested within the long 
term repopulating HSCs and therefore not observable by the 
xenotransplantation models.
Fu t u r e  w o r k
The results from the in vitro methylcellulose assays demonstrate that it 
is likely that mutation combinations in CEBPA play important roles in myeloid 
differentiation. The work that has been reported here today raises some 
interesting questions and further experimentation should be undertaken, such 
as:
- the examination of the "C" mutation alone
- the examination of both "N" and "C" mutations together 
(mimicking biallelic mutation distribution)
- inclusion of wild type and mock controls
- silencing of endogenous C/EBPa
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- targeting cell types (HSCs and early progenitors)
- further proliferation assays
Since transduction of the same cells with the "N" and "NC" constructs 
yielded quite different results, the next logical step would be to examine the 
effect of just the C-terminal mutation. If the effects of the "NC" construct are 
due to the abolishment of DNA binding ability of the protein, a "C" construct 
would likely produce a similar effect. Furthermore, although both the N and 
C-terminal mutations are observed on the same allele in some cases, the more 
prevalent situation is biallelic mutations, with an N-mutation on one allele and 
a C-mutation on the other. To emulate this in our assay, both the "N" and "C" 
construct would be used to transduce cells together to observe the effects of 
the two mutations in concert.
Furthermore, silencing endogenously expressed CEBPA via siRNA 
targeted to the 3' UTR would eliminate any remaining wild type allele. In 
work performed by Nerlov's group, they have demonstrated that the 
expression of the 30kDa isoform of Cebpa in a Cebpa null background results in 
the development of overt leukaemia in mice. Silencing endogenous CEBPA in 
human cells and then transforming them with the various mutant constructs 
could potentially give an indication of whether a similar system would have 
transformation properties in human cells.
Furthermore, the possibility of targeting specfic cell types for
transformation should allow further refinement of the assay system. In a
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similar manner to the studies examining the transformation ability of fusion 
proteins, cells sorted into different cell types, such as HSCs, CMPs and GMPs 
could be transduced with the CEBPA mutant constructs to determine whether 
the mutation has the same effects in different cell types.
Although the in vitro assay gave a good readout of the effects on 
differentiation of the m utant constructs, possible proliferation effects were not 
assessed within this assay. To determine whether the expression of the mutant 
forms of C/EBPa alter the self-renewal capabilities of the cells, serial replating 
and proliferation assays can be conducted.
As discussed briefly previously, the inclusion of control wild type 
CEBPA is important to ensure that effects observed are due to the action of the 
mutations in the gene and not merely a product of expression of CEBPA via 
the lentiviral system. However, since different effects were observed for the 
two mutant constructs it is unlikely that these results are due to the expression 
of CEBPA alone. Poor transduction efficiency was a limiting factor in the case 
of the wild type control, therefore future work would benefit from adjusting 
methodology (such as adding a spinoculation step) to improve transduction 
efficiency.
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C h a p t e r  S ix : D i s c u s s i o n
AML is a clonal, malignant proliferation of undifferentiated 
haematopoietic cells that is morphologically, genetically and therapeutically 
heterogeneous. The leukaemic blasts that make up the bulk of the disease have 
low proliferative potential and are maintained by a rare population of LSCs 
responsible for propagating the disease. Following completion of the human 
genome-mapping project, we find ourselves in the fortunate position to be 
able to interrogate each gene for both mutation and gene expression changes 
in AML and how these events arise in the LSC population. The success of these 
approaches is evident from several recent reviews from the Bloomfield group5' 
70 who have compiled these data into a speculative molecular prognostic 
discriminator (Figure 1.9). Satisfyingly, we have made several contributions to 
these analyses. These have been discussed at the end of each chapter and are 
summarised below. An important new consideration however is not only the 
nature of these mutational events but also the order and timing by which these 
events arise. We have tried therefore to trace how these events might have 
arisen by analysing or inferring mutational patterns within the initial HSC, the 
corresponding LSC and more typically myeloblast cell population.
We sought to answer some simple questions relating to the nature, 
pattern and order by which these mutations arise in NK AML, rather than 
confining ourselves to merely testing for the presence or absence of mutation.
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What types of mutations are present?
How many genes are involved?
What length of time does it take for the disease to develop?
In which order do the mutations arise?
What is the function of mutations in AML?
What types of mutations are present and how many genes are involved?
Mutation screening of a panel of 88 NK AML patients for 8 genes (FLT3, 
CEBPA, RUNX1, NRAS, cKIT, PTPN11, NPM1 and WT1) allowed us to build a 
picture of the pattern of gene mutations involved in leukaemogenesis. The 
majority (85%) of patients harbour mutation in at least one gene, with a large 
proportion containing multiple mutations. Of these, 44% of the AMLs 
contained mutations in both Class I (deregulation of proliferation) and Class II 
(block in differentiation) that supported the hypothesis, put forward by 
Gilliland and colleagues that deregulation of both pathways are required for 
the development of overt leukaemia.
Mutations occur in a non-random manner
In keeping with this hypothesis mutations do not arise independently 
of each other. This is a well described phenomenon in the literature. In our 
series for example FLT3-YTD and mutations in NRAS  occurred independently 
of each other. In work published by our group143, cKIT mutations were 
observed exclusively in favourable risk patients and absent in both
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intermediate and poor karyotype. Similarly, mutations in CEBPA and NPM1 
occur almost exclusively in intermediate/NK cases. The description by our 
group100 of a familial case of AML involving CEBPA mutations yields further 
insight into the process of leukaemogenesis whereby N-terminal mutations 
occurred in the germ-line and somatic C-terminal mutations were required for 
the onset of overt disease. Such long latency periods preceding AML in this 
family indicate the requirement of additional cooperative mutations and that 
mutations in CEBPA are a key event in leukaemogenesis. In contrast, patients 
with familial Wilms' tum our inheriting a germline WT1 mutation are not 
predisposed to the development of AML. This suggests that although WT1 
mutations may play a role in AML, they are not an initiating event in 
leukaemogenesis.
Since a proportion of our cases (15%) showed no mutation in any of the
genes tested we also performed selective mutational studies in 2 candidate
genes, CCND3 and FES, based on their cellular function. In keeping with the
trend in mutation studies of AML mutation analysis was restricted to
particular motifs rather then analysing the entire coding region of the gene.
No mutations were found within the TKD of FES and a single mutation was
observed within exon 5 of CCND3. This mutation results in an in frame
deletion of 51bp of exon 5 and follows a very similar theme to many of the
other mutational events in AML where in frame (CEBPA, FLT3) and out of
frame (CEBPA, RUNX1, WT1) insertions or deletions occur frequently. Despite
performing extensive mutation analysis we failed to detect mutations in
several cases within our cohort demonstrating that additional genes or other
231
mechanisms of gene deregulation must exist.
Mutations and prognosis
Although mutations in NK AML can be used to stratify patients within 
the NK cytogenetic risk group into favourable and poor prognostic cases5, our 
panel was not sufficiently large to recapitulate these findings. This is not 
surprisingly as cases from our centre were selected based on the quantity of 
frozen material rather than on age or the treatment regimes ascribed to the 
individual patient. However, given the literature on prognostic relevance of 
gene specific mutations in NK AML, we would strongly support the 
introduction of routine mutation screening of commonly mutated genes, 
particularly FLT3, CEBPA and NPM1 at diagnosis for evaluation as part of the 
clinical management of patients with this disease.
In what order do mutations arise?
Although the mutation screening of our panel of NK AML patients was 
able to shed light on the types and numbers of mutations required for the 
generation of AML, merely examining the myeloblast compartment did not 
address the order by which these genetic lesions arise. The work presented in 
this thesis on aUPD acting as a second hit in the generation of homozygous 
mutations has started to address these points and identify how normally 
occurring mitotic recombination can contribute to leukaemogenesis. In these 
studies homozygous mutations of FLT3, CEBPA, RUNX1 and WT2 were
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identified in 7 cases. Until this point and the work of Bryan Young and 
colleagues183-202 it had been difficult to provide a plausible explanation for 
increased mutation dosage observed for mutations such as FLT3-YTD71. This is 
particularly relevant in AML since patients having a high FLT3 mutant to wild 
type ratio have a poorer prognosis than patients with lower mutation loads. 
The link with aUPD provides a clear explanation for how this arises and 
discriminates between other possible causes, for example hemizygosity of 
chromosome 13 or localised deletion of the FLT3 locus. Regions of aUPD has 
also been observed in other haematological disorders and solid tumours 
giving the impression that mitotic recombination leading to homozygosity of a 
pre-existing lesion plays a role in cancer in general.
It is important to point out that we were not able to determine the basis
of daughter selection in all cases (aUPD 6p, 9p, l ip  and llq )  studied. Based on
our current experience it seems plausible that within these regions of
homozygosity there must exist genetic lesions that confer an advantage to the
cell and effect clonal outgrowth with the removal of the wild-type allele. aUPD
of 6p appears to be a common phenomena in haematological malignancies,
including follicular lymphoma203 and therefore should be an area of focus for
future research. CCND3, which is located on 6p, was screened for mutations
and while a mutation was identified exon 5 within the NK panel, the gene was
not mutated in aUPD cases suggesting that the selective basis is located
elsewhere on chromosome 6. We are also unable to rule out the possibility that
epigenetic changes or shifts in tumour allelotype could be responsible for
daughter selection following mitotic recombination. The further refinement of
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the technology to provide more targeted information on the regions of 
homozygosity should be able to narrow the focus of these positional studies 
further.
Besides looking for mutations in genes known to be involved in other 
types of cancers, another approach to discovering new mutations within AML 
would be to conduct systematic genome wide screening on several cancers to 
elucidate possible key changes. A recent study by Sjoblom et al204 utilised this 
method of systematic screening in breast and colorectal cancers, finally 
identifying 189 genes out of the 13,000 they screened as playing a key role in 
the generation of these diseases. While an advantage of AML over solid 
tumours is a general lack of chromosomal instability, the absence of known 
mutations in a subset of patients with NK AML indicate that there are likely to 
be genetic events contributing to the development of these diseases that have 
not yet been identified that may benefit from such a systematic screening 
approach.
The occurrence of homozygous WT1 mutation has proven particularly
important to our group168. We have since evaluated the role of WT2 mutation
in NK AML. These mutations occur in approximately 10% of cases with
30-50% of mutations indicative of increased mutation dosage and the
occurrence of aUPD. The group is in the process of determining the prognostic
relevance of these mutations; early suggestion is that these mutations are
associated with failure of induction chemotherapy and a trend towards
inferior overall survival168. It is of interest that not all cases of aUPD in l ip
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involve mutations at the WT1 locus. We have excluded mutations within the 
coding region of PU.l transcription factor in these cases and are now 
considering the possibility for mutation or allelotype alteration in an upstream 
enhancer element as the causative mutation as the underlying selective 
mechanism. It has been recently shown that a polymorphism in an upstream 
enhancer element of PU.l affects transcription of the gene205. As was discussed 
in the introduction, the concentration of transcription factors plays an 
important role in the generation of AML and therefore any alterations to the 
production of these proteins may be the mechanism of leukaemogenesis in this 
model.
Minimal Residual Disease
Reflecting an inability of current treatments to specifically target the
LSC, greater than 50% of patients with NK AML will relapse having achieved
complete remission. Unlike in the favourable risk setting where fusion
transcripts are routinely used to monitor MRD and are predictive for
impending relapse, the absence of a molecular signature in NK patients has
limited MRD analysis in these patients. WT1 gene expression has long been
considered a good marker for MRD detection for about 70% of all cases18. The
identification of NPM1 mutation probably offers a better strategy in the future
for NK patients since it occurs in approximately 60% of cases of NK AML and
the group of Falini and colleagues206 have reported its application for the
routine testing of MRD. In the Bart's cases we chose to analyse CEBPA,
mutations in this gene are less frequent and although clustered to particular
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regions of the gene require the development of patient specific assays. In 
keeping with NPM1, CEBPA mutations appear to be an initiating event in 
leukaemogenesis being present with greater than 90% concordance between 
diagnostic and relapse samples119. In the absence of an appropriate 
retrospective material we utilised our CEBPA mutation specific assays to 
examine the occurrence of mutation within the leukaemia equivalents of the 
HSC compartments. We were able to show that CEBPA mutations occurred 
within all tested compartments which is in agreement with familial cases 
involving the mutations.
What is the function of mutations in AML?
The gene CEBPA is particularly suitable for studies examining the 
clonal evolution of AML due to its intronless structure, which allows us to 
examine the allelic distributions of mutations. While commonly the occurrence 
of 2 mutations within a gene is presupposed to reflect mutations on alternative 
alleles, in CEBPA we did noticed the occurrence of biallelic mutations, but also 
the co-localisation of mutations on the same allele, a phenomenon also 
reported by other groups119.
We made two m utant constructs of the CEBPA gene, one containing the 
N-terminal mutation ("N") and the other containing both mutations ("NC"). 
Our work was able to demonstrate that Lin- MNCs were driven to either 
myeloid or erythroid lineage when transduced with "N" and "NC" 
respectively as compared to non-transduced cells within in vitro
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methylcellulose assays.
In CEBPA it is clear that this transcription factor plays an important role 
in leukaemogenesis. Evidence from familial cases and from its presence within 
the LSC indicates that mutations in this gene are an early event however are 
not enough for the development of frank leukaemia immediately on its own.
Target cell of mutation events in leukaemogenesis and CEBPA
As studies have shown that the location of mutations and genetic 
events can play an important role in AML development it is important to 
determine when these key events take place. In our study, leukaemia samples 
were sorted into the LSC, and the equivalent of CMP and GMP compartments 
in normal haematopoiesis and then tested for presence of CEBPA mutations, 
which were detected in all compartments for all samples. This however, does 
not address in particular where the mutation may arise if the mutation itself is 
able to alter the phenotype of the cell. An issue that may arise is whether the 
leukaemogenic event (ie the mutation in CEBPA) dictates the cell phenotype or 
whether the cell type in which the mutation occurs may influence the 
phenotype of the abnormality.
As discussed in the introduction, transduction of various cell types with 
fusion proteins may dictate the phenotype of the cell, resulting in a rather 
homogenous phenotype, however this is generally not reflective of what is 
observed in patient samples, where a hierarchy of cells is maintained. The
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expression of a particular mutation could be controlled by a cell specific 
transcription factor. It is also possible that an abnormality only has the 
opportunity to occur in a certain cell type. Furthermore, it may be that a 
mutation is molecularly dependent on a cell-specific co-factor. Research has 
shown that patients with mutations in CEBPA have a distinctive 
immunophenotype119 however this was examining the bulk of the disease, not 
the more primitive compartments.
The lack of engraftment for AMLs containing CEBPA mutations, which 
confer favourable prognosis, is consistant with research presented by our 
laboratory that the ability of a particular AML to engraft in the NOD/SCID 
model is related to the prognosis of individual AML cases. AMLs with poor 
prognosis were able to readily engraft in the NOD/SCID model, while those 
with favourable prognosis are unable to engraft. Specifically, examination of 
the follow-up of younger patients with intermediate-risk AML revealed a 
significant difference in overall survival between NOD/SCID-engrafting and 
non-engrafting cases. We could not detect a difference between engrafting and 
non-engrafting cases in various engraftment variables including: homing 
ability, AML initiating cell frequency, immune rejection by the host or 
alternative tissue sources. Hence, the ability to engraft NOD/SCID recipients 
seems to be an inherent property of the cells that is directly related to 
prognosis.
A possible explanation is that NOD/SCID engraftment reflects the stem
cell nature of each individual AML case. AML cases that engraft in the
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NOD/SCID assay at six weeks may represent diseases driven by potent 
leukaemia-initiating cells with stem cell-like self-renewal and proliferation 
abilities whereas non-engrafting AML cases may involve less potent 
leukaemia-initiating cells with more restricted progenitor-type self-renewal 
and proliferation abilities.
In the case of CEBPA this ties in with the effects we observed when 
examining the function of mutations in this gene. While it was clear that the 
mutations had an effect on early prognitors this same effect was not observed 
in the in vivo assays. Technical difficulties aside, the lack of engraftment in Lin- 
MNCs by cells transduced with the "N" construct could be explained if the 
N-terminal mutation offers no advantage over normal HSCs. This fits with the 
hypothesis that an effect on progenitors is required, and fits with the theory of 
engraftment being dependant on the cell type that drives the AML. 
Furthermore, this indicates that CEBPA mutations alone are not enough to 
result in overt leukaemia but may possibly provide a more suspectable target 
cell for further genetic events This is supported by long latency periods in 
familial cases involving germline "N" mutations indicating that an 
accumulation of events is required for development of AML.
From the work presented in this thesis we are able to conclude that gene
specific mutations play an important role in leukaemogenesis for patients with
normal cytogenetics. Due to the observation of a high proportion of
leukaemias containing mutations that disrupt both proliferation and
differentiation it is likely that cooperative mutations are required for
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leukaemogenesis. Elucidating the order by which mutations arise in AML 
provides insight into disease progression and the process of leukaemogenesis. 
Through SNP arrays, we were able to investigate the phenomenon of aUPD 
and demonstrate that mitotic recombination may be acting as a second hit in 
leukaemogenesis. Furthermore the examination of areas of aUPD can point to 
the location of novel genetic aberrations, resulting in our laboratory's further 
investigations of mutations in the WT1 gene. The development of mutation 
specific real-time PCR assays for CEBPA offers an additional technique for 
examination of minimal residual disease in patients with these mutations and 
has allowed us to examine more closely where the mutations are present 
within the stem cell and early progenitor compartments of AML. Finally, 
studying the function of mutations involved in AML and their effects on 
normal haematopoiesis has provided insight into the target cell for CEBPA 
mutations and what role different mutation combinations may play in AML.
Throughout this thesis, we have demonstrated that there is a wealth of 
information that can be gained from studying gene specific mutations in AML. 
Continuing research into these kinds of mutations will one day lead to better 
understanding of the disease, more accurate prognosis and tailored therapies 
for patients.
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